Methods and compositions for treatment of bag3 mutation-associated dilated cardiomyopathy

Recombinant adeno-associated viral particles with an engineered AAV9 capsid protein variant are used to treat BAG3 mutation-associated DCM, enhancing BAG3 expression and improving cardiac function, addressing the lack of effective therapies for this condition.

WO2026236093A1PCT designated stage Publication Date: 2026-11-12AFFINIA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026480
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-11-11
Filing Date
2026-05-04
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There are currently no disease-modifying therapies available for BAG3 mutation-associated dilated cardiomyopathy (DCM), a condition that leads to heart failure and requires interventions like LVAD implantation and heart transplantation.

Method used

The use of recombinant adeno-associated viral particles (rAAV) with an engineered AAV9 capsid protein variant encapsulating a polynucleotide encoding a BAG3 polypeptide under a muscle-specific promoter to treat BAG3 mutation-associated DCM, enhancing cardiac BAG3 protein expression.

Benefits of technology

The rAAV treatment significantly improves cardiac function and structure in animal models, reducing the need for heart failure therapies and potential interventions by increasing BAG3 protein levels and improving heart muscle contractility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000106_0001
    Figure IMGF000106_0001
  • Figure IMGF000018_0001_TABLE
    Figure IMGF000018_0001_TABLE
  • Figure IMGF000019_0001_TABLE
    Figure IMGF000019_0001_TABLE
Patent Text Reader

Abstract

The disclosure pertains to methods of treating an adult human subject suffering from BCL2-Associated Athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy with a recombinant AAV.
Need to check novelty before this filing date? Find Prior Art

Description

AFF-005WQ METHODS AND COMPOSITIONS FOR TREATMENT OF BAG3 MUTATION-ASSOCIATED DILATED CARDIOMYOPATHY1. CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the priority benefit of U.S. provisional application nos. 63 / 800,293, filed May 5, 2025, 63 / 915,349, filed November 11, 2025, and 64 / 034,120, filed April 9, 2026, the contents of each of which are incorporated herein in their entireties by reference thereto.2. SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML Sequence Listing, created on April 29, 2026, is named AFF-005WO_SL and is 250,989 bytes in size.3. BACKGROUND

[0003] Dilated cardiomyopathy (DCM) is the most common cause of heart failure (HF) in the young and the most frequent indication for heart transplantation. The prevalence of DCM is estimated to be 1 in 250 individuals. More than 50% of patients with DCM have a genetic predisposition to the disease. Mutations in BCL2- Associated Athanogene 3 (BAG3) have been associated with DCM. The prevalence of BAG3 mutation associated DCM is reported to be between 23 and 3.6% in DCM patient cohorts from US, Europe and Japan. BAG3 is a sarcomeric protein that is mainly expressed in skeletal muscle cells and cardiomyocytes. BAG3 functions as a co-chaperone and interacts with members of the heat shock protein (HSP) family. Its putative role is to stimulate the repair and degradation of abnormal proteins that accumulate under stressful situations BAG3 mutations are autosomal dominant and frequently cause truncation of the coding sequence. Nonsense truncating mutations are hypothesized to result in increased mRNA decay and reduced protein expression resulting in haploinsufficiency. The reduced BAG3 protein levels result in decreased contractile force and consequently, the heart failure phenotype. In the largest clinical study of BAG3 DCM conducted by the European Genetic Cardiomyopathies Initiative consisting of n=129 patients, 86% of individuals carried truncating mutations of BAG3. In this study, the mean age at presentation for BAG3 DCM was 36.9 years and 47% of patients with BAG3 associated DCM presented with New York Heart Association (NYHA) Class II or III HF and another 20% presented with Class IV HF. During the follow up of this cohort, the incidence of adverse cardiac events (death, implantation of Left Ventricular Assist Devices (LVAD), heart transplantation and sustained ventricular arrhythmia) was 5.1% per year and ultimately, 22% of patients with BAG3 DCM received heart transplantation.

[0004] There are currently no disease modifying therapies available for BAG3 mutation associated DCM. Patients with BAG3 DCM receive guideline-directed medical therapies for heart failure with reduced ejection fraction (HFrEF) including angiotensin receptor-neprilysin inhibitor (ARNI), beta blockers, mineralocorticoid receptor antagonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors.Patients with advanced HF are eligible for implantation of left ventricular assist devices (LVAD), defibrillator (ICD) implantation and heart transplantation.

[0005] Accordingly, new therapies for BAG3 mutation associated DCM are needed.4. SUMMARY

[0006] The present disclosure addresses the need in the art for gene therapies for treating dilated cardiomyopathy (DCM). In some aspects, the disclosure provides methods of treating adult human subjects suffering from BAG3 mutation-associated dilated cardiomyopathy with recombinant adeno-associated viral particles (rAAV) having a capsid comprising an engineered AAV9 capsid protein variant with high cardiac tropism encapsulating a polynucleotide encoding a BAG3 polypeptide operably linked to a muscle-specific CK8e promoter. This disclosure further provides rAAV for use in the methods disclosed herein.

[0007] In some aspects, the rAAV comprises a capsid comprising a VP1 capsid protein comprising the amino acid sequence of SEQ ID NO:10 and VP2 and VP3 portions thereof, and an encapsulated polynucleotide (sometimes referred to herein as a genome or vector genome) comprising a 5’ inverted terminal repeat (ITR), a CK8e promoter, a coding sequence for a BAG3 polypeptide, a posttranscriptional regulatory element, a bovine growth hormone (BGH) polyadenylation signal, and a 3’ ITR. In some embodiments, the rAAV comprises a capsid comprising a VP1 capsid protein comprising the amino acid sequence of SEQ ID NO:10 and VP2 and VP3 portions thereof, and an encapsulated polynucleotide comprising the nucleotide sequence of SEQ ID NQ:810.

[0008] Further exemplary features of rAAV that can be used in methods of the disclosure are described in Section 6.2 and specific embodiments 1 to 12, infra.

[0009] Further exemplary features of methods of treating BAG3 mutation-associated dilated cardiomyopathy and of rAAV for use in methods of treating BAG3 mutation-associated dilated cardiomyopathy are described in Section 6.4 and specific embodiments 1 to 211, infra.

[0010] The disclosure further provides liquid pharmaceutical compositions comprising rAAV of the disclosure, methods of preparing solutions for infusion (e.g., for infusion to a subject in a method as described herein), and IV infusion bags comprising a diluted liquid pharmaceutical composition obtained or obtainable by the preparation methods. Features of liquid pharmaceutical compositions, methods of preparing solutions for infusion, and IV infusion bags are described in Section 6.3 and specific embodiments 212 to 258, infra5. BRIEF DESCRIPTION OF THE FIGURES

[0011] FIG. 1 schematically illustrates the rAAV genome of Example 1.

[0012] FIG. 2 schematically illustrates the timeline of the study of Example 1

[0013] FIG. 3 shows HA tagged BAG3 expression in the heart as measured by IHC (Example 1)

[0014] FIG. 4 shows HA tagged BAG3 expression in the heart as measured by JESS™ automated western blot (Example 1).

[0015] FIG. 5 shows HA tagged IHC staining of heart (left panel), liver (middle panel) and quadriceps muscle (right panel) (Example 1). All images shown at 4X magnification.

[0016] FIGS.6A-6D show ejection fraction of mice of Example 1 at various time points (FIGS 6A and 6C) and nine weeks post-surgery (three weeks post-AAV injection) (FIGS. 6B and 6D). Values are mean ± SEM. Ml untreated ejection fraction data (from a previous characterization study) at 3, 6, and 9 weeks post Ml surgery are included for reference. *p < 005 compared with Mi-Untreated (ANOVA).

[0017] FIGS.7A-7D show ejection fraction (FIG. 7A), fractional shortening (FIG. 7B), treatment condition-related changes to left ventricular posterior wall (LVPW) thickness (FIG. 7C) at 2 WPI, and change in ejection fraction percentage from 0 WPI to 2 WPI (FIG. 7D) in hearts of WT and BAG3 cKO mice that received rAAVs with Variant 3 capsid proteins encapsulating polynucleotides comprising a BAG3 transgene under the control of CK8e promoter and comprising or lacking OPRE (Example 2).

[0018] FIGS.8A-8R show vector genome levels in hearts (FIG. 8A) and livers (FIG. 8B) at 8 days post injection, vector genome levels in hearts (FIG. 8C) and livers (FIG. 8D) at 28 days post injection, BAG3 RNA levels in hearts (FIG. 8E) and livers (FIG. 8F) at 8 days post injection, BAG3 RNA levels in hearts (FIG. 8G) and livers (FIG. 8H) at 28 days post injection ofWT mice that received rAAVs with Variant s capsid proteins encapsulating a polynucleotide comprising a BAG3 transgene under the control of a MLC2 promoter; and ejection fraction between 0 WPI and 4 WPI (FIG. 8I) and ejection fraction (FIG. 8J), fractional shortening (FIG. 8K), left ventricular interior diameter (FIG. 8L) and left ventricular posterior wall thickness (FIG. 8M) at 4 WPI, as well as BAG3 RNA expression (FIG. 8N), vector genome (FIG. 80), BAG3 protein levels (FIG. 8P) in hearts and HA tagged IHC staining (FIG. 8Q) and protein quantification (FIG. 8R) in hearts of BAG3 cKO mice that received rAAVs with Variant 3 or AAV9 capsid proteins encapsulating polynucleotides comprising a BAG3 transgene under the control of MLC2 promoter (Example 3).

[0019] FIGS.9A-9D show vector genome levels in hearts (FIG. 9A) and livers (FIG. 9B), BAG3 RNA levels in hearts (FIG. 9C) and livers (FIG. 9D) of WT mice that received rAAVs with Variant 3 capsid proteins encapsulating polynucleotides comprising a BAG3 transgene under the control of MLC2 promoter or Ck8e promoter (Example 4).

[0020] FIGS. 10A-10G show BAG3 RNA levels (FIG. 10A), vector genome levels (FIG. 10B), BAG3 protein levels (FIGS. 10C and 10D), HA tagged IHC staining (FIG. 10E and 18F) and protein quantification (FIG. 10G) in hearts of WT mice that received rAAVs with Variant 1 capsid proteins encapsulating polynucleotides comprising a BAG3 transgene under the control of MLC2, TNNT2-400, TNNT2-600, aMHC, or BAG3 promoter (Example 5).

[0021] FIGS. 11A-11D show ejection fraction (FIG. 11 A), vector genome (FIG. 11B), BAG3 RNA (FIG.11 C) and BAG3 protein levels (FIG 11 D) in hearts of mice that received rAAVs with Variant 1 capsidproteins encapsulating polynucleotides comprising a BAG3 transgene under the control of a BAG3 promoter in a mouse model of myocardial infarction (Ml) (Example 6).

[0022] FIGS. 12A-12C show BAG3 RNA expression (FIG. 12A), BAG3 protein levels (FIG. 12B), and vector genome levels (FIG. 12C) in hearts of WT mice 14, 28, and 60 days after they received 2e13 vg / kg or 1e14 vg / kg rAAV comprising Variant 1 capsid proteins encapsulating a polynucleotide comprising a BAG3 transgene under the control of a BAG3 promoter (Example 7)

[0023] FIGS. 13A-13D show BAG3 RNA expression (FIG. 13A) and vector genome levels (FIG 13B) in hearts of WT mice that received 2e12 vg / kg or 6.32e11 vg / kg rAAV comprising Variant 4 capsid proteins encapsulating a polynucleotide comprising a BAG3 transgene under the control of a MLC2 promoter; and BAG3 RNA expression (FIG. 13C) and vector genome levels (FIG. 13D) in hearts of WT mice that received 2e12 vg / kg rAAV comprising Variant 1 or Variant 4 capsid proteins encapsulating polynucleotides comprising a BAG3 transgene under the control of a MLC2 promoter or a BAG3 promoter (Example 8).

[0024] FIGS. 14A-14B show BAG3 RNA expression (FIG. 14A) and vector genome levels (FIG 14B) in hearts of WT mice that received a 2e13 vg / kg or 6.32e12 vg / kg dose of rAAV comprising Variant 2 capsid proteins encapsulating a polynucleotide comprising a BAG3 transgene under the control of a MLC2 promoter (Example 9).

[0025] FIGS. 15A-15K show ejection fraction (FIG. 15A), fractional shortening (FIG. 15B), corrected left ventricle (LV) mass per body weight (FIG. 15C), LV mass (FIG. 15D), left ventricle wall diameter (FIG.15E), vector genome levels (FIG. 15F), BAG3 RNA expression (FIG. 15G), BAG3 protein levels (FIG.15H-15K) in BAG3 cKO mice that received a 2e13 vg / kg dose of rAAV comprising Variant 2 or Variant 4 capsid proteins encapsulating a polynucleotide comprising a BAG3 transgene under the control of a MLC2 promoter (Example 10).

[0026] FIGS. 16A-16E show BAG3 protein concentration obtained with JESS™ automated western blot (FIG. 16A) and ELISA (FIG. 16B), GFP levels obtained by flow cytometry (FIG. 16C) in C2C12 cells and BAG3 protein expression (FIGS. 16D and 16E) in iPSC-CM cells that were transduced with rAAV comprising Variant 3 capsid proteins comprising BAG3 under the control of MLC-2, CK8e, or CBh promoter (Example 11 ).

[0027] FIG. 17 shows H&E and HA-tagged IHC staining in heart of a cynomolgus macaque that received a 3e13 vg / kg dose of rAAV with Variant 3 capsid proteins encapsulating polynucleotides comprising a BAG3 transgene under the control of a CK8e promoter (Example 12).

[0028] FIG. 18 shows H&E and HA-tagged IHC staining in heart of two cynomolgus macaques that received a 1e13 vg / kg dose of rAAV with Variant 3 capsid proteins encapsulating polynucleotides comprising a BAG3 transgene under the control of a CK8e promoter (Example 12).

[0029] FIG. 19 shows the schema for the clinical study of Example 13.

[0030] FIGS.20A-20E show cardiac function as measured by transthoracic echocardiography or cardiac ultrasound in BAG3 cKO+ / - (n=67) and WT (n=24) mice utilized in the study of Example 15 at 9 weeks of age. Bar graphs show five measurements of cardiac-function (%EF, %FS) and structure (LVIDs, LVIDd, LVPWs) in mice at baseline (prior to treatment with test or control article). Bar graphs show mean value of each group ± standard error of the mean (SEM). Ejection Fraction% (FIG. 20A), fractional shortening% (FIG. 20B) are measurements of functional-output of cardiac contractility, LVIDs (left ventricular internal diameter and end-systole; FIG 20C); LVIDd (left ventricular internal diameter at end-diastole; FIG. 20D) and LVPWs (left ventricular posterior wall thickness at end-systole; FIG. 20E) are measures of cardiac structure. P-value per student’s t-Test ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05.

[0031] FIGS.21 A-21 E show AFF-01 improves cardiac function and structure in BAG3 cKO+ / - mouse model at 9.5e11 vg / kg dose (Example 15). Transthoracic echocardiography performed in BAG3 cKO+ / -and WT mouse treatment and control groups relevant to AFF-01 (groups 1, 2, 3, 4, 7 and 8) are shown at 8-weeks post dosing. Values are expressed as means±SEM EF% (% Ejection Fraction; FIG. 21A), FS% (% Fractional Shortening; FIG. 21 B), LVIDs (left ventricular internal diameter at end-systole; FIG 21 C); LVIDd (left ventricular internal diameter at end-diastole; FIG 21 D); LVPWs (left ventricular posterior wall thickness at end-systole; FIG. 21 E). P-value per student’s t-Test comparing BAG3 cKO+ / - and individual treatment groups. P-value per student’s t-Test ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05

[0032] FIG. 22 shows echocardiogram M-mode images showing representative WT mice treated with FB (WT / FB, left, Groups 1-2); BAG3 cKO+ / - mice treated with FB (BAG3 cKO+A / FB, center, Groups 3-4); BAG3 cKO+ / - mice treated with AFF-01 at 9.5e11 vg / kg (BAG3 cKO+ / - / AFF-01, right, Groups 7-8) at 8 weeks post dosing (Example 15).

[0033] FIGS.23A-23B show AFF-01 improves cardiac function in the BAG3 cKO+Z- mouse model at 9.5e11 vg / kg. Transthoracic echocardiography performed in BAG3 cKO+Z- and WT mice up to 8 weeks post dosing. Bi-monthly(FIG. 23A) and monthly (FIG. 23B) EF% (% Ejection Fraction) values are expressed as average for each treatment group ± standard error of the mean (SEM). P-value per student’s t-Test comparing BAG3 cKO+ / - / FB group and individual AFF-01 treatment groups *P<005 (Example 15).

[0034] FIGS.24A-24C show vector genome biodistribution quantified using droplet digital polymerase chain reaction (ddPCR) normalized to housekeeping gene RPP30 (FIG. 24A); mRNA expression quantified using reverse transcription-ddPCR (RT-ddPCR) normalized to %RPP30 housekeeping gene (FIG. 24B); BAG3 protein expression level expressed as fold change over corresponding BAG3 protein level observed in FB treated wildtype mice (FIG. 24C) (Example 15). Comparison shown between WT mice treated with FB (WT / FB) (n=12, Group 1 ), BAG3 cKO+ / - mice treated with FB (BAG3 cKO+ / - / FB) (n=10, Group 3), and BAG3 cKO+ / - mice treated with AFF-01 (BAG3 cKO+ / - / AFF-01) (n=10, Group 7). Individual animal samples represented as black dots with bars representing average value for each treatment group ± standard error of the mean (SEM). N.D. = not done. P-value per student’s t-Test ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05.

[0035] FIGS.25A-25B show representative images showing human BAG3-positive immunostaining in the myocardium of mouse heart sections 9 weeks post injection with AFF-01 (Example 15). FB treated animals show lack of specific staining (FIG. 25A). Animals treated with AFF-01 show homogenous human BAG3 immunostaining across the myocardium (FIG. 25B). Scale bars: 200 pm.

[0036] FIGS.26A-26E show results of cardiac function assessments as measured by transthoracic echocardiography or cardiac ultrasound in BAG3 cKO+ / - (n=67) and WT (n=24) mice utilized at 9 weeks of age (Example 16) Bar graphs show five measurements of cardiac function and structure in mice at baseline (prior to treatment with AFF-01 or control article). Bar graphs show mean value of each group ± standard error of the mean (SEM). Ejection Fraction% (EF%; FIG. 26A), Fractional Shortening% (FS%; FIG. 26B) are measurements of functional output of cardiac contractility. LVIDs (left ventricular internal diameter and end systole; FIG. 26C); LVIDd (left ventricular internal diameter at end-diastole; FIG. 26D) and LVPWs (left ventricular posterior wall thickness at end-systole; FIG. 26E) are measurements of cardiac dilation and structure. P-value per student’s t-Test ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05.

[0037] FIGS.27A-27E show AFF-01 improves cardiac function and structure in the BAG3 cKO+ / -mouse model (Example 16). Transthoracic echocardiography performed in BAG3 cKO+ / - and WT mouse treatment and control groups relevant to AFF-01 (groups 5, 6, 7, 8 and 9) are shown at 8 weeks post dosing Values are expressed as means+SEM EF% (% Ejection Fraction; FIG 27A); FS% (% Fractional Shortening, FIG. 27B); LVIDs (left ventricular internal diameter at end-systole; FIG. 27C); LVIDd (left ventricular internal diameter at end-diastole; FIG. 27D); LVPWs (left ventricular posterior wall thickness at end-systole; FIG. 27E). Comparison shown between WT mice treated with FB (WT / FB) (n=15, Group 5), BAG3 cKO+ / - mice treated with FB (BAG3 cKO+ / - / FB) (n=14, Group 6), and BAG3 cKO+ / - mice treated with AFF-01 (BAG3 cKO+ / - / AFF-01 ), LD = Low Dose (3e11 vg / kg, n=14, Group 7), MD = Mid Dose (6e11 vg / kg, n=15, Group 8), and HD = High Dose (9e11 vg / kg, n=15, Group 9). Individual animal samples represented as black dots with bars representing average value for each treatment group ± standard error of the mean (SEM). P-value per student’s t-Test comparing BAG3 cKO+ / - FB treatment group and other treatment groups. P-value per student’s t-Test P-value per student’s t-Test **P<0.01, *P<0.05, ns=not significant.

[0038] FIGS.28A-28E show echocardiogram M-mode images showing representative WT mice treated with FB (WT / FB, Groups 1-2, FIG. 28A); BAG3 cKO+ / - mice treated with FB (BAG3 CKO+ / - / FB, Groups 3-4; FIG. 28B); BAG3 cKO+ / - mice treated with AFF-01 at low dose (LD, 3e11 vg / kg; FIG. 28C), medium dose (MD, 6e11 vg / kg; FIG. 28D), or high dose (HD, 9e11 vg / kg) (BAG3 cKO+ / - / AFF-01 , Groups 7-8; FIG. 28E) at 8 weeks post dosing (Example 16).

[0039] FIGS.29A-29C show results of pharmacodynamics assessments of AFF-01 in BAG3 cKO+ / -mouse heart: Vector genome biodistribution quantified using droplet digital polymerase chain reaction (ddPCR) normalized to housekeeping gene RPP30 (FIG 29A); mRNA expression quantified using reverse transcriptase-ddPCR (RT-ddPCR) normalized to %RPP30 housekeeping gene (FIG 29B); BAG3 protein expression level expressed as fold change over corresponding BAG3 protein level observed in FB treated wild type (WT) mice in study (FIG. 290) (Example 16). From left, comparison shown betweenWT mice treated with FB (WT / FB) (n=23, Groups 1 and 5), BAG3 cKO+ / - mice treated with FB (BAG3 cKO+ / - / FB) (n=14), BAG3 cKO+Z- mice treated with AFF-01 LD = Low Dose (3e11 vg / kg, n=15, Group 7), BAG3 cKO+ / - mice treated with AFF-01 MD = Medium Dose (6e11 vg / kg, n=15, Group 8), and BAG3 cKO+ / - mice treated with AFF-01 HD = High Dose (9e11 vg / kg, n=15, Group 9). Individual animal samples represented as black dots with bars representing average value for each treatment group ± standard error of the mean (SEM) P-value per student’s t-Test ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05.

[0040] FIGS.30A-30E show representative images of immunohistochemical (IHC) staining of mouse heart sections with hBAG3 antibody (Example 16). Representative images showing human BAG3-positive immunostaining (brown) in the myocardium of mouse heart sections 9 weeks post injection with AFF-01. FB (FB) treated WT (FIG. 30A) and BAG3 cKO+ / - (FIG. 30B) mouse hearts showed lack of specific staining. BAG3 cKO+ / - mice treated with AFF-01 (FIGS. 30C-E) show homogenous and dosedependent increase in human BAG3 immunostaining across the myocardium. LD = Low Dose (3e11 vg / kg, Group 7; FIG. 30C), MD = Medium Dose (6e11 vg / kg, Group 8; FIG. 30D), and HD = High Dose (9e11 vg / kg, Group 9; FIG 30E)

[0041] FIGS.31 A-31 B show vector genome biodistribution quantified using droplet digital polymerase chain reaction (ddPCR) in AFF-01 -treated BAG3 cKO+ / - mice across five time points (14-, 28-, 42-, 90-, and 140-Days Post-Injection) (Example 17). Vector genome (vg) measurements fortissue samples were normalized to housekeeping gene (RPP30) to generate vector genomes per diploid genome (vg / dg) (FIG.31A). vg measurements in biofluid / blood were normalized to mass of input DNA per reaction (i e., 10 ng) (FIG. 31 B). Each data-point represents the average of all animals in the treatment group. Data represented as average vg / dg + / - standard error of the mean across AFF-01 -treated study animals. Dotted line represents average background vg / dg level across all listed tissues in (FIG. 31 A) and corresponding vg / 10 ng whole blood DNA in naive BAG3 cKO+ / - mice.

[0042] FIG. 32 shows RNA expression levels in mouse tissues following AFF-01 administration, quantified by RT-ddPCR and expressed as % RNA expression normalized to housekeeping gene RPP30 (Example 17). Data are shown for all extracted tissues across five time points (14-, 28-, 42-, 90-, and 140-days post-injection). Dotted line represents average background level in naive BAG3 cKO+ / - mice Data represented as average vg / dg + / - standard error of the mean across AFF-01 treated study animals.

[0043] FIG. 33 shows protein expression levels in mouse tissue following AFF-01 administration, quantified by ProteinSimple Jess™ Western Blot (Example 17). Black dotted line represents average BAG3 expression level (AUG) in FB treated BAG3 cKO+ / - mice. BAG3 overexpression in AFF-01 treated mice was represented as fold-change over FB treated BAG3 cKO+ / - mice. Data are shown across five time points (14-, 28-, 42-, 90-, and 140-days post-injection. Each data-point represents the average of 5 animals with error bars representing + / - standard error of the mean

[0044] FIG. 34A-34H show ejection fraction in baseline levels (FIG. 34A) and at 8 weeks post injection (WPI) (FIG. 34B), fractional shortening at 8 weeks WPI (FS%; FIG. 34C), left ventricular internal diameter at end-systole at 8 WPI (LVIDs; FIG. 34D), vector genome at 8 WPI (FIG. 34E), 8 WPI quantified resultsof immunohistochemistry (IHC; FIG. 34F) and 8 week WPI BAG3 protein levels (fold change; FIG. 34G and AUC; FIG. 34H) in hearts of WT or BAG3 cKO+ / - mice treated with AFF-01 (+HA) or rAAV with Rh74 rAAV (Example 18). Group 1: WT mice administered formulation buffer (FB); Groups 2-5: BAG3 cKO+ / -mice treated with FB, AFF-01 (+HA), Rh74 rAAV (low dose), or Rh74 rAAV (high dose).

[0045] FIG. 35 representative images of immunohistochemical (IHC) staining of mouse heart sections with hBAG3 antibody in mice treated with FB, AFF-01 (+HA) or rAAV with Rh74 capsid (Example 18). Group 1: WT mice administered FB; Groups 2-5: BAG3 cKO+ / - mice treated with FB, AFF-01 (+HA), Rh74 rAAV (low dose), or Rh74 rAAV (high dose).

[0046] FIG. 36 shows vector genome biodistribution in heart tissue quantified using droplet digital polymerase chain reaction (ddPCR) normalized to housekeeping gene RPP30 (Example 20). Individual NHP samples represented as black dots with bars representing average value for each treatment group ± standard error of the mean (SEM). Group 2 (n=3) treated with AFF-01 at 3e12 vg / kg, Group 3 (n=3) treated with AFF-01 at 6e12 vg / kg.

[0047] FIG. 37 shows RNA expression in the heart tissue quantified using reverse transcriptase ddPCR (RT-ddPOR) normalized to housekeeping gene RPP30 (Example 2). Individual NHP samples represented as black dots with bars representing average value for each treatment group ± standard error of the mean (SEM) Group 2 (n=3) treated with AFF-01 at 3e12 vg / kg, Group 3 (n=3) treated with AFF-01 at 6e12 vg / kg.

[0048] FIGS.38A-38B show BAG3 protein expression in multiple heart regions of NHPs 3 months post AFF-01 administration (Example 20). BAG3 protein level is expressed as fold change over protein levels observed in NHPs dosed with formulation buffer control material (1X, dotted line). Specifically, fold change was calculated as the ratio of BAG3 protein level (AUC) observed in cardiac protein lysate from AFF-01 -treated animals, normalized to the average BAG3 protein (AUC) observed in the NHP control material treated group (Group 1) in the study. FIG. 38A: Protein expression shown across individual heart regions. FIG. 28B: Cumulative protein expression averaged across all areas of the heart. The dotted line represents BAG3 endogenous levels of control material administered animals.6. DETAILED DESCRIPTION6.1. Definitions

[0049] As used herein, the following terms are intended to have the following meanings:

[0050] A, An, The: As used herein, the term “a”, “an”, “the” and similar terms used in the context of the present disclosure (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. As such, the terms “a” (or “an”), “one or more”, and “at least one” can be used interchangeably herein.

[0051] AAV: AAV is adeno-associated virus, and may be used to refer to the virus itself or derivatives thereof. The term covers all subtypes, serotypes and pseudotypes, and both naturally occurring and recombinant forms, except where required otherwise.

[0052] AAV capsid protein: The term “AAV capsid protein” or simply “capsid protein” refers to a VP1, VP2, or VP3 capsid protein. A capsid protein that is modified as compared to a naturally occurring or synthetic I artificial capsid protein capsid protein is referred to as a “modified AAV capsid protein” or simply “modified capsid protein” or “variant capsid protein."

[0053] And / or: The term “and / or” means that each one or both or all the components or features of a list are possible variants, especially two or more thereof in an alternative or cumulative way.

[0054] BAG3 Polypeptide: The term “BAG3 polypeptide” or “BAG3 protein” refers to human B-cell lymphoma 2 (Bcl-2) associated anthanogene-3 (BAG3) or a functional fragment or functional variant thereof. An exemplary BAG3 protein sequence is provided as UniProt Accession No. 095817. In some embodiments, a BAG3 protein has at least 90%, at least 95%, at least 98%, at least 99% or 100% identity to SEQ ID NO: 100 or a functional fragment or functional variant thereof.

[0055] Coding Sequence: The term “coding sequence” is used herein to refer to a specific sequence of nucleotides in a polynucleotide, such as an rAAV genome or mRNA produced thereby, that encodes a polypeptide.

[0056] Functional Fragment: The term “functional fragment” in the context of a BAG3 protein refers to a biologically functional fragment of full length BAG3. As would be understood in the art, a biologically functional fragment is a portion or portions of a full length sequence that retain a biological function of the full length sequence. Biological functions of BAG3 include acting as a co-chaperone for HSP70 and HSC80 chaperone proteins, acting as a nucleotide-exchange factor (NEF) promoting the release of ADP from the HSP70 and HSC70 proteins thereby triggering client / substrate protein release, anti-apoptopic activity, and playing a role in HSF1 nucleocytoplasmic transport.

[0057] Functional Variant: The term “functional variant” in the context of BAG3 refers to various splicing isoforms, variants, fusion proteins, and modified forms of a wild-type BAG3 polypeptide or a functional fragment thereof. Such isoforms, bioactive fragments or variants, fusion proteins, and modified forms of the BAG3 polypeptides retain at least one biological function of the full-length protein.

[0058] Inverted Terminal Repeat: The term “inverted terminal repeat” (or “ITR”) refers to a polynucleotide sequence found at the ends of AAV genomes that form a hairpin, which contributes to the genome’s ability to self-prime (allowing for primase-independent synthesis of the complementary second DNA strand) and provides for encapsidation of the genome into an AAV particle. An ITR can be a wildtype ITR or a variant thereof.

[0059] Operably Linked: The terms “operably linked” and “operatively linked” refer to the functional relationship of the nucleic acid sequences with regulatory sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences and indicates that two or more DNA segments are joined together such that they function in concert for their intended purposes For example, operative linkage of nucleic acid sequences, typically DNA, to a regulatory sequence or promoter region refers to the physical and functional relationship between the DNA and the regulatorysequence or promoter such that the transcription of such DNA is initiated from the regulatory sequence or promoter, by an RNA polymerase that specifically recognizes, binds and transcribes the DNA.

[0060] Or: Unless indicated otherwise, an “or” conjunction is intended to be used in its correct sense as a Boolean logical operator, encompassing both the selection of features in the alternative (A or B, where the selection of A is mutually exclusive from B) and the selection of features in conjunction (A or B, where both A and B are selected). In some places in the text, the term “and / or” is used for the same purpose, which shall not be construed to imply that “or” is used with reference to mutually exclusive alternatives.

[0061] Peptide: The terms “peptide,” “polypeptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues.

[0062] Percent Sequence Identity: The terms “percent sequence identity” (% sequence identity), “percent identical” (% identical) and the like refer to percent sequence identity between two nucleotide sequences or between two amino acid sequences calculated by aligning the two sequences, determining the number of matches of nucleotides or amino acid residues between the two sequences, dividing the number of matches by the length of the aligned region (i.e., the number of aligned nucleotides or amino acid residues), and multiplying by 100 to arrive at a percent sequence identity value For calculation of the percent sequence identity (% sequence identity), two or more sequences are aligned using the EMBOSS Needle Pairwise Sequence Alignment software tool based on the Needleman and Wunsch algorithm (available at www.ebi.ac.uk / jdispatcher / psa / emboss_needle) with the following parameters: Matrix: BLOSUM62 (for protein sequences) or DNAfull (for DNA sequences); Gap Open: 10; Gap Extend: 0.5; End Gap Penalty: false; End Gap Open: 10; and End Gap Extend: 0.5.

[0063] rAAV: The abbreviation “rAAV” refers to a recombinant adeno-associated viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide, sometimes referred to herein as a “genome”. rAAV can include a genome that comprises a heterologous polynucleotide (i.e., a polynucleotide other than a wild-type AAV genome), such as a heterologous polynucleotide encoding a gene delivered to a mammalian cell such as the BAG3 gene. The heterologous nucleotide is sometimes referred to as a transgene.

[0064] Subject The term “subject” refers to an adult human. In some embodiments, the subject is 18-50 years old. In some embodiments, the subject is 18-65 years old (e.g., 18-60 or 18-55 years old).

[0065] Targeting Peptide: The term “targeting peptide" refers to a 10 amino acid sequence within the variable region VIII (VRVIII) of a modified AAV capsid protein. AAVs comprising a capsid protein with a targeting peptide can have localization and distribution in a target cell, tissue or organ (e.g., heart) different from the AAV with a capsid protein without the target peptide.

[0066] T reatment: The terms “treatment", “treating”, and the like are used herein to generally mean obtaining a desired pharmacologic and / or physiologic effect. The effect may be therapeutic in terms of a partial or complete cure for a disease or condition and / or adverse effect attributable to the disease orcondition. “Treatment” as used includes relieving the disease or condition (e.g., causing regression of the disease or condition and / or providing improvement in one or more symptoms).

[0067] Variable Region: The terms “variable region” or “VR” refer to one or more of nine sequence variable regions (e.g., VRI to VRIX) in an AAV capsid protein previously defined by comparison and alignment of various AAV capsid proteins. See e.g., Govindasamy etal., 2006, J Virol. 80(23): 11556-70; Meyer eta / ., 2019, Elife 22:8:e44707; DiMattia et al., J Virol. 86(12):6947-6958.

[0068] Vector: The terms “vector,” “AAV vector,” and “rAAV vector” refer to an rAAV that comprises a heterologous polynucleotide, e.g., a transgene.

[0069] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods and compositions of matter belong. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the methods and compositions of matter, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety6.2. Recombinant Adeno-Associated Virus

[0070] The rAAV for use in the treatment methods and compositions described herein comprises (a) a capsid comprising a VP1 polypeptide comprising the amino acid sequence of SEQ ID NO:10 and (b) a polynucleotide encapsulated by the capsid and comprising a coding sequence for a BAG3 polypeptide 6.2.1. Capsid

[0071] The rAAV for use in the treatment methods and compositions described herein has a capsid comprising a VP1 polypeptide comprising the amino acid sequence of SEQ ID NO:10.

[0072] The rAAV used in various embodiments of the present disclosure comprises a capsid formed with VP1, VP2 and VP3 capsid proteins. In a particular embodiment, the capsid is formed with VP1, VP2 and VP3 capsid proteins of SEQ ID NQ:10. The VP1 protein of SEQ ID NQ:10 has a targeting peptide of SEQ ID NO:3 and a peptide segment of SEQ ID NO:7 In some embodiments, the rAAV comprises a VP2 protein having a sequence corresponding to amino acids 138 to 743 of SEQ ID NQ:10 and a VP3 protein having a sequence corresponding to amino acids 203 to 743 of SEQ ID 1X10:10 In some embodiments, the rAAV comprises a VP1 capsid protein comprising the amino acid sequence of SEQ ID NQ:10, a VP2 capsid polypeptide comprising the amino acid sequence of SEQ ID NQ:20, and a VP3 capsid polypeptide comprising the amino acid sequence of SEQ ID NO:21.6.2.2. Polynucleotide

[0073] The rAAV disclosed herein comprises a polynucleotide encapsulated by the capsid and having a coding sequence for a BAG3 protein. The coding sequence can be codon optimized, e.g., for expression in human cardiac cells. Alternatively, the coding sequence can be a wild-type sequence.

[0074] The BAG3 protein is preferably a human BAG3 protein, for example having an amino acid sequence of UniProt accession no. 095817, set forth herein as SEQ ID NO: 100. In some embodiments, the coding sequence encodes a BAG3 protein comprising an amino acid sequence having at least 95% sequence identity to SEQ ID N0:100. In some embodiments, the coding sequence encodes a BAG3 protein comprising an amino acid sequence having at least 96% sequence identity to SEQ ID NO: 100. In some embodiments, the coding sequence encodes a BAG3 protein comprising an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 100. In some embodiments, the coding sequence encodes a BAG3 protein comprising an amino acid sequence having at least 98% sequence identity to SEQ ID NO:100 In some embodiments, the coding sequence encodes a BAG3 protein comprising an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 100 In some embodiments, the coding sequence encodes a BAG3 protein comprising an amino acid sequence having 100% sequence identity to SEQ ID NO: 100.

[0075] In some embodiments, the coding sequence encoding the BAG3 protein has at least 80% sequence identity to SEQ ID NO:101. In some embodiments, the coding sequence encoding the BAG3 protein has at least 85% sequence identity to SEQ ID NO:101 In some embodiments, the coding sequence encoding the BAG3 protein has at least 90% sequence identity to SEQ ID NO: 101. In some embodiments, the coding sequence encoding the BAG3 protein has at least 95% sequence identity to SEQ ID NO:101 In some embodiments, the coding sequence encoding the BAG3 protein has at least 96% sequence identity to SEQ ID NO: 101. In some embodiments, the coding sequence encoding the BAG3 protein has at least 97% sequence identity to SEQ ID NO:101. In some embodiments, the coding sequence encoding the BAG3 protein has at least 98% sequence identity to SEQ ID NO: 101. In some embodiments, the coding sequence encoding the BAG3 protein has at least 99% sequence identity to SEQ ID NO:101 In some embodiments, the coding sequence encoding the BAG3 protein has 100% sequence identity to SEQ ID NO:101.

[0076] In some embodiments, the coding sequence encoding the BAG3 protein has at least 80% sequence identity to SEQ ID NO:102. In some embodiments, the coding sequence encoding the BAG3 protein has at least 85% sequence identity to SEQ ID NQ:102. In some embodiments, the coding sequence encoding the BAG3 protein has at least 90% sequence identity to SEQ ID NO: 102. In some embodiments, the coding sequence encoding the BAG3 protein has at least 95% sequence identity to SEQ ID NQ:102 In some embodiments, the coding sequence encoding the BAG3 protein has at least 96% sequence identity to SEQ ID NO: 102 In some embodiments, the coding sequence encoding the BAG3 protein has at least 97% sequence identity to SEQ ID NO:102. In some embodiments, the coding sequence encoding the BAG3 protein has at least 98% sequence identity to SEQ ID NO: 102. In some embodiments, the coding sequence encoding the BAG3 protein has at least 99% sequence identity to SEQ ID NO:102 In some embodiments, the coding sequence encoding the BAG3 protein has 100% sequence identity to SEQ ID NO: 102.

[0077] The polynucleotide encapsulated by the capsid further comprises a CK8e promoter, which is a muscle-specific promoter, operably linked to the BAG3 polypeptide coding sequence.

[0078] In some embodiments, the CK8e promoter comprises a nucleotide sequence having at least 90%, at least 95%, at least 96%, at least 97%, or at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:302. In some embodiments, the promoter comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NO:302. In some embodiments, the promoter comprises a nucleotide sequence having at least 95% sequence identity to SEQ ID NQ:302. In some embodiments, the promoter comprises a nucleotide sequence having at least 96% sequence identity to SEQ ID NO:302 In some embodiments, the promoter comprises a nucleotide sequence having at least 97% sequence identity to SEQ ID NO:302. In some embodiments, the promoter comprises a nucleotide sequence having at least 98% sequence identity to SEQ ID NO:302. In some embodiments, the promoter comprises a nucleotide sequence having at least 99% sequence identity to SEQ ID NQ:302. In some embodiments, the promoter comprises a nucleotide sequence having 100% sequence identity to SEQ ID NO:302

[0079] The polynucleotide encapsulated by the capsid typically further comprises a posttranscriptional regulatory element sequence, for example an OPRE comprising a nucleotide sequence of SEQ ID N0:400, or comprising a nucleotide sequence having at least 90%, at least 95%, at least 96%, at least 97%, or at least 98%, at least 99%, or 100% sequence identity to SEQ ID N0:400. In some embodiments, the posttranscriptional regulatory element sequence comprises a nucleotide sequence having at least 90% sequence identity to SEQ ID NQ:400. In some embodiments, the posttranscriptional regulatory element sequence comprises a nucleotide sequence having at least 95% sequence identity to SEQ ID NQ:400 In some embodiments, the posttranscriptional regulatory element sequence comprises a nucleotide sequence having at least 96% sequence identity to SEQ ID NQ:400. In some embodiments, the posttranscriptional regulatory element sequence comprises a nucleotide sequence having at least 97% sequence identity to SEQ ID NO:400. In some embodiments, the posttranscriptional regulatory element sequence comprises a nucleotide sequence having at least 98% sequence identity to SEQ ID NQ:400 In some embodiments, the posttranscriptional regulatory element sequence comprises a nucleotide sequence having at least 99% sequence identity to SEQ ID NQ:400. In some embodiments, the posttranscriptional regulatory element sequence comprises a nucleotide sequence having 100% sequence identity to SEQ ID NO:400.

[0080] The polynucleotide typically further comprises a polyadenylation signal sequence, for example a bovine growth hormone (BGH) polyadenylation signal sequence or a synthetic polyadenylation signal sequence In some embodiments, a polyadenylation signal sequence comprises a nucleotide sequence at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:401 In some embodiments, a polyadenylation signal sequence comprises a nucleotide sequence at least 95% identical to SEQ ID NQ:401. In some embodiments, a polyadenylation signal sequence comprises a nucleotide sequence at least 96% identical to SEQ ID NO:401. In some embodiments, a polyadenylation signal sequence comprises a nucleotide sequence at least 97% identical to SEQ ID NO:401 In some embodiments, a polyadenylation signal sequence comprises a nucleotide sequence at least 98% identical to SEQ ID NQ:401 In some embodiments, a polyadenylation signal sequence comprises a nucleotide sequence at least 99% identical to SEQ ID NQ:401. In some embodiments, a polyadenylation signal sequence comprises a nucleotide sequence 100% identical to SEQ ID NQ:401.

[0081] The polynucleotide further comprises AAV-derived inverted terminal repeat sequences (ITRs). In some embodiments, the ITRs are derived from AAV serotype 2. In some embodiments, the rAAV comprises a 5’ ITR having at least 90% sequence identity to SEQ ID NQ:600, SEQ ID NO:601, SEQ ID NO:602, or SEQ ID NO:603 and a 3’ ITR (a 3’ ITR) having at least 90% sequence identity to SEQ ID NQ:604 or SEQ ID NQ:605. In some embodiments, the 5’ ITR has at least 95% sequence identity to SEQ ID NQ:600, SEQ ID NO:601, SEQ ID NO:602, or SEQ ID NQ:603 and the 3’ ITR has at least 95% sequence identity to SEQ ID NQ:604 or SEQ ID NO:605. In some embodiments, the 5’ ITR has at least 98% sequence identity to SEQ ID NQ:600, SEQ ID NQ:601 , SEQ ID NQ:602, or SEQ ID NO:603 and the 3’ ITR has at least 98% sequence identity to SEQ ID NQ:604 or SEQ ID NQ:605. In some embodiments, the 5’ ITR has at least 99% sequence identity to SEQ ID NQ:600, SEQ ID NQ:601 , SEQ ID NQ:602, or SEQ ID NQ:603 and the 3’ ITR has at least 99% sequence identity to SEQ ID NQ:604 or SEQ ID NQ:605 In some embodiments, the 5’ ITR has 100% sequence identity to SEQ ID NQ:600, SEQ ID NO:601, SEQ ID NQ:602, or SEQ ID NQ:603 and the 3’ ITR has 100% sequence identity to SEQ ID NO:604 or SEQ ID NO:605.

[0082] In some embodiments, the rAAV comprises a 5’ ITR having at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NQ:600, SEQ ID NO:601, SEQ ID NQ:602, or SEQ ID NO:603 and a 3’ ITR having at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NQ:604 SEQ ID NQ:605, SEQ ID NQ:606, SEQ ID NQ:607, SEQ ID NQ:608, SEQ ID NQ:609, or SEQ ID NQ:610.

[0083] In some embodiments, the rAAV comprises a 5’ ITR comprising a sequence having 100% sequence identity to SEQ ID NQ:600. In some embodiments, the rAAV comprises a 3’ ITR having 100% sequence identity to SEQ ID NO:608. In some embodiments, the rAAV comprises a 5’ ITR comprising a sequence having 100% sequence identity to SEQ ID NQ:600 and a 3’ ITR comprising a sequence having 100% sequence identity to SEQ ID NQ:608.

[0084] An exemplary polynucleotide that can be included in rAAV of the disclosure is set forth in SEQ ID NO:810 SEQ ID NQ:810 comprises, in 5’ to 3’ direction, a 5’ ITR, a CK8e promoter, a BAG3 coding sequence, a OPRE transcriptional regulatory element, a BGH polyadenylation signal and a 3’ ITR.6.2.3. Methods of Producing rAAV

[0085] The BAG3 polypeptide coding sequence and expression regulatory elements (ERE) (e.g., ERE as described in Section 6.2.2) can replace the AAV genomic coding region (e g., replace the AAV rep and cap genes). The transgene coding sequence and ERE are flanked on either side by AAV inverted terminal repeat (ITR) regions as described in Section 6.2.2.

[0086] In order to replicate and package the vector, the missing functions are complemented with a packaging gene, or a plurality thereof, which together encode the necessary functions for the various missing rep and / or cap gene products The packaging genes or gene cassettes are in one embodiment not flanked by AAV ITRs and in one embodiment do not share any substantial homology with the rAAV genome.

[0087] The rAAV vector construct, and the complementary packaging gene constructs can be implemented in a number of different forms. Viral particles, plasmids, and stably transformed host cells can all be used to introduce such constructs into the packaging cell, either transiently or stably.

[0088] In certain embodiments, the AAV vector and complementary packaging gene(s), if any, are provided in the form of bacterial plasmids, AAV particles, or any combination thereof. In other embodiments, either the AAV vector sequence, the packaging gene(s), or both, are provided in the form of genetically altered (preferably inheritably altered) eukaryotic cells. The development of host cells inheritably altered to express the AAV vector sequence, AAV packaging genes, or both, provides an established source of the material that is expressed at a reliable level.

[0089] A variety of different genetically altered cells can thus be used in the context of this disclosure. By way of illustration, a mammalian host cell may be used with at least one intact copy of a stably integrated rAAV vector. An AAV packaging plasmid comprising at least an AAV rep gene operably linked to a promoter can be used to supply replication functions (as described in U.S. Pat. No. 5,658,776). Alternatively, a stable mammalian cell line with an AAV rep gene operably linked to a promoter can be used to supply replication functions (see, e.g., WO 95 / 13392; WO 98 / 23018; and U.S. Patent No.5,656,785). The AAV cap gene, providing the encapsidation proteins as described above, can be provided together with an AAV rep gene or separately (see, e g , the above-referenced patent documents as well as WO 98 / 27204

[0090] Thus, the rAAV of the disclosure can be assembled by, for example, expression of its components in a packaging host cell. The components of a virus particle (e.g., rep sequences, cap sequences, inverted terminal repeat (ITR) sequences) can be introduced into a packaging host cell using one or more viral vectors.

[0091] Once assembled, rAAV particles can be purified, if desired, using routine methods. As used herein, “purified” virus particles refer to virus particles that are removed from components in the mixture in which they were made such as, but not limited to, viral components (e.g., rep sequences, cap sequences), packaging host cells, and partially- or incompletely- assembled virus particles.6.3. Pharmaceutical Compositions

[0092] In one aspect, the present disclosure provides liquid pharmaceutical compositions comprising a rAAV of the disclosure and a pharmaceutically acceptable carrier.

[0093] In some embodiments, the pharmaceutical composition comprises a solution comprising the rAAV and one or more of (e.g., all of) KCI, KH2PO4, NaCI, Na2HPC>4, L-arginine, and poloxamer 188 (e.g., Pluronic® F68). In some embodiments, the pharmaceutical composition comprises 1.5mM KH2PO4, 172mM NaCI, 8.1mM Na2HPO4, 250mM L-arginine, and 0.005% (w / v) poloxamer 188 (e.g., Pluronic® F68).

[0094] In some embodiments, the pharmaceutical composition has a pH of 6.5 to 7.5. In some embodiments, the pH is 7.0.

[0095] In some embodiments, the concentration of rAAV in the pharmaceutical composition is 1e13 vg / mL to 2e14 vg / mL. In some embodiments, the concentration of rAAV in the pharmaceutical composition is 5e13 vg / mL to 2e14 vg / mL, e.g., 1e14 vg / mL. In some embodiments, the concentration of rAAV in the pharmaceutical composition is 2e13 vg / mL to 5e13 vg / mL, e.g., 2.5e13 vg / mL In some embodiments, the concentration of rAAV in the pharmaceutical composition is 2.2e13 vg / mL to 2.8e13 vg / mL (e.g., 2.2e13 vg / mL, 23e13 vg / mL, 2.4e13 vg / mL, 2.5e13 vg / mL, 2.6e13 vg / mL, 2.7e13vg / mL or 2.8 vg / mL).

[0096] A pharmaceutical composition in accordance with the present disclosure can be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single unit doses. As used herein, a unit dose refers to a discrete amount of the pharmaceutical composition including a predetermined amount of the rAAV. In some embodiments, a unit dose comprises 0.5-5 ml_ of the pharmaceutical composition (e.g., 0.5 ml_ to 2 ml_ or 2 mL to 5 ml_ or 3 ml_ to 5 mL, e.g., 1 ml_, 2 ml_, 3 mL, 4 mL, or 5 ml_. In some embodiments, a unit dose comprises 1.7 ml_ of the pharmaceutical composition. In some embodiments, a unit dose comprises 4.2 ml_ of the pharmaceutical composition. In some embodiments, a unit dose is in a 5 mL vial

[0097] The pharmaceutical composition of the disclosure can, in some embodiments, be diluted prior to administration For example, a method for preparing a solution for infusion can comprise diluting a liquid pharmaceutical composition with a saline solution, e.g , a 0.9% saline solution. The dilution can be, for example, 2- to 12-fold or 2- to 10-fold, 2- to 4-fold, 7-fold to 9-fold, or 3-fold to 12-fold. In some embodiments, the dilution is 2-fold. In some embodiments, the dilution is 3-fold. In some embodiments, the dilution is 4-fold. In some embodiments, the dilution is 5-fold. In some embodiments, the dilution is 6-fold. In some embodiments, the dilution is 7-fold. In some embodiments, the dilution is 8-fold. In some embodiments, the dilution is 9-fold. In some embodiments, the dilution is 10-fold. In some embodiments, the dilution is 11-fold. In some embodiments, the dilution is 12-fold. In some embodiments, the pharmaceutical composition (from a single unit dose or multiple unit doses) is diluted to a volume of 50 mLto 200 mL, e.g , 150 mL. For example, the pharmaceutical composition can be combined with the appropriate amount of saline solution in an IV infusion bag Accordingly, the disclosure provides an IV infusion bag comprising a diluted liquid pharmaceutical composition as described herein (e.g., comprising a volume of 20 mL to 200 mL of the diluted liquid pharmaceutical composition).6.4. Methods of T reatment

[0098] In one aspect, the disclosure provides methods of treating an adult human subject suffering from BAG3 mutation-associated dilated cardiomyopathy comprising intravenously administering to the subject a rAAV as described herein. The rAAV can be administered, for example, in a dose ranging from 5e11 vg / kg to 4e12vg / kg (e.g., 6e11vg / kg to 3e12vg / kg, 7e11 vg / kg to 2e12vg / kg, 8e11 vg / kg to 1e12vg / kg) or 4e12 vg / kg to 5e13 vg / kg (e.g., 5e12 vg / kg to 5e13 vg / kg, 4e12 vg / kg to 2e13 vg / kg, 4e12 vg / kg to 1.25e13 vg / kg, 6e12 vg / kg to 1 25e13 vg / kg, 6e12 vg / kg to 1e13 vg / kg, 08e13 vg / kg to 1.25e13 vg / kg or 3e13 vg / kg to 5e13 vg / kg). In some embodiments, the dose of the rAAV is 4e12 vg / kg to 1.25e13 vg / kg (e g , 6e12 vg / kg, 7e12 vg / kg, 8e12 vg / kg, 9e12 vg / kg, or 1e13 vg / kg) In some embodiments, the dose of the rAAV is 0.8e13 vg / kg to 1.25e13 vg / kg (e.g., 1e13 vg / kg). In other embodiments, the dose of therAAV is 1e13 vg / kg to 5e13 vg / kg (e.g., 1e13 vg / kg, 2e13 vg / kg, 3e13 vg / kg, or 4e13 vg / kg). In some embodiments, the dose is 9e11 vg / kg. In some embodiments, the dose is 6e12 vg / kg. In some embodiments, the dose is 1e13 vg / kg. In some embodiments, the dose is 4e13 vg / kg.

[0099] The methods typically entail administering the rAAV as a single dose, e g., as a single infusion having a volume of 50 ml_ to 200 ml_, e.g., 150 mL. In some embodiments, a 150 mL infusion volume is administered over two hours. The rAAV can be, for example, formulated as a liquid pharmaceutical composition as described in Section 6.3, and diluted with saline prior to administration, e.g., as described in Section 6.3.

[0100] The methods of treating BAG3 mutation-associated dilated cardiomyopathy can further comprise administering one or more medications for immunomodulation, for example one or more steroids and / or an anti-CD20 antibody such as Rituximab and / or an mTOR inhibitor such as sirolimus.

[0101] In some embodiments, the methods comprise administering a first steroid (e.g., methylprednisolone) and optionally a second steroid (e.g., prednisone or dexamethasone) to the subject. An exemplary administration regimen for methylprednisolone and prednisone is as follows:Administer methylprednisolone prior to rAAV administration on Day 1; administer methylprednisolone again on Day 2 and Day 3;Administer prednisone beginning on Day 3 or Day 4 and administer prednisone daily until at least Day 30.

[0102] Methylprednisolone can be administered by IV (e.g., at a dose of 1 mg / kg to 10 mg / kg). In some embodiments, methylprednisolone is administered by IV at a dose of 10 mg / kg. In some embodiments, methylprednisolone is administered by IV at a dose of 2 mg / kg

[0103] Prednisone can be administered orally (e.g., 1 mg / kg / day, up to a maximum dose of 100 mg or a maximum dose of 60 mg / kg). In some embodiments, administration of an initial dose of prednisone is followed by a taper regimen whereby the dose is reduced, for example by reducing the dose by 5 mg per week until a dose of 2.5 mg once daily is reached. In some embodiments, once the 2.5 mg dose is reached, prednisone is discontinued. In some embodiments, administration of an initial dose of prednisone is followed by a taper regimen whereby the dose is reduced by 5 mg per week until a dose of 5 mg once daily is reached. Once the 5 mg once daily prednisone dose is reached, it can be continued for one week, subsequently reduced to 2.5 mg once daily for one week, then discontinued

[0104] In some embodiments, the treatment methods further comprise administering an anti-CD20 antibody such as Rituximab, for example for a total intravenous dose of 1500 mg / m2. The total dose can be, for example, administered in four individual administrations of 375 mg / m2, e g., on Days -14, -13, -7, and -6, where the rAAV is administered on Day 1. Administration of an anti-CD20 antibody can be preceded by a pretreatment with acetaminophen (e.g., at a dose of 15 mg / kg, up to 1,000 mg) diphenhydramine (e.g., 12.5 mg to 50 mg given orally 30 minutes prior to infusion) and methylprednisolone (e.g., at 10 mg / kg IV)

[0105] In some embodiments, the treatment methods further comprise administering sirolimus, for example at a starting dose of 2 mg once daily starting one week prior to administration of the rAAV followed by dose titration to reach a trough concentration of 4-8 ng / mL. Alternative trough concentrations that can be targeted include 20-30 ng / ml, 16-24 ng / ml, 12-20 ng / ml, 10-20 ng / ml, and 5-15 ng / ml. In some embodiments, administration of sirolimus is discontinued after three months.

[0106] In some embodiments, the treatment methods comprise administering the rAAV and medications for immunomodulation as described in Example 16.

[0107] In some embodiments, the subject is male (e.g., a male aged 18-65, or 18-60, 18-55, or 18-50). In other embodiments, the subject is female (e.g., a female aged 18-65, or 18-60, 18-55, or 18-50)

[0108] In some embodiments, the subject has a truncating BAG3 mutation, for example, as set forth in Table ATable AGenomic position Coding DNA reference Protein rs (NM_004281.3) reference(NP 004272.2)g.121411259_ p.Gly25Argfs*3 rs7723512 121411260insC c.72_73insC 3 08 g 121411295G>A c 108G>A p.Trp36* - g.121411356_121411358delGAG g.121411356_121411358delGAG p.Glu57Lysfs*1insAA insAA 54 - g.121411360delG c.173delG p.Gly58Alafs*1531-g.121429543C>T c.361C>T p.Arg121* -g 121429549C>T c 367C>T p.Arg123* rs387906875 g.121429564_p.Ala128Glufs* 121429565insAG c.382_383insAG 84 - g.121429590_121429596delACCp.Pro137Glyfs*TOTG c 408_414delACCTCTG 72 - g.121429639C>T c.457C>T p.Gln153* -g.121431790dupT c.531dup p.Asp178*g.121431986delC c.727delC p.His243Thrfr*64 - g.121432080C>A c.821C>A p.Ser274* - g.121432162delG c.903delG p.Arg301 Serfs*6 -g.121435991C>T c.925C>T p.Arg309* rs869248137g 121436093delC c 1027delC p.Arg343Alafs -Table AGenomic position Coding DNA reference Protein rs (NM_004281.3) reference(NP 004272.2) g.121436121delG c.1055delG p.Gln353Argfs*10 - g.121436153G>T c.1087G>T p.Glu363*2-g.121436200delG c.1135delG p.Gly379Alafs*45 -p.Ser385Glnfs* g.121436218_ c.1153_1160 del 5612143625del -g.12143271delC c.1205delC p.Pro402Leufs*22 -g.121436367_121436378 c.1300_1309dupGGG p.Gln437Argfs* dupGGGCTGGAGC CTGGAGC 10 -g.121436382_ c.1316_1317delTA p.Val439Glyfs* 121436383delTA 4 - g 121436419C>A 01353OA p.Tyr451* - Deletion ofg.121431768_121436795del c.508_1728del exons 3 and 4(17990 bp) g.121431765A>G c.508-2 A>G N / A -

[0109] In some embodiments, the truncating mutation is c.746C>A or c.925C>T. Truncating mutations are described in Chami et al., 2014, Canadian Journal of Cardiology 30:1655-1661 and Dominguez et al., 2018 JAAC 72(20):2471-2481, the contents of which are incorporated herein by reference in their entireties.

[0110] In some embodiments, the subject has symptomatic BAG3 mutation-associated dilated cardiomyopathy.

[0111] In some embodiments, the subject has a LVEF that is less than 50%, less than 45%, or less than 40%, optionally as measured by MRI or echocardiogram.

[0112] In some embodiments, the subject’s dilated cardiomyopathy is classified as New York Heart Association (NYHA) Class I. In other embodiments, the subject’s dilated cardiomyopathy is classified as New York Heart Association (NYHA) Class II. In other embodiments, the subject’s dilated cardiomyopathy is classified as New York Heart Association (NYHA) Class III In other embodiments, the subject’s dilated cardiomyopathy is classified as New York Heart Association (NYHA) Class IV.

[0113] In some embodiments, the subject has sinus or paced rhythm and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 150 pg / mL, > 200 pg / mL, > 250 pg / mL, or > 300 pg / mL.

[0114] In some embodiments, the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 400 pg / mL, > 450 pg / mL, > 500 pg / mL, > 550 pg / mL, or > 600 pg / mL.

[0115] In some embodiments, the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is s 400 pg / mL, s 450 pg / mL, s 500 pg / mL, s 550 pg / mL, or > 600 pg / mL.

[0116] In some embodiments, the subject’s BMI is < 35 kg / m2

[0117] In some embodiments, the subject’s body weight is less than 100 kg. In some embodiments, the subject’s body weight is > 100 kg. In some embodiments, the subject’s body weight is <110 kg, <120 kg, <130 kg, or <140.

[0118] In some embodiments, the subject’s ALT or AST is 2 1.3x upper normal level, 1.5x upper normal level, or 2x upper normal level.

[0119] In some embodiments, the subject’s eGFR is s 15 ml_ / min / 1.73m2, s 30 mL / min / 1.73m2, ors 45 ml_ / min / 1.73m2 based on MDRD or CKD-EPI.

[0120] In some embodiments, the subject’s hemoglobin is s 10 g / dL.

[0121] In some embodiments, the subject’s platelet count is s 75,000 / mm3.

[0122] In some embodiments, the subject’s white blood cell (WBC) count is less than 11,000 cells / pl.

[0123] In some embodiments, the subject has not received prior AAV therapy.

[0124] In some embodiments, the subject is negative for neutralizing antibodies against the capsid of the rAAV. In some embodiments, the subject is negative for neutralizing antibodies against the VP1 polypeptide. In some embodiments, the subject is negative for neutralizing antibodies against the VP2 polypeptide. In some embodiments, the subject is negative for neutralizing antibodies against the VP3 polypeptide.

[0125] In some embodiments, the subject has no prior myocardial infarction.

[0126] In some embodiments, the subject has no prior heart transplant.

[0127] In some embodiments, the subject does not have and does not require a left ventricular assist device (LVAD).

[0128] In some embodiments, the subject does not require IV therapy with positive inotropes, vasodilators, or diuretics within 30 days of administration of the rAAV or any adjunct treatment (e.g., anti-CD20 antibody).

[0129] In some embodiments, the subject is able to walk > 100 meter unassisted on baseline 6MWT.

[0130] In some embodiments, the subject, when female, is not pregnant

[0131] In some embodiments, the subject does not have an active viral infection (including human immunodeficiency virus (HIV) or positive serology for hepatitis B or C).

[0132] In some embodiments, the subject has no acute illness requiring hospitalization within 30 days of administration of the rAAV or any adjunct treatment (e g., anti-CD20 antibody).

[0133] In some embodiments, the subject has no known hypersensitivity or contraindication to methylprednisolone, prednisone or other glucocorticosteroids or their excipients.

[0134] In some embodiments, the subject does not have active cancer or a cancer diagnosis within the 5 years prior to administration of the rAAV or any adjunct treatment (e.g., anti-CD20 antibody).

[0135] In some embodiments, the subject has not been treated with an investigational product within 4 weeks prior to administration of the rAAV or any adjunct treatment (e g., anti-CD20 antibody) or within 5 half-lives of the investigational product, whichever is later.

[0136] In some embodiments, the subject meets the inclusion criteria described in Example 16 and does not meet any of the exclusion criteria described in Example 16.

[0137] In further aspects, the disclosure provides rAAV as described herein for use in a method of treating BAG3 mutation-associated dilated cardiomyopathy described herein.7. SPECIFIC EMBODIMENTS

[0138] The present disclosure is exemplified by the specific embodiments below.1. A method of treating an adult human subject suffering from BCL2-Associated Athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy, comprising intravenously administering to the subject a dose ranging from 5e11 vg / kg to 5e13 vg / kg of a recombinant adeno-associated virus (rAAV) comprising:(a) a capsid comprising a VP1 polypeptide having the amino acid sequence of SEQ ID NO:10;(b) a genome comprising:(i) a 5' inverted terminal repeat (ITR);(ii) a CK8e promoter;(iii) a coding sequence for a BAG3 polypeptide;(iv) a posttranscriptional regulatory element;(v) a bovine growth hormone (BGH) polyadenylation signal; and(vi) a 3' ITR.A recombinant adeno-associated virus (rAAV) comprising:(a) a capsid comprising a VP1 polypeptide having the amino acid sequence of SEQ ID NQ:10;(b) a genome comprising:(i) a 5' inverted terminal repeat (ITR);(ii) a CK8e promoter;(iii) a coding sequence for a BAG3 polypeptide;(iv) a posttranscriptional regulatory element;(v) a bovine growth hormone (BGH) polyadenylation signal; and(vi) a 3' ITRfor use in a method of treating an adult human subject suffering from BCL2-Associated Athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy, wherein the method comprises intravenously administering to the subject a rAAV dose ranging from 5e11 vg / kg to 5e13 vg / kg.The method of embodiment 1 or rAAV for use according to embodiment 2, wherein the capsid further comprises a VP2 polypeptide having the amino acid sequence of SEQ ID NO:20. The method or rAAV for use according to any one of embodiments 1 to 3, wherein the capsid further comprises a VP3 polypeptide having the amino acid sequence of SEQ ID NO:21. The method or rAAV for use according to any one of embodiments 1 to 4, wherein the 5' ITR comprises the nucleotide sequence of SEQ ID NQ:600.The method or rAAV for use according to any one of embodiments 1 to 5, wherein the CK8e promoter comprises the nucleotide sequence of SEQ ID NQ:302The method or rAAV for use according to any one of embodiments 1 to 6, wherein the BAG3 polypeptide comprises the amino acid sequence of SEQ ID NQ:100.The method or rAAV for use according to any one of embodiments 1 to 7, where the coding sequence for the BAG3 polypeptide comprises the nucleotide sequence of SEQ ID NQ:102. The method or rAAV for use according to any one of embodiments 1 to 8, wherein the posttranscriptional regulatory element comprises the nucleotide sequence of SEQ ID NQ:400. The method or rAAV for use according to any one of embodiments 1 to 9, wherein the BGH polyadenylation signal comprises the nucleotide sequence of SEQ ID NQ:401.The method or rAAV for use according to any one of embodiments 1 to 10, wherein the 3' ITR comprises the nucleotide sequence of SEQ ID NO:608The method or rAAV for use according to any one of embodiments 1 to 11 , wherein the genome comprises the nucleotide sequence of SEQ ID NO:810.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 4e12 vg / kg to 5e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 5e11 vg / kg to 4e12vg / kg.-zz-The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 6e11 vg / kg to 3e12vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 7e11 vg / kg to 2e12vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 8e11 vg / kg to 1e12vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 9e11 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 5e12 vg / kg to 5e13 vg / kgThe method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 4e12 vg / kg to 2e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 4e12 vg / kg to 1.25e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 6e12 vg / kg to 1.25e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 6e12 vg / kg to 1e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 8e12 vg / kg to 1 25e13 vg / kgThe method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 4e12 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 5e12 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 6e12 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 7e12 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 8e12 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 9e12 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 1e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 1e13 vg / kg to 5e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 1e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 2e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 3e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 3e13 vg / kg to 5e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 12, wherein the dose of the rAAV is 4e13 vg / kg.The method or rAAV for use according to any one of embodiments 1 to 37, wherein the rAAV is administered as a single dose.The method or rAAV for use according to any one of embodiments 1 to 38, wherein the rAAV is formulated as a liquid pharmaceutical compositionThe method or rAAV for use according to embodiment 39, wherein the liquid pharmaceutical composition is at a pH of 6.5 to 7.5 (e g., 7.0) and comprises 2.7mM KCI, 1.5mM KH2PO4, 172mM NaCI, 8.1mM Na2HPO4, 250mM L-Arginine, and 0.005% (w / v) poloxamer 188 (e.g., Pluronic® F68).The method or rAAV for use according to embodiment 39 or embodiment 40, wherein the liquid pharmaceutical composition comprises 1e13 vg / mLto 2e14 vg / mL of the rAAV.The method or rAAV for use according to embodiment 39 or embodiment 40, wherein the liquid pharmaceutical composition comprises 5e13 vg / mLto 2e14 vg / mL of the rAAV.The method or rAAV for use according to any one of embodiments 39 to 42, wherein the liquid pharmaceutical composition comprises 1e14 vg / mL of the rAAV.The method or rAAV for use according to any one of embodiments 39 to 43, wherein the liquid pharmaceutical composition is in a unit dose of 1 ,7e14 vg per vial.The method or rAAV for use according to embodiment 39 or embodiment 40, wherein the liquid pharmaceutical composition comprises 2e13 vg / mLto 5e13 vg / mL of the rAAV.The method or rAAV for use according to embodiment 39 or embodiment 40, wherein the liquid pharmaceutical composition comprises 2.2e13 vg / mL to 2.8e13 vg / mL of the rAAV.The method or rAAV for use according to embodiment 45 or 46, wherein the liquid pharmaceutical composition comprises 2.5e13 vg / mL of the rAAV.The method or rAAV for use according to any one of embodiments 45 to 47, wherein the liquid pharmaceutical composition is in a unit dose of 9e13 vg per vialThe method or rAAV for use according to any one of embodiments 39 to 48, wherein the liquid pharmaceutical composition is diluted prior to administration.The method or rAAV for use according to embodiment 49, wherein the liquid pharmaceutical composition is diluted to a volume of 50 ml_ to 200 ml_ prior to administration.The method or rAAV for use according to embodiment 50, wherein the liquid pharmaceutical composition is diluted to a volume of 150 mL prior to administration.The method or rAAV for use according to any one of embodiments 49 to 51 , wherein the liquid pharmaceutical composition is diluted with saline.The method or rAAV for use according to embodiment 51 , wherein the saline is a 0.9% saline solution.The method or rAAV for use according to any one of embodiments 49 to 53, wherein the liquid pharmaceutical composition is diluted 2- to 12-fold prior to administration.The method or rAAV for use according to any one of embodiments 49 to 53, wherein the liquid pharmaceutical composition is diluted 2- to 10-fold prior to administration.The method or rAAV for use according to any one of embodiments 49 to 53, wherein the liquid pharmaceutical composition is diluted 3- to 12-fold prior to administration.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 2-fold to 4-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 7-fold to 9-foldThe method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 3-fold to 8-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 2-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 3-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 4-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 5-foldThe method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 6-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 7-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 8-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 9-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 10-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 11-fold.The method or rAAV for use according to embodiment 54, wherein the liquid pharmaceutical composition is diluted 12-fold.The method or rAAV for use according to any one of embodiments 1 to 70, wherein the rAAV is administered as an infusion.The method or rAAV for use according to embodiment 69, wherein the infusion comprises administering a volume of 50 ml_ to 200 ml_ to the subject.The method or rAAV for use according to embodiment 72, wherein the infusion comprises administering a volume of 150 mL to the subjectThe method or rAAV for use according to any one of embodiments 71 to 73, wherein the rAAV is administered over two hours (e.g., by administering a volume of 150 mL over two hours) The method or rAAV for use according to any one of embodiments 1 to 74, wherein the method further comprises administering a first steroid and optionally a second steroid to the subject. The method or rAAV for use according to embodiment 75, wherein the first steroid is administered in multiple doses.The method or rAAV for use according to embodiment 76, wherein the first dose of the first steroid is administered prior to administration of the rAAV (e.g., on the same day or up to three days prior to administration of the rAAV)The method or rAAV for use according to embodiment 77, wherein the first dose of the first steroid and the rAAV are administered on the same day.The method or rAAV for use according to any one of embodiments 73 to 78, wherein the method further comprises administering a second dose of the first steroid.The method or rAAV for use according to embodiment 79, wherein the second dose of the first steroid is administered one day following administration of the rAAV.The method or rAAV for use according to embodiment 79 or embodiment 80, wherein the method further comprises administering a third dose of the first steroid.The method or rAAV for use according to embodiment 81, wherein the third dose of the first steroid is administered two days following administration of the rAAV.The method or rAAV for use according to any one of embodiments 73 to 82, wherein the first steroid is methylprednisolone (e.g., at a dose of 1 mg / kg to 10 mg / kg).The method or rAAV for use according to embodiment 83, wherein the methylprednisolone is administered at a dose of 2 mg / kg.The method or rAAV for use according to embodiment 83, wherein the methylprednisolone is administered at a dose of 10 mg / kgThe method or rAAV for use according to any one of embodiments 83 to 85, wherein the methylprednisolone is administered intravenously.The method or rAAV for use according to any one of embodiments 73 to 86, wherein the method comprises administering a second steroidThe method or rAAV for use according to embodiment 87, wherein the second steroid is first administered at an initial dose.The method or rAAV for use according to embodiment 88, wherein the second steroid is first administered the day of the last dose of the first steroid.The method or rAAV for use according to embodiment 88, wherein the second steroid is first administered the day after the last dose of the first steroid.The method or rAAV for use according to any one of embodiments 88 to 90, wherein the second steroid is administered daily at the initial dose.The method or rAAV for use according to any one of embodiments 88 to 91 , wherein the second steroid is administered at the initial dose until at least 30 days following administration of the rAAV.The method or rAAV for use according to any one of embodiments 88 to 92, which further comprises administering one or more reduced doses of the second steroid.The method or rAAV for use according to any one of embodiments 88 to 93, wherein the second steroid is prednisone.The method or rAAV for use according to embodiment 94, wherein the prednisone is administered orally.The method or rAAV for use according to embodiment 95, wherein the maximum initial dose is up to 100 mg / day.The method or rAAV for use according to embodiment 95, wherein the maximum initial dose is up to 60 mg / dayThe method or rAAV for use according to any one of embodiments 95 to 97, wherein the prednisone is administered at an initial dose of 1 mg / kg / day.The method or rAAV for use according to any one of embodiments 94 to 98, wherein the method further comprises administering a reduced dose of the prednisone in a taper regimen.The method or rAAV for use according to embodiment 99, wherein the taper regimen comprises decreasing the dose of prednisone dose by 5 mg weeklyThe method or rAAV for use according to embodiment 99 or embodiment 100, wherein the prednisone is discontinued after a dose of 25 mg once daily is reached.The method or rAAV for use according to embodiment 99 or embodiment 100, wherein the taper regimen comprises decreasing the dose of prednisone by 5 mg weekly until a dose of 5 mg once daily is reached; administering the 5 mg dose once daily for one week; subsequently administering a 2.5 mg dose once daily for one week; and subsequently discontinuing prednisone administration.The method or rAAV for use according to any one of embodiments 1 to 102, wherein the method further comprises administering an anti-CD20 antibody to the subject.The method or rAAV for use according to embodiment 103, wherein the anti-CD20 antibody is RituximabThe method or rAAV for use according to embodiment 103 or embodiment 104, wherein the anti-CD20 antibody is administered intravenously.The method or rAAV for use according to embodiment 105, wherein the anti-CD20 antibody is administered at a total dose of 1500 mg / m2.The method or rAAV for use according to any one of embodiments 103 to 106, wherein the anti-0020 antibody is administered in 2 administrations.The method or rAAV for use according to any one of embodiments 103 to 106, wherein the anti-0020 antibody is administered in 3 administrations.The method or rAAV for use according to any one of embodiments 103 to 106, wherein the anti-0020 antibody is administered in 4 administrations.The method or rAAV for use according to embodiment 109, wherein the four administrations are on days -14, -13, -7 and -6 prior to administration of the rAAV.. The method or rAAV for use according to any one of embodiments 103 to 110, which comprises pretreating the subject with acetaminophen, diphenhydramine and methylprednisolone.. The method or rAAV for use according to embodiment 111, wherein the maximum dose of acetaminophen is 1,000 mg.. The method or rAAV for use according to embodiment 111 or embodiment 112, wherein the acetaminophen is administered at a dose of 15 mg / kg.. The method or rAAV for use according to any one of embodiments 111 to 113, wherein the diphenhydramine is administered orally at a dose between 12.5 mg and 50 mg prior to administration of the methylprednisolone. They method or rAAV for use according to any one of embodiments 111 to 114, wherein the methylprednisolone is administered intravenously at a dose of 10 mg / kg.. They method or rAAV for use according to any one of embodiments 1 to 115, wherein the method further comprises administering sirolimus to the subject.. The method or rAAV for use according to embodiment 116, wherein the first dose of sirolimus is administered one week prior to administration of the rAAV.. The method or rAAV for use according to embodiment 116 or 117, wherein the sirolimus is administered to the subject once daily.. The method or rAAV for use according to any one of embodiments 116 to 118, wherein the sirolimus is administered to the subject until three months after administration of the rAAV. . The method or rAAV for use according to any one of embodiments 116 to 119, wherein sirolimus is administered at an initial dose of 2 mg.. The method or rAAV for use according to embodiment 120, wherein the dose level is adjusted to reach a trough level of 4-8 ng / mL. The method or rAAV for use according to embodiment 120, wherein the dose level is adjusted to reach a trough level of 20-30 ng / ml.. The method or rAAV for use according to embodiment 120, wherein the dose level is adjusted to reach a trough level of 16-24 ng / ml.. The method or rAAV for use according to embodiment 120, wherein the dose level is adjusted to reach a trough level of 12-20 ng / ml.. The method or rAAV for use according to embodiment 120, wherein the dose level is adjusted to reach a trough level of 10-20 ng / ml.. The method or rAAV for use according to embodiment 120, wherein the dose level is adjusted to reach a trough level of 5-15 ng / ml.. The method or rAAV for use according to any one of embodiments 1 to 126, wherein the subject is male.. The method or rAAV for use according to any one of embodiments 1 to 126, wherein the subject is female.The method or rAAV for use according to any one of embodiments 1 to 128, wherein the subject is 18-65 years old, e.g., 18-60 or 18-55.The method or rAAV for use according to any one of embodiments 1 to 128, wherein the subject is 18-50 years old.The method or rAAV for use according to any one of embodiments 1 to 130, wherein the subject has a truncating BAG3 mutation (e.g., a truncating BAG3 mutation set forth in Table A).The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.72_73insC.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c 108G>AThe method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is g.121411356_121411358delGAGinsAA.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.173delG.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.361C>T.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.367C>T.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c 382_383insAGThe method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.408_414delACCTCTG.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.457C>T.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.531dup.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.727delC.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.821C>A.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.903delG.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.925C>T.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.746C>A.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.1027delC.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.1055delG.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.1087G>T.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.1135delG.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.1153_1160 del.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.1205delC.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c 1300_1309dupGGGCTGGAGC (“GGGCTGGAGC” disclosed as SEQ ID NO: 811) The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.1316_1317delTA.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.13530 A.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.508_1728del.The method or rAAV for use according to embodiment 131, wherein the truncating BAG3 mutation is c.508-2 A>G.The method or rAAV for use according to any one of embodiments 1 to 157, wherein the subject has symptomatic mutation-associated dilated cardiomyopathyThe method or rAAV for use according to any one of embodiments 1 to 158, wherein the subject’s LVEF is less than 50%, optionally as measured by MRI or echocardiogram.The method or rAAV for use according to any one of embodiments 1 to 158, wherein the subject’s LVEF is less than 45%, optionally as measured by MRI or echocardiogram.The method or rAAV for use according to any one of embodiments 1 to 158, wherein the subject’s LVEF is less than 40%, optionally as measured by MRI or echocardiogram.The method or rAAV for use according to any one of embodiments 1 to 161, wherein the subject’s dilated cardiomyopathy is classified as New York Heart Association (NYHA) Class I. The method or rAAV for use according to any one of embodiments 1 to 161, wherein the subject’s dilated cardiomyopathy is classified as New York Heart Association (NYHA) Class II. The method or rAAV for use according to any one of embodiments 1 to 161, wherein the subject’s dilated cardiomyopathy is classified as New York Heart Association (NYHA) Class III. The method or rAAV for use according to any one of embodiments 1 to 161, wherein the subject’s dilated cardiomyopathy is classified as New York Heart Association (NYHA) Class IV The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has sinus or paced rhythm and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is 150 pg / mLThe method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has sinus or paced rhythm and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 200 pg / mLThe method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has sinus or paced rhythm and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 250 pg / mLThe method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has sinus or paced rhythm and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is 300 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 400 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 400 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 450 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 450 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 500 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is s 500 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 550 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 550 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 600 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 165, wherein the subject has atrial fibrillation and the subject’s N-terminal pro-B-type natriuretic peptide (NT-proBNP) blood level is > 600 pg / mL.The method or rAAV for use according to any one of embodiments 1 to 179, wherein the subject’s BMI is < 35 kg / m2.The method or rAAV for use according to any one of embodiments 1 to 180, wherein the subject’s body weight is less than 100 kg.The method or rAAV for use according to any one of embodiments 1 to 180, wherein the subject’s body weight is > 100 kg.The method or rAAV for use according to any one of embodiments 1 to 182, wherein the subject’s body weight is less than 110 kg.The method or rAAV for use according to any one of embodiments 1 to 182, wherein the subject’s body weight is less than 120 kg.The method or rAAV for use according to any one of embodiments 1 to 182, wherein the subject’s body weight is less than 130 kg.The method or rAAV for use according to any one of embodiments 1 to 182, wherein the subject’s body weight is less than 140 kgThe method or rAAV for use according to any one of embodiments 1 to 186, wherein the subject’s ALT or AST is < 1.3x upper normal level.The method or rAAV for use according to any one of embodiments 1 to 186, wherein the subject’s ALT or AST is < 1.5x upper normal level.The method or rAAV for use according to any one of embodiments 1 to 186, wherein the subject’s ALT or AST is 22x upper normal level.The method or rAAV for use according to any one of embodiments 1 to 189, wherein the subject’s eGFR is s 15 mL / min / 1.73m2 based on MDRDThe method or rAAV for use according to any one of embodiments 1 to 189, wherein the subject’s eGFR is > 30 mL / min / 1 73m2 based on MDRDThe method or rAAV for use according to any one of embodiments 1 to 189, wherein the subject’s eGFR is > 45 mL / min / 1.73m2 based on MDRDThe method or rAAV for use according to any one of embodiments 1 to 189, wherein the subject’s eGFR is > 15 ml_ / min / 1.73m2 based on CKD-EPI.The method or rAAV for use according to any one of embodiments 1 to 189, wherein the subject’s eGFR is s 30 mL / min / 1.73m2 based on CKD-EPI.The method or rAAV for use according to any one of embodiments 1 to 189, wherein the subject’s eGFR is s 45 mL / min / 1.73m2 based on CKD-EPI.The method or rAAV for use according to any one of embodiments 1 to 195, wherein the subject’s hemoglobin is > 10 g / dL.The method or rAAV for use according to any one of embodiments 1 to 196, wherein the subject’s platelet count is > 75,000 / mm3.The method or rAAV for use according to any one of embodiments 1 to 197, wherein the subject’s white blood cell (WBC) count is less than 11,000 cells / pl.The method or rAAV for use according to any one of embodiments 1 to 198, wherein the subject has not received prior AAV therapy.The method or rAAV for use according to any one of embodiments 1 to 199, wherein the subject is negative for neutralizing antibodies against the capsid.The method or rAAV for use according to any one of embodiments 1 to 200, wherein the subject has no prior myocardial infarction (to exclude potential ischemic cardiomyopathy)The method or rAAV for use according to any one of embodiments 1 to 201 , wherein the subject has no prior heart transplant.The method or rAAV for use according to any one of embodiments 1 to 202, wherein the subject does not have and does not require a left ventricular assist device (LVAD).The method or rAAV for use according to any one of embodiments 1 to 203, wherein the subject does not require IV therapy with positive inotropes, vasodilators, or diuretics within 30 days of administration of the rAAV or any adjunct treatment (e.g., anti-CD20 antibody).The method or rAAV for use according to any one of embodiments 1 to 204, wherein the subject is able to walk > 100 meter unassisted on baseline 6MWTThe method or rAAV for use according to any one of embodiments 1 to 205, wherein the subject is not pregnant.The method or rAAV for use according to any one of embodiments 1 to 206, wherein the subject does not have an active viral infection (including human immunodeficiency virus [HIV] or positive serology for hepatitis B or C).The method or rAAV for use according to any one of embodiments 1 to 207, wherein the subject has no acute illness requiring hospitalization within 30 days of administration of the rAAV or any adjunct treatment (e.g., anti-CD20 antibody).The method or rAAV for use according to any one of embodiments 1 to 208, wherein the subject has no known hypersensitivity or contraindication to methylprednisolone, prednisone or other glucocorticosteroids or their excipients.The method or rAAV for use according to any one of embodiments 1 to 209, wherein the subject does not have active cancer or a cancer diagnosis within the 5 years prior to administration of the rAAV or any adjunct treatment (e.g., anti-CD20 antibody).The method or rAAV for use according to any one of embodiments 1 to 210, wherein the subject has not been treated with an investigational product within 4 weeks prior to administration of the rAAV or any adjunct treatment (e.g., anti-CD20 antibody) or within 5 half-lives of the investigational product, whichever is laterA liquid pharmaceutical composition in the form of a solution having a pH of 65 to 7.5 and comprising:(a) a recombinant adeno-associated virus (rAAV) comprising:(i) a capsid comprising a VP1 polypeptide having the amino acid sequence of SEQ ID NO:10; and(ii) a genome comprising:(1) a 5' inverted terminal repeat (ITR);(2) a CK8e promoter;(3) a coding sequence for a BAG3 polypeptide;(4) a posttranscriptional regulatory element;(5) a bovine growth hormone (BGH) polyadenylation signal sequence; and (6) a 3' ITR;(b) 2.7mM KOI;(C) 1.5mM KH2PO4;(d) 172mM NaCI;(e) 8.1mM Na2HPO4;(f) 250mM L-Arginine; and(g) 0.005% poloxamer 188 (e.g., Pluronic® F68).The liquid pharmaceutical composition of embodiment 212, wherein the pH is 7.0.The liquid pharmaceutical composition of embodiment 212 or embodiment 213, wherein the capsid further comprises a VP2 polypeptide having the amino acid sequence of SEQ ID NQ:20. The liquid pharmaceutical composition of any one of embodiments 212 to 214, wherein the capsid further comprises a VP3 polypeptide having the amino acid sequence of SEQ ID NO:21. The liquid pharmaceutical composition of any one of embodiments 212 to 215, wherein the 5' ITR comprises the nucleotide sequence of SEQ ID NQ:600.The liquid pharmaceutical composition of any one of embodiments 212 to 216, wherein the CK8e promoter comprises the nucleotide sequence of SEQ ID NO:302.The liquid pharmaceutical composition of any one of embodiments 212 to 217, wherein the BAG3 polypeptide comprises the amino acid sequence of SEQ ID NO: 100.The liquid pharmaceutical composition of any one of embodiments 212 to 218, wherein the coding sequence for the BAG3 polypeptide comprises the nucleotide sequence of SEQ ID NO:102.The liquid pharmaceutical composition of any one of embodiments 212 to 219, wherein the posttranscriptional regulatory element comprises the nucleotide sequence of SEQ ID NQ:400. The liquid pharmaceutical composition of any one of embodiments 212 to 220, wherein the BGH polyadenylation signal comprises the nucleotide sequence of SEQ ID NO:401The liquid pharmaceutical composition of any one of embodiments 212 to 221, wherein the 3' ITR comprises the nucleotide sequence of SEQ ID NO:608.The liquid pharmaceutical composition of any one of embodiments 212 to 222, wherein the genome comprises the nucleotide sequence of SEQ ID NO:810.The liquid pharmaceutical composition of any one of embodiments 212 to 223, wherein the rAAV is at a concentration of 1e13 vg / mL to 2e14 vg / mL.The liquid pharmaceutical composition of any one of embodiments 212 to 223, wherein the rAAV is at a concentration of 5e13 vg / mL to 2e14 vg / mL.The liquid pharmaceutical composition of any one of embodiments 212 to 224, wherein the rAAV is at a concentration of 1e14 vg / mL.The liquid pharmaceutical composition of any one of embodiments 212 to 223, wherein the rAAV is at a concentration of 2e13 vg / mL to 5e13 vg / mL.The liquid pharmaceutical composition of any one of embodiments 212 to 223, wherein the rAAV is at a concentration of 2.2e13 vg / mL to 2.8e13 vg / mL.The liquid pharmaceutical composition of embodiment 227 or embodiment 228, wherein the rAAV is at a concentration of 2.5e13 vg / mL.The liquid pharmaceutical composition of any one of embodiments 212 to 229, which is in the form of a unit dose comprising 0.5-5 mL of the solution.The liquid pharmaceutical composition of any one of embodiments 212 to 229, which is in the form of a unit dose comprising 3-5 mL of the solution.The liquid pharmaceutical composition of any one of embodiments 212 to 230, which is in the form of a unit dose comprising 0.5-2 mL of the solution.The liquid pharmaceutical composition of any one of embodiments 212 to 230, which is in the form of a unit dose comprising 1 mL of the solution.The liquid pharmaceutical composition of any one of embodiments 212 to 230, which is in the form of a unit dose comprising 1 7 mL of the solutionThe liquid pharmaceutical composition of any one of embodiments 212 to 231, which is in the form of a unit dose comprising 4.2 mL of the solution.The liquid pharmaceutical composition of any one of embodiments 212 to 235, for use in the method of embodiment 1 or any one of embodiments 3 to 211.A method of preparing a solution for infusion, comprising diluting the liquid pharmaceutical composition of any one of embodiments 212 to 235 with a saline solution.The method of embodiment 237, wherein the saline solution is an 0.9% saline solution.The method of embodiment 237 or embodiment 238, wherein the liquid pharmaceutical composition is diluted 2- to 12-fold.The method of embodiment 237 or embodiment 238, wherein the liquid pharmaceutical composition is diluted 2- to 10-foldThe method of embodiment 239, wherein the liquid pharmaceutical composition is diluted 2-fold to 4-fold.The method of embodiment 239, wherein the liquid pharmaceutical composition is diluted 7-fold to 9-fold.The method of embodiment 239, The method of embodiment 54, wherein the liquid pharmaceutical composition is diluted 2-fold.The method of embodiment 239 or embodiment 240, wherein the liquid pharmaceutical composition is diluted 3-fold.The method of embodiment 239 or embodiment 240, wherein the liquid pharmaceutical composition is diluted 4-fold.The method embodiment 239 or embodiment 240, wherein the liquid pharmaceutical composition is diluted 5-fold.The method of embodiment 239 or embodiment 240, wherein the liquid pharmaceutical composition is diluted 6-fold.The method of embodiment 239 or embodiment 240, wherein the liquid pharmaceutical composition is diluted 7-fold.The method of embodiment 239 or embodiment 240, wherein the liquid pharmaceutical composition is diluted 8-fold.250. The method of embodiment 239 or embodiment 240, wherein the liquid pharmaceutical composition is diluted 9-fold.251. The method of embodiment 239 or embodiment 240, wherein the liquid pharmaceutical composition is diluted 10-fold.252. The method of embodiment 239, wherein the liquid pharmaceutical composition is diluted 11- fold.253. The method of embodiment 239, wherein the liquid pharmaceutical composition is diluted 12- fold.254. The method of any one of embodiments 237 to 253, wherein the liquid pharmaceutical composition is diluted to a volume of 50 ml_ to 200 ml_255. The method of embodiment 254, wherein the liquid pharmaceutical composition is diluted to a volume of 150 ml_.256. The method of embodiment 254 or embodiment 255, which comprises combining the contents of a plurality of vials comprising the liquid pharmaceutical composition with the saline solution. 257. The method of embodiment 256, wherein liquid pharmaceutical composition and the saline solution are combined in an IV infusion bag.258. An IV infusion bag comprising a diluted liquid pharmaceutical composition obtained or obtainable by the method of any one of embodiments 237 to 257.8. EXAMPLES8.1. Materials and Methods8.1.1. Variant capsid proteins

[0139] A VP1 capsid polypeptide comprising the amino acid sequence of SEQ ID NO:8 is sometimes referred to herein as “Variant 1 a VP1 capsid polypeptide comprising the amino acid sequence of SEQ ID NO:9 is sometimes referred to herein as “Variant 2”; a VP1 capsid polypeptide comprising the amino acid sequence of SEQ ID NO: 10 is sometimes referred to herein as “Variant 3”; and a VP1 capsid polypeptide comprising the amino acid sequence of SEQ ID NO:11 is sometimes referred to herein as “Variant 4 ” SEQ ID NO:8 has a targeting peptide comprising the amino acid sequence of SEQ ID NO:1 (SEQ ID NO:8 also has a peptide segment comprising the amino acid sequence of SEQ ID NO:5); SEQ ID NO:9 has a targeting peptide comprising the amino acid sequence of SEQ ID NO:2 (SEQ ID NO:9 also has a peptide segment comprising the amino acid sequence of SEQ ID NO:6); SEQ ID NQ:10 has a targeting peptide comprising the amino acid sequence of SEQ ID NO:3 (SEQ ID NQ:10 also has a peptide segment comprising the amino acid sequence of SEQ ID NO:7); and SEQ ID NO: 11 has a targeting peptide comprising the amino acid sequence of SEQ ID NO:4 (SEQ ID NO:11 also has a peptide segment comprising the amino acid sequence of SEQ ID NO:7).8.1.2. Murine cKO and KI models of cardiomyopathy8.1.2.1 BAG3 cKO model

[0140] A mouse model of BAG3 haplo-insufficiency that mirrors the observations in patients with heart failure due to BAG3 haplo-insufficiency was generated This model utilizes a cardiac-specificheterozygous (+ / -) deletion in BAG3. Mice with one allele of BAG3 flanked by loxP recombination sites (BAG3fl / +) were crossed with a-MHC-Cre mice to generate conditional KO mice with cardiac-specific haplo-insufficiency (BAG3 cKO+ / ). This mouse model with cardiomyocyte-restricted heterozygous BAG3 expression has been previously characterized and has been reported to show changes in cardiac morphology, function, and gene expression relative to wild type control mice and reflect the impact of BAG3 haplo-insufficiency on dilated cardiomyopathy (Myers et al., 2018 J Cell Phsiol. 233(9):6319-26; Fang et al., 2017, J Clin Invest. 127(8):3189-200; Myers et al., 2018 JAMA Cardiol. 3( 10): 929-38; Wang et al., 2023, JACC Basic Transl Sci. 8(7):820-39).8.1.3. Murine myocardial infarction (Ml) model

[0141] Myocardial infarction (Ml) was surgically induced in mice by a distal ligation of the left anterior descending (LAD) coronary artery creating sustained ischemia and infarction in the LV anterior wall. Cardiac infarction was confirmed by weekly echocardiography. Six weeks following surgery, when Ml mice showed significantly diminished LV function compared to WT control mice (no surgery), Ml mice received IV injection of rAAV Global LV function was evaluated in all mice after light sedation (2% isoflurane) using a Vevo™ 770 imaging system and a scan head (VisualSonics, Miami, Florida). The left ventricular ejection fraction (LVEF) was calculated using the formula EF% = ([LV end-diastolic volume -LV end-systolic volume] / LV end-diastolic volume) x 100. Fractional shortening (FS) was calculated as FS%= ([LV end diastolic dimension LV end-systolic dimension] / LV end-diastolic dimension) x 100. Ten weeks following study start all animals were sacrificed and heart, quadricep and liver were taken for biochemical and histological analyses8.1.4. Assessment of cardiac function by ultrasound

[0142] Cardiac function was assessed by transthoracic echocardiography using high resolution microimaging systems (Vevo™ F2 LT Preclinical Imaging System, VisualSonics). Briefly, anesthetized spontaneously breathing mice (0.5-3% isoflurane and 98.5-99% O2) were placed in the supine position on a temperature-controlled heating platform to maintain their body temperature at ~37°C. The heating platform also contained electrocardiography (ECG) leads that connect to the animal’s upper and lower paws and measure the animal’s heart rate during recordings For animals 2 weeks of age, due to their size, copper tape was used to extend the ECG leads to their paws. Nair™ was used to remove hair and expose the skin to the probe. Parasternal short-axis M mode tracings of left ventricle (LV) were recorded for LV mass and LV ejection fraction (EF) calculations. For mice at 2 weeks of age, transducer head UHF71x was utilized and for mice s 4 weeks of age transducer head UHF46x was utilized This was due to the size of the heart and frequency required to obtain a clear image. EF was used to determine systolic function, whereas LV mass was used to determine hypertrophy. Vevo™ Lab software was used for analyses.8.1.5. Ultrasound echocardiography analysis

[0143] Analysis of ultrasound measurements was performed utilizing the Vevo™ Lab software. Trained personnel reviewed multiple recordings acquired in M-Mode (4-5) per animal and the recording with the median score for ejection fraction percentage was then selected to move forward for statistical analysis ofall parameters. Recordings were only used if they met the following criteria: papillary muscles are visible and vertically aligned, heart rate between 300-600 bpm, anterior and posterior ventricle walls clearly visible, systole and diastole can be differentiated and clearly seen, and the intraventricular septum (IVS) is not visible. Recordings meeting these criteria were then run using the AutoLV and values for the following parameters were recorded: ejection fraction percentage (EF%), fractional shortening percentage (FS%), left ventricle mass corrected (LVMass cor) left ventricle internal diameter during systole and diastole (LVIDs & LVIDd) Left ventricle mass was additionally calculated as a ratio to bodyweight outside of the Vevo™ Lab software.8.1.6. Biochemical Assessments8.1.6.1 Vector Genome Biodistribution via ddPCR

[0144] Distribution of vector genomes in mouse and nonhuman primate (NHP) tissues (including, but not limited to heart, liver, quadriceps, and liver) were analyzed by using droplet digital PCR (ddPCR; Biorad, Hercules, CA, USA) Briefly, DNA was extracted from different mouse / NHP tissues (QiaAMP™ Fast DNA tissue kit, Qiagen, 51404) and diluted to the same concentration across study samples in nuclease-free water (Invitrogen, AM9937). Diluted DNA was then used to generate thousands of water-oil emulsion droplets using manufacturer recommended protocol (Bio-Rad, 1864101). Duplex PCR amplification was then performed within the water-oil emulsion droplets for vector genome and host-species normalization / housekeeping gene (e.g., RPPrpp30) targets using different fluorescent tags. Droplets were then stratified into positive or negative based on fluorescent signal for respective gene targets (QX200, Bio-Rad, 1864003). Concentration of positive droplets as a function of total droplets in ddPCR reaction was used to calculate vector genomes biodistribution per diploid genome. Primer and probe sets used for vector genome biodistribution ddPCR assay detect coding region of the transgene (e.g., BAG3) or regulatory element (e.g., OPRE) within the transgene and the host-RPP30 gene for normalization.8.1.6.2 Transgene Expression Assessment via RT -ddPCR

[0145] Expression of transgenes in various mouse and nonhuman primate (NHP) tissues (including, but not limited to heart, liver, quadriceps, and liver) were analyzed by Bio-Rad One-Step reverse transcription Droplet Digital™ PCR (RT-ddPCR; Bio-rad, Hercules, CA, USA). Droplet Digital™ PCR uses TaqMan™ technology to generate a fluorescent signal when PCR occurs across a specific target amplicon. Briefly, RNA was extracted from different mouse / NHP tissues (RNeasy kit, Qiagen, 74104) and diluted to the same concentration across study samples in nuclease-free water (Invitrogen, AM9937), followed by DNase treatment (Thermoscientific, AM1907). Diluted RNA was then used to perform RT-ddPCR using the One-step Reverse transcription ddPCR (RT-ddPCR) Advanced kit (Bio-Rad, 1864021) followed by generation of thousands of water-oil emulsion droplets using manufacturer recommended protocol (BioRad, 1864101). Duplex ddPCR amplification was then performed within the water-oil emulsion droplets for transgene and host-species normalization / housekeeping gene (e.g., RPPrpp30) targets using different fluorescent tags. Droplets were then stratified into positive or negative based on fluorescent signal for respective gene targets (QX200, Bio-Rad, 1864003). Concentration of positive droplets as a function of total droplets in ddPCR reaction was used to calculate relative transgene expression levels.Primer and probe sets used for relative transgene expression assay detect transgene (e.g., BAG3) or regulatory element (e.g. OPRE) within the transgene, and the host-RPP30 RNA for normalization.8.1.6.3 Therapeutic Protein Expression Assessment via ProteinSimple Jess™

[0146] Expression of the therapeutic protein in various mouse and nonhuman primate tissues (including, but not limited to heart, liver, quadriceps, and liver) was analyzed by ProteinSimple Jess™ automated Western Blot. Protein lysate was prepared in RIPA buffer (Abeam, ab156034) with Halt protease and phosphatase inhibitor (Thermo Fisher, 78442), and ~10 ng of total protein was loaded into the ProteinSimple Jess™ automated Western Blot apparatus Proteins were separated using the 12-230kDa Separation Module (ProteinSimple SM-W004). BAG 3 was detected using a Rabbit monoclonal Pan BAG3 antibody (Abeam, ab92309) combined with a Goat anti-Rabbit HRP-conjugated secondary antibody (Protein Simple, DM-001). Peak height for the BAG3 signal normalized to Total Protein were used to generate a semi-quantitative readout of relative protein expression between samples. To normalize protein levels using Jess™, a standard curve was generated using recombinant human BAG3 protein (Novus, NBP1-72276).8.1.7. Immunohistochemistry (IHC)

[0147] Immunohistochemistry was performed on the automated BondRX™ platform (Leica) using 5 pm thick sections of formalin-fixed paraffin-embedded mouse tissues mounted on charged slides. All steps were performed at ambient temperature unless otherwise noted. Slides were baked for 30 minutes at 60°C followed by deparaffinization and epitope retrieval using Bond™ Epitope Retrieval Solution ER1 (Leica) for HA-Tag IHC or Bond™ Epitope Retrieval Solution ER2 (Leica) for Human BAG3 IHC. A peroxide block (Leica) and protein block (Dako) were applied prior to HA-Tag antibody (0.2pg / mL, Cell Signaling Technology, 3724S) or Human BAG3 (0.4pg / mL, abeam, ab246225) incubation for 15 minutes. Detection included Anti-HRP Polymer (Leica) with DAB chromogen (Leica) color development and hematoxylin counterstain (Leica). Upon protocol completion, slides were removed from Bond™ RX, dehydrated in a series of graded alcohols and xylenes, and cover slipped with Micromount (Leica). T o quantify the fraction of % positive cells in the heart, individual scores were assigned for each heart section for both 10 and 20X magnification fields of view (FOV). These included 2 FOV of the inner left ventricular free wall containing papillary muscle (P1, P2), 3 FOV of the outer left ventricular free wall (LV1, LV2, LV3), 2 FOV centered on the interventricular septum (IVS1, IVS2) and 3 FOV of the right ventricular free wall (RV1 , RV2, RV3). Individual FOV scores and individual and group means were recorded.8.1.8. Hematoxylin and Eosin (H&E) Stain

[0148] 5 pm thick sections of formalin-fixed paraffin-embedded mouse tissues mounted on charged slides were deparaffinized in xylene and then hydrated through graded alcohols into water. Slides were then put in Carazzi’s hematoxylin, washed in tap water, and placed into 95% ethanol Then, slides were put in eosin-phloxine solution and ran through graded alcohols to xylene. After, stained slides were cover slipped using Permount™.8.1.9. Masson’s T richrome Stain

[0149] 5 m thick sections of formalin-fixed paraffin-embedded mouse tissues mounted to charged slides were deparaffinized in xylene and then hydrated through grade alcohols into water. Bouin's solution was used as a mordant After Bouin's, the slides were rinsed well before transferring to Weigert's hematoxylin. Next, they were placed in Biebrich scarlet / acid fuchsin, followed by phosphomolybdic acid. The slides were stained with aniline blue before dehydrating with graded alcohol alcohols, clearing with xylene, and cover slipping with Permount.8.1.10. In situ hybridization (ISH)

[0150] OPRE ISH was completed on heart sections mounted on charged slides using RNAscope™ assay (Advanced Cell Diagnostics) and OPRE probe (ACD, cat#518628) on a BondRX™ autostainer (Leica Microsystems) according to manufacturer guidelines

[0151] Whole hearts were surveyed at 100x (10x objective) to assess distribution of OPRE ISH staining.50% of each area (left ventricle, right ventricle, interventricular septum) was evaluated at 200x and assigned to a semiquantitative increment of 5% total OPRE ISH positive cardiomyocytes (final value for each region is between 0-100).8.2. Example 1 : Cardiotropic AAV Vector Encoding BAG3 in a Mouse Model of Myocardial Infarction

[0152] This Example describes a study with a rAAV having a capsid with significantly improved cardiac transduction and robust liver detargeting compared to wild-type AAV9. The study employed a mouse model of myocardial infarction (Ml) with diminished left ventricular (LV) function and employed B-cell lymphoma 2 (Bcl-2) associated anthanogene-3 (BAG3) as a therapeutic transgene.8.2.1. Materials and Methods8.2.1.1 Construct Design and Myocardial Infarction Model

[0153] A rAAV vector having modified capsid proteins with a SAQRGDRGQI targeting peptide (SEQ ID NO:1) in VR III and liver-toggle mutations in VR I (alanine at position 267 and threonine at position 269) (VP1 sequence as set forth in SEQ ID NO:8 (“Variant 1”)) and an encapsidated polynucleotide encoding human BAG3 under the control of an MLC2 promoter was designed and produced. The encapsidated nucleic acid is shown schematically in FIG. 1. The encapsidated nucleic acid included, in the 5’ to 3’ direction, a 5’ ITR, MLC-2 promoter, the BAG3 coding sequence, three hemagglutinin (HA) tags, an optimized posttranscriptional regulatory element (OPRE), a bovine growth hormone (BGH) polyadenylation signal sequence, and a 3' ITR.

[0154] Myocardial infarction (Ml) was surgically induced in mice by a distal ligation of the left anterior descending (LAD) coronary artery creating sustained ischemia and infarction in the LV anterior wall. Cardiac infarction was confirmed by weekly echocardiography. Six weeks following surgery, when Ml mice showed significantly diminished LV function compared to WT control mice (no surgery), Ml mice received IV injection of rAAV at 2e12vg / kg (a dose that led to >70% transduction of the mousemyocardium in unoperated wild type mice in biodistribution studies). Global LV function was evaluated in all mice after light sedation (2% isoflurane) using a Vevo 770 imaging system and a scan head (VisualSonics, Miami, Florida). The left ventricular ejection fraction (LVEF) was calculated using the formula EF% = ([LV end-diastolic volume - LV end-systolic volume] / LV end-diastolic volume) x 100. Fractional shortening (FS) was calculated as FS%= ([LV end diastolic dimension - LV end-systolic dimension] / LV end-diastolic dimension) x 100 Ten weeks following study start all animals were sacrificed and heart, quadricep and liver were taken for biochemical and histological analyses. The study timeline is shown schematically in FIG. 2.8.2.1.2 HA Immunohistochemistry (IHC) Methods

[0155] Protein expression in the heart was assessed 10 weeks post Ml surgery (4 weeks post AAV injection) with IHC using an HA antibody or JESS™ automated western blot (ProteinSimple®, Bio-Techne) using an antibody that recognizes human and mouse BAG3

[0156] Immunohistochemistry was performed on the automated Bond™-RX platform (Leica) using 5 pm thick sections of formalin-fixed paraffin-embedded mouse tissues mounted on charged slides. All steps were performed at ambient temperature unless otherwise noted Slides were baked for 30 minutes at 60 °C followed by deparaffinization and epitope retrieval using Bond™ Epitope Retrieval Solution ER1 (Leica). A peroxide block (Leica) and protein block (Dako) were applied prior to HA-Tag antibody (Cell Signaling Technology, 3724S) incubation for 15 minutes Detection included Anti-HRP Polymer (Leica) with DAB chromogen (Leica) color development and hematoxylin counterstain (Leica) Upon protocol completion, slides were removed from the Bond™-RX, dehydrated in a series of graded alcohols and xylenes, and coverslipped with Micromount™ medium (Leica).8.2.1.3 Therapeutic Transgene Expression (RT-ddPCR)

[0157] Expression of the vector derived transgene in mouse and NHP tissues was analyzed by Bio-Rad One-Step reverse transcription Droplet Digital™ PCR. Droplet Digital™ PCR uses TaqMan™ technology to generate a fluorescent signal when PCR occurs across a specific target amplicon. PCR reactions are divided into thousands of nano-droplets prior to thermal cycling. The presence of fluorescent signal is used to sort droplets into positive and negative groups. Positive droplets are counted in order to determine the number of template molecules in the original sample. Copies of the vector derived transgene transcript are detected by a primer / probe set targeted within the coding region. RPP30 transcripts are quantified in a duplex reaction and transgene expression is reported as a percentage of RPP30 expression.8.2.2. Results

[0158] Histological analysis of heart tissues confirmed the presence of a surgically-induced infarct in all Ml mice with no evidence of test article related safety findings in any tissue analyzed (heart, skeletal muscle and liver). Immunohistochemistry demonstrated transduction of 70% of the myocardium and BAG3 expression throughout the heart with little to no expression in liver or skeletal muscle, (see FIGS.3-5). The rAAV rescued the cardiac functional deficit in Ml mice (FIGS. 6A-6B), with an approximately40% improvement in LV function by echocardiography. Hearts of mice treated with Variant 1 rAAV was associated with 38% increase in ejection fraction three weeks after the rAAV treatment (FIGS. 6C-6D).

[0159] In summary, the rAAV having Variant 1 capsid proteins demonstrated safety and robust therapeutic efficacy in an animal model of cardiac dysfunction at doses significantly lower than previously reported with a rAAV with wild-type AAV9 capsid proteins (Knezevic et al, 2016, J Am Coll Cardiol Basic Trans Science 1 (7):647-656)8.3. Example 2: Efficacy of cardiotropic rAAV having Variant 3 capsid proteins in a murine conditional KO model of BAG dilated cardiomyopathy

[0160] Two rAAV having Variant 3 capsid proteins, one encapsulating a polynucleotide comprising an OPRE and one lacking the OPRE, each further comprising BAG3 transgene under the control of the CK8e promoter were designed and produced Efficacy of constructs with or without OPRE was assessed to determine lowest expression for therapeutic efficacy in a mouse BAG3-cKO model. Mice were injected intravenously (I. v.) with capsids and monitored with ultrasound echocardiography as described in Section 8.1.5, with the first echocardiography assessment taken before the i.v. injection and later at weeks 2, 4, 6, 10, and 14 post-injection (WPI). Treatment details for each group are provided in Table 1.Table 1Group Mouse Capsid Promoter / Regulatory Dose N SEQ ID NO Lineage Transgene Element (vg / kg)1 WT Formulation N / A N / A N / A 10 N / A (C57BL / 6) Buffer only2 cKO Formulation N / A N / A N / A 8 N / ABuffer only3 cKO Variant 3 CK8e / BAG3 OPRE 6.32e11 9 8084 cKO Variant 3 CK8e / BAG3 OPRE 2e12 10 8085 cKO Variant 3 CK8e / BAG3 No OPRE 2e12 10 8096 cKO Variant 3 CK8e / BAG3 No OPRE 2e13 10 809

[0161] Ejection fraction percentage at 2 WPI are shown in FIG. 7A. Differences in percentage of fractional shortening associated with each treatment condition are presented in FIG. 7B. Assessment of treatment condition-related changes to left ventricular posterior wall (LVPW) thickness is shown in FIG.7C. Change in ejection fraction percentage from 0 WPI to 2 WPI is shown in FIG. 7D.8.4. Example 3: Evaluation of a cardiotropic rAAV having Variant 3 capsid proteins in WT mice and in a conditional KO mouse model of BAG dilated cardiomyopathy

[0162] A rAAV having Variant 3 capsid polypeptides and encapsulating a polynucleotide comprising BAG3-3xHA under the control of the MLC-2 promoter was designed and produced. In a first set of assessments, WT mice were injected intravenously (i v ) with the rAAV or buffer and biodistribution of vector genome in heart and liver tissues were assessed as described in Sections 8.1.6.1 at 8 and 28 days post injection. BAG3 RNA expression was assessed as described in Section 8.1 6.2 at 8 and 28 days post injection. Treatment details for each group of mice in the first set of assessments are provided in Table 2A.Table 2AGroup Mouse Capsid Promoter / Evaluation Dose N SEQ ID NO Lineage Transgene Timepoint (vg / kg)(days postinjection)1 WT Formulation N / A 8 N / A 2 N / A (C57BL / 6) Buffer only2 WT Variant 3 MLC2Z 8 2e13 3 806 (C57BL / 6) BAG3-3xHA3 WT Formulation N / A 28 N / A 2 N / A (C57BL / 6) Buffer only4 WT Variant 3 MLC2 / 28 2e13 5 806(C57BL / 6) BAG3-3xHA

[0163] Vector genome levels in the heart and liver at 8 days post injection are shown in FIGS 8A-8B and vector genome levels in the heart and liver at 28 days post injection are shown in FIGS. 8C-8D, respectively BAG3 RNA levels in hearts and livers at 8 days post injection are shown in FIGS. 8E-8F and BAGS RNA expression levels in hearts and livers at 28 days post injection are shown in FIGS. 8G-8H, respectively

[0164] In a second set of assessments, cKO mice and control WT mice were injected intravenously (i.v.) with the rAAV or formulation buffer and monitored with ultrasound echocardiography as described in Section 8.1.5. Biodistribution of vector genome in heart tissues was assessed as described in Section 8.1.6.1. BAG 3 expression was assessed as described in Sections 8.1.6.2 and 8.1.6.3. Percentage HA-positive cells were determined with IHC as described in Section 8.1.7. Treatment details for each group of mice in the second set of assessments are provided in Table 2BTable 2BGroup Mouse Capsid Promoter / T ransgene / Dose N SEQ ID Lineage Regulatory element (vg / kg) NO 1 WT Formulation N / A N / A 6 N / A Buffer only2 cKO Formulation N / A N / A 8 N / A Buffer only3 cKO Variant 3 MLC2-BAG3-3xHA-OPRE 2e13 8 8064 cKO Variant 3 MLC2-BAG3-3XHA-OPRE 2e12 8 8065 cKO AAV9 MLC2-BAG3-3xHA-OPRE 2e13 8 8066 cKO AAV9 MLC2-BAG3-3xHA-OPRE 2e12 8 806

[0165] Ejection fraction percentage at 4 WPI is shown in FIGS. 8I and 8J. Fractional shortening is shown in FIG. 8K. Left ventricular interior diameter and left ventricular posterior wall thickness values are shown in FIGS. 8L and 8M, respectively.

[0166] BAG3 RNA expression and vector genome levels in hearts of mice are shown in FIGS. 8N and 80, respectively BAG3 protein expression is shown in FIG. 8P. BAG3 protein levels assessed by HA-IHC of heart tissues are shown in FIG. 8Q. BAG3-HA protein levels as measured by JESS™ are shown in FIG. 8R.8.5. Example 4: Comparative Evaluation of two cardiotropic rAAV having Variant 3 capsid proteins in WT mice

[0167] Two rAAV having Variant 3 capsid proteins, one encapsulating a polynucleotide encoding BAG3 under the control of the CK8e promoter (see Example 2 in Section 8.3), and the other encapsulating a polynucleotide encoding BAG3 under the control of the MLC-2 promoter (see Example 3 in Section 8.4) were intravenously (i.v ) delivered to WT mice at the dose of 2e13 vg / kg. Eight days post injection, biodistribution of vector genome in heart and liver tissues was assessed as described in Section 8.1.6.1 and BAG 3 RNA expression in heart and liver tissues was assessed as described in Sections 8.1.6.2.

[0168] Levels of vector genome trended higher in hearts of mice treated with the rAAV whose polynucleotide comprised the CK8e promoter (FIG. 9A). Similarly, levels of vector genome trended higher in livers of mice treated with the rAAV whose polynucleotide comprised the CK8e promoter (FIG. 9B). BAG3 mRNA expression was approximately four times higher in hearts of mice treated with the rAAV whose polynucleotide comprised the CK8e promoter as compared to the MLC2 promoter (FIG 90); this effect was not seen in liver (FIG. 9D).8.6. Example 5: Biodistribution of Vector Genome and Expression of BAG3 in Heart of Mice Treated with Cardiotropic rAAV having Variant 1 Capsid Proteins

[0169] A first set of rAAV comprising Variant 1 capsid proteins and encapsulating polynucleotides comprising a BAG3 coding sequence under the control of MLC-2, aMHC, TNNT2-400 or TNNT2-600 promoters were designed. Each of the rAAV was assessed in WT mice at two dose levels, 2e12 vg / kg and 2e13 vg / kg. Biodistribution of vector genome in heart tissues was assessed as described in Section 8.1.6.1. BAG 3 expression was assessed as described in Sections 8.1.6.2 and 8.1.6.3. Percentage HA-positive cells were determined by IHC as described in Section 8.1.7. The results of these assessments are provided in Table 3.Table 3Group N Promoter Dose DNA bioRNA Protein % HA SEQ ID # or distribution Expression Expression positive NO Name (vg / dg) (% of (Fold Cells by Reference) change IHCover WT)1 2 N / A Buffer N / A N / A N / A N / A N / A only2 5 MLC-2 2e12 027 354.9 0.82 <15 806 3 5 aMHC 2e12 03 390.0 0.78 <15 802 4 5 TNNT2- 2e12 800400 04 8299 092 <155 5 TNNT2- 2e12 04 15 801600 07.0 0.97 <156 5 MLC-2 2e13 45 47620.3 1.82 17 806 7 5 aMHC 2e13 32 13556.6 1.70 23 802 8 5 TNNT2- 2e13 800400 47 44728.0 5.15 419 5 TNNT2- 2e13 3 801600 7 45915.8 1.18 39

[0170] A second set of rAAV having Variant 1 capsid proteins and encapsulating a polynucleotide comprising a BAG3 coding sequence were designed. The first rAAV (Native 1) comprised a polynucleotide comprising a BAG35’UTR in addition to a native BAG3 promoter sequence; the second construct (Native 2) comprised a BAG35’ and a 3’ UTR in addition to a native BAG3 promoter sequence; and the third construct (Native 3) comprised a native BAG3 promoter sequence and a BAG35' UTR, a portion of which was deleted. Each rAAV was assessed in WT mice at two dose levels, 2e12 vg / kg and 2e13 vg / kg. Treatment details for each group are provided in Table 4Table 4Group # or Mouse Capsid Promoter / T ransgene / Dose N SEQ Name Lineage Regulatory Element (vg / kg) ID NO1 WT Formulation NA N / A 2 N / A Buffer only2 (Native 1) WT Variant 1 Native Promoter + 5’UTR / 2e12 5 805 low dose Bag3 / OPRE3 (Native 2) WT Variant 1 Native Promoter + 5’UTR + 2e12 5 804 low dose 3’UTR / Bag3 / OPRE4 (Native 3) WT Variant 1 Native Promoter + 5’UTR 2e12 5 803 low dose (deletion) / Bag3 / OPRE5 (Native 1) WT Variant 1 Native Promoter + 5’UTR / 2e13 5 805 high dose Bag3 / OPRE6 (Native 2) WT Variant 1 Native Promoter + 5’UTR + 2e13 5 804 high dose 3’UTR / Bag3 / OPRE7 (Native 3) WT Variant 1 Native Promoter + 5’UTR 2e13 5 803high dose (deletion) / Bag3 / OPRE

[0171] Biodistribution of vector genomes of both the first and second set of rAAV was assessed in heart tissues as described in Section 8 1.6.1 and BAG 3 RNA expression obtained with the first and second set of rAAV was assessed as described in Section 8.1.6.2. Protein expression obtained with two of the rAAV of the second set of constructs was assessed as described in Section 8.1.6.3 Percentage HA-positive cells were determined with IHC as described in Section 8.1.7.

[0172] BAG3 mRNA expression levels for each treatment group were assessed in the heart at two dose levels, 2e12 vg / kg and 2e13 vg / kg. Overall, the level of BAG3 RNA expression was higher when mice were treated with 2e13 (FIG. 10A). Vector genome levels for the 2e12 vg / kg dose resulted lower levels of vector genome in the heart as compared to the 2e13 vg / kg dose (FIG. 10B). BAG3 protein expression in the heart was assessed for Native 1 and Native 2 rAAV constructs against controls with different amounts of BAG3 relative to baseline level of protein (FIGS. 10C-10D). IHC assessments revealed a higher percentage of HA-positive cells in heart of mice treated with rAAV construct comprising Native 2 when compared to those treated with constructs comprising Native 1 or Native 3 at both dose levels (FIGS 10E-10G).8.7. Example 6: Evaluation of Cardiotropic rAAV Comprising Variant 1 Capsid Proteins and Native 2 Polynucleotide in a Mouse Model of Myocardial Infarction

[0173] rAAV comprising Variant 1 capsid polypeptides and encapsulating the “Native 2” polynucleotide as described in Section 8.6 was evaluated in a mouse model of Ml (n=10) as described in Section 8.1.3against mice that had a sham surgery (n=5). Mice were injected intravenously (i.v ) with 2e13 vg / kg of the rAAV (Ml mice) or formulation buffer (sham mice) and monitored with ultrasound echocardiography as described in Section 8.1.5, with the first echocardiography assessment taken two weeks prior to the Ml or sham surgery (FIG. 11 A).

[0174] Biodistribution of vector genomes was assessed in heart tissues as described in Section 81.6.1 and BAG 3 mRNA expression was assessed as described in Section 8.1.6.2. BAG3 protein expression in hearts was assessed as described in Section 8.1.6.3.

[0175] Vector genome and BAG3 mRNA expression are shown in FIGS. 11 B and 110, respectively. FIGS. 11B-11C also include data obtained in WT mice (see Example 3 in Section 8.4), and data from rAAV having Variant 1 capsid proteins and encapsulating polynucleotides having a BAG3 coding sequence operably linked to a MLC2 promoter (see Example 1 in Section 8.2). Protein expression of human BAG3 in hearts of Ml mice is shown in FIG. 11D (Native 2 data is shown for 2e13 vg / kg dose 5 WPI; MLC2 data is shown for 2e12 vg / kg dose 3 WPI)8.8. Example 7: Evaluation of the Safety and Time Course of Expression of Cardiotropic rAAV Comprising Variant 1 Capsid Proteins and Native 2 Polynucleotide in WT Mice

[0176] A study was conducted to evaluate the safety and time course of expression of rAAV comprising Variant 1 capsid proteins and the “Native 2” polynucleotide at two doses (2e13 vg / kg and 1e14 vg / kg) in WT O57BL / 6 mice at 14, 28, and 60 days after i v. delivery. Briefly, mice (N=4 in all groups) were injected intravenously (i.v.) with either 2e13 vg / kg or 1e14 vg / kg rAAV or formulation buffer and monitored for the duration of the assessments until tissue collection. Biodistribution of vector genomes was assessed in heart tissues as described in Section 8.1.6.1 and BAG 3 mRNA expression in heart tissues was assessed as described in Section 8.1.62. BAG3 protein expression in heart tissues was assessed as described in Section 8.1.6.3. Treatment details for each group are provided in Table 5.Table 5Group # or Mouse Capsid Promoter / T ransgene / Dose N SEQ Name Lineage Regulatory Element (vg / kg) ID NO1 WT Formulation NA N / A 4 N / A Buffer only2 WT Variant 1 Native 2 / Bag3 - 3xHA / 2e12 4 804 OPRE3 WT Variant 1 Native 2 / Bag3 - 3xHA / 2e12 4 804 OPRE4 WT Variant 1 Native 2 / Bag3 - 3xHA / 2e12 4 804 OPRE5 WT Variant 1 Native 2 / Bag3 - 3xHA / 2e13 4 804 OPRE6 WT Variant 1 Native 2 / Bag3 - 3xHA / 2e13 4 804 OPRE7 WT Variant 1 Native 2 / Bag3 - 3xHA / 2e13 4 804OPREBAG3 mRNA expression is shown in FIG. 12A. BAG3 protein levels are shown in FIG 12B. Vector genome biodistribution in hearts is shown in FIG. 12C.8.9. Example 8: Evaluation of Cardiotropic rAAV Comprising Variant 4 Capsid Proteins and Polynucleotides Comprising MLC-2 or Native Promoters

[0177] rAAV having Variant 4 capsid proteins and encapsulating polynucleotides comprising either MLC-2 or Native promoters were designed. rAAV were assessed in WT mice at two dose levels, 2e12 vg / kg and 6.32e11 vg / kg. Biodistribution of vector genome in heart tissues was assessed as described in Section 8.1.6.1. Transgene RNA expression in heart tissues was assessed as described in Section 8 1 62 Details of each treatment group are provided in Table 6Table 6Group # or Mouse Capsid Promoter / T ransgene Dose N SEQ ID Name Lineage / Regulatory Element (vg / kg) NO1 WT Formulation NA N / A 4 N / A Buffer only2 WT Variant 4 MLC2-BAG3-3xHA- 2e12 4 806OPRE-bGHpA3 WT Variant 4 MLC2-BAG3-3xHA- 6.32e11 4 806OPRE-bGHpA4 WT Variant 4 Native2-BAG3-3xHA- 2e12 4 804OPRE-bGHpA5 WT Variant 4 Native2-BAG3-3xHA- 6.32e11 4 804OPRE-bGHpA6 WT Variant 4 MLC2-BAG3-3XHA- 2e12 4 806OPRE-bGHpA7 WT Variant 4 MLC2-BAG3-3xHA- 6.32e11 4 806OPRE-bGHpA

[0178] Transgene RNA expression in heart tissues is shown in FIG. 13A. Vector genome biodistribution in heart tissues is shown in FIG. 13B.

[0179] Comparison of BAG3 RNA expression and vector biodistribution data obtained with rAAV having Variant 4 capsid proteins comprising BAG3 transgene under the control of MLC-2 or Native 2 promoters to their Variant 1 rAAV counterparts for the same dose (2e12 vg / kg) showed similar levels for both measures (FIGS. 13C and 13D).8.10. Example 9: Evaluation of Cardiotropic rAAV Comprising Variant 2 Capsid Proteins and Polynucleotide Encoding BAG3 under the Control of a MLC-2 Promoter

[0180] A rAAV having Variant 2 capsid proteins and encapsulating a polynucleotide comprising a BAG3 coding sequence under the control of MLC-2 promoter was designed The construct was assessed in hearts of WT mice at three dose levels, 2e13 vg / kg, 2e12 vg / kg and 632e12 vg / kg, 28 days after i v delivery of the rAAV. Biodistribution of vector genome in heart tissues was assessed as described in Section 8.1.6.1. Transgene RNA expression in heart tissues was assessed as described in Section 8.1.6.2. Details of each treatment group are provided in Table 7.Table 7Group # or Mouse Capsid Promoter / Regulatory Dose N SEQ ID NO Name Lineage Element / T ransgene (vg / kg)1 WT Formulation NA N / A 2 N / ABuffer only2 WT Variant 2 MLC2 - BAG3 - no HA 2e13 5 807- no OPRE3 WT Variant 2 MLC2 - BAG3 - no HA 6.32e12 5 807- no OPRE4 WT Variant 2 MLC2 - BAG3 - no HA 2e12 5 807- no OPRE

[0181] BAG3 mRNA expression increased in a dose-dependent manner (FIG. 14A). Similarly, vector genome level correlated with the dose of the rAAV (FIG. 14B).8.11. Example 10: Comparative Evaluation of Cardiotropic rAAV Comprising Variant 2 and Variant 4 Capsid Proteins in cKO Model of BAG3 Dilated Cardiomyopathy

[0182] A rAAV comprising Variant 2 capsid proteins and a rAAV comprising Variant 4 capsid proteins, each encapsulating a polynucleotide comprising BAG3 under the control of a MLC-2 promoter was assessed in the hearts of BAG3 cKO mice at 2e13 vg / kg with ultrasound electrocardiography as described in Section 8.1.5 at 2-week intervals Biodistribution of vector genome in heart tissues was assessed six weeks after treatment as described in Section 8.1.6.1. Transgene RNA expression in heart tissues was assessed six-weeks after treatment as described in Section 8.1.6.2. Details of each treatment group are provided in Table 8.Table 8Group # or Mouse Capsid Promoter / Regulatory Dose N SEQ ID NO Name Lineage Element / T ransgene (vg / kg)1 WT Formulation N / A N / A 7 N / ABuffer only2 cKO Formulation N / A N / A 10 N / ABuffer only3 cKO Variant 4 MLC2 - BAG3 - HA 2e13 11 8064 cKO Variant 2 MLC2 - BAG3 - HA 2e13 11 806

[0183] Two weeks after i.v. delivery, ejection fraction percentage values improved with both rAAV, but returned to baseline levels at six weeks after delivery (FIG. 15A). Similarly, fractional shortening percentage values for both constructs increased initially and returned to baseline levels at six weeks after delivery (FIG. 15B). Cardiac structural endpoints (LV mass and wall diameter) showed slower progression to dilation with rAAV (FIGS 15C-15E)

[0184] Vector genome and BAG3 mRNA levels in heart tissues are shown in FIGS 15F and 15G, respectively Both rAAV were associated with an increase in BAG3 protein expression relative to controls; however, BAG3 protein expression was higher in hearts of mice treated with rAAV comprising Variant 4 capsid proteins (FIGS. 15H-15K).8.12. Example 11: In Vitro assessment of BAG3 protein production

[0185] In the first part of the assessment, BAG3 or GFP protein production was evaluated in C2C12 mouse myoblast cells that were transduced with rAAV comprising a polynucleotide comprising BAG3 or GFP under the control of MLC-2, CK8e, or CBh promoter. The rAAV used in the first and second parts of the assessment are provided in Table 9.Table 9Assessment Group # Variant Transgenepart1 1 Variant 3 / MLC-2 BAG31 2 Variant 3 / CK8e BAG3-HA-OPRE1 3 Variant 1 / CBh BAG3-3xHA-OPRE-BGHpA2 1 Variant 3 / CBh GFP-Luc2 2 Variant 3 / CK8e GFP2 3 Variant 3 / MLC-2 GFP

[0186] BAG3 protein concentration obtained with JESS™ automated western blot and ELISA are shown in FIGS 16A and 16B, respectively. GFP levels obtained by flow cytometry are shown in FIG. 16C

[0187] In the second part of the assessment, iPSC-CM cells were transduced with rAAV comprising Variant 3 capsid proteins comprising BAG3 under the control of MLC-2, CK8e, or CBh promoter. Cells transformed with rAAV comprising Ck8e promoter were associated with higher BAG3 protein expression than those transformed with rAAV comprising MLC-2 promoter (FIGS. 16D and 16E).8.13. Example 12: Evaluation of Cardiotropic rAAVs Having Variant 3 Capsid Proteins in Non-Human Primates

[0188] Two rAAV having Variant 3 capsid proteins, one encapsulating a polynucleotide encoding BAG3 under the control of a CK8e promoter (see Example 2 in Section 8.3), and the other encapsulating a polynucleotide encoding BAG3 under the control of a MLC-2 promoter (see Example 3 in Section 8.4) were intravenously (i.v ) delivered to adult cynomolgus macaques at the assigned doses. Four weeks after the injections, biodistribution of vector genome in heart, quadriceps and liver tissues was assessed as described in Section 8 1.6.1. BAG 3 RNA expression in heart, quadriceps and liver tissues was assessed as described in Sections 8.1.6.2. BAG3 protein expression in heart, quadriceps and liver tissues was assessed as described in Section 8.1.6.3. Percentage HA-positive cells in heart was determined with IHC as described in Section 8.1.7. The treatment groups used in these assessments are provided in Table 10.Table 10Group # Species Capsid / Transgene Dose N SEQ ID or Name Promoter (vg / kg) NO1 Cynomolgus Variant 3 / MLC- BAG3-3XHA- 5e13 3 806macaque 2 OPRE2 Cynomolgus Variant 3 / Ck8e BAG3-3xHA- 3e13 2*macaque OPRE3 Cynomolgus Variant 3 / Ck8e BAG3-3XHA- 1e13 2 808macaque OPRE* one of the animal subjects was excluded from analyses due to seroconversion prior to dosing.

[0189] Initial results of the vector genome biodistribution and BAG3 RNA expression assessments and BAG3 protein levels obtained with JESS™ automated western blot of the first group are summarized in Table 11 below:Table 11Group 1 Left Right IVIS Atria Liver Quadriceps Assessments ventricle ventricleDNA (VG / DG) 4.70 5.50 3.70 630 525.40 2.80 RNA (%RPPE30) 6.30 6.50 11.70 12.80 451.70 72.30 BAG 3 protein (pg / pl) 205.90 204.90 211.65 146.9 183.4 BAG3 protein foldchange from 0.93 1.10 0.97 1 36 NA NAendogenous

[0190] Results of the IHC assessment of a group 2 animal are shown in FIG. 17. Initial results of the vector genome biodistribution and BAG3 RNA expression assessments and BAG3 protein levels obtained with JESS™ automated western blot of the second group are summarized in Table 12 below:Table 12Group 2 Left Right IVIS Atria Liver Quadriceps Assessments ventricle ventricleDNA (VG / DG) 1.04 2.7 0.99 43 238RNA (%RPPE30) 108 54 180 94BAG 3 protein (pg / pl) 210.9 192.4 223.2 87.5BAG3 protein foldchange from 2 2.2 1.9 45 NA NAendogenous

[0191] Results of the IHC assessment of two group 3 animals are shown in FIG. 18. Initial results of the vector genome biodistribution and BAG3 RNA expression assessments and BAG3 protein levels obtained with JESS™ automated western blot of the third group are summarized in Table 13 below:Table 13Group 3 Left Right IVIS Atria Liver Quadriceps Assessments ventricle ventricleDNA (VG / DG) 1.4 1.5 1.0 1 6 96RNA (%RPPE30) 506 573BAG 3 protein (pg / pl) 2783 151 221 585BAG3 protein foldchange from 2.5 1.8 1.8 30endogenous8.14. Example 13: Phase 1 / 2 Multicenter, Open-Label, Dose-Escalation and Dose- Expansion Trial to Assess the Safety, Tolerability, Pharmacodynamics, and Preliminary Efficacy of AFF-01 Administered to Adult Participants with BCL2- Associated Athanogene 3 (BAG3) Mutation-Associated Dilated Cardiomyopathy 8.14.1. Overview

[0192] The purpose of this study is to measure safety and benefits to the heart with AFF-01 gene therapy infused through an IV in participants with heart disease and having BAG3 mutations AFF-01 is an rAAV gene therapy comprising Variant 3 capsid polypeptides (VP1 of SEQ ID NO:10 and VP2 and VP3 portions thereof), a CK8e promoter, and a full-length human BAG3 transgene. The rAAV genome comprises the nucleotide sequence set forth in SEQ ID NO:810.

[0193] The nonclinical data presented in the foregoing Examples have shown that the Variant 3 capsid is superior to conventional AAV9 capsid on cardiomyocyte transduction, and vector constructs with Variant 3 and human BAG3 transgene efficiently transduce mice and NHP cardiomyocytes and reverses the functional cardiac phenotype in BAGS cKO+Amice in a dose dependent manner.

[0194] The study has three cohorts and a duration of up to 5 years. The treatment is a one-time treatment through an IV. The visit frequency is every day for the first week, then at Day 10, and then at week 2, 3, 4, and 6, month 2, 3, 6, 9 and 12 and then yearly from year 2 to 5. A schema for the study is shown in FIG. 19.

[0195] A schedule of assessments for the first two cohorts is shown in Table 14. A schedule of assessments for the third cohort is shown in Table 15.Table 14Procedure Screening3PreBaseline, AFF-01 Administrationbaseline15and Immediate Follow UpStudy Visit Week 1 W2 W3 W4 W6 W8 W12 W26 W36 W52 WeekStudy D1 D2 D3 D4 D5 D6 D7 D10 D14 D21 D28 D42 2IVI 3M 6M 9M* 12M Day / MonthVisit Window (± 2 2 5 5 7 7 14 30 30 30 days)InformedConsent XReview Inclusionand Exclusion XCriteriaBAG3 DiagnosisGenotype XMedical History X X X X X ConcomitantMedications / X X X X X X X X X X X X X X X X X X X ProceduresAE Assessment X X X X X X X X X X X X X X X X X X X Height X X X Weight X X X X X X X X X X X X X CompletePhysical Exam X X X X X X Abbreviated PE X X X X X X X X X X X XVital Signs0X X X X X X X X X X X X X X X X X X 6MWT XTable 14Procedure Screening3PreBaseline, AFF-01 Administrationbaseline15and Immediate Follow UpStudy Visit Week 1 W2 W3 W4 W6 W8 W12 W26 W36 W52 WeekStudy D1 D2 D3 D4 D5 D6 D7 D10 D14 D21 D28 D42 2IVI 3M 6M 9M* 12M Day / MonthVisit Window (± 2 2 5 5 7 7 14 30 30 30 days)AFF-01Administration X(IV)HospitalAdministration &Discharge* Per X XPi’s discretionlmmunomodulationdMethylX X X Xprednisolone IVsOral X X X X X X X X X X X Corticosteroids’Rituximabs XSirolimushX X X X X X X X X X X X X X XLaboratory TestsPregnancy Test XHepB / HepC / HIV XSerologySerum AntiXVariant 3 NAbTable 14Procedure Screening3PreBaseline, AFF-01 Administrationbaseline15and Immediate Follow UpStudy Visit Week 1 W2 W3 W4 W6 W8 W12 W26 W36 W52 WeekStudy D1 D2 D3 D4 D5 D6 D7 D10 D14 D21 D28 D42 2IVI 3M 6M 9M* 12M Day / MonthVisit Window (± 2 2 5 5 7 7 14 30 30 30 days)Hematology X X X X X X X X X X X X X X Chemistry X X X X X X X X X X X X X X LFT X X X X X X X X X X X X X X CPK and X X X X X X X X X X X X hsTroponin ILipid Panel X X X X X X X X Coagulation: X X X X X X X X X X X X X PT / PTT / D-dimer,FibrinogenComplement X X X X X X X X X X X X XLabs: C3, C4,SC5b-9CRP, TNFa, IL-6 X X X X X X X X X X X X X ELISPOT X1X X X X X X X Urinalysis X X X X X X X X X X X X XVector DNA X X X X X X X X X X Shedding: urine,saliva, feces'Table 14Procedure Screening3PreBaseline, AFF-01 Administrationbaseline15and Immediate Follow UpStudy Visit Week 1 W2 W3 W4 W6 W8 W12 W26 W36 W52 WeekStudy D1 D2 D3 D4 D5 D6 D7 D10 D14 D21 D28 D42 2IVI 3M 6M 9M* 12M Day / MonthVisit Window (± 2 2 5 5 7 7 14 30 30 30 days)Serum AntiX X X X X X Variant 3 capsidantibodiesSerum transgene X X X X X X antibodiesSkeletal muscle X X X X X biopsyjCardiac AssessmentsEndomyocardial X X X biopsykCardiac X X X X X X X X biomarkers(NT-proBNP)Echocardiogram X X X X X X Cardiac MRI X X X CPET (pVO2) X X X X NYHA Class X X X X X X X KCCQ-23 X X X X X X 12-lead ECG X X X X X X X X X XTable 14Procedure Screening3PreBaseline, AFF-01 Administrationbaseline1’ and Immediate Follow UpStudy Visit Week 1 W2 W3 W4 W6 W8 W12 W26 W36 W52 WeekStudy D1 D2 D3 D4 D5 D6 D7 D10 D14 D21 D28 D42 2IVI 3M 6M 9M* 12M Day / MonthVisit Window (± 2 2 5 5 7 7 14 30 30 30 days)D=day; W=week; M=months; X: Denotes an on-site visit.D=day; W=week; M=months; X: Denotes an on-site visit.Patients complete daily outpatient visits after D1 (D2-D7)‘virtual visita The screening period lasts up to 12 weeks. Procedures may occur over the course of several days during the screening period. The decision as to the duration of each visit is at the discretion of the PI and is based on availability of the subject, required site staff, and / or overall burden on the subject Subjects are not hospitalized overnight during the screening unless deemed necessary.b Pre-baseline visit is completed once eligibility of the participant has been confirmed and an enrollment number issued. The pre-baseline visit is completed before the immunomodulation is initiated (ie, before visit Day -14)c Vital signs are monitored frequently, including assessments every 15 minutes (± 5 minutes) for 1 hour, every 30 minutes for 2 hours, every 1 hour for 2 hours, and then every 2-4 hours for the remainder of the first 24 hours following the infusion and can be extended at the discretion of the investigator d Immunomodulation is started after baseline procedures are complete and prior to AFF-01 administration.e Methylprednisolone IV is used for the Pretreatment of Rituximab. It is administered as 10 mg / kg IV on Day 1 (pre-dose), Day 2 and Day 3f Oral prednisone (1 mg / kg / day with maximum dose of 100 mg / day) beginning on Day 4 and continuing until Day 30. Prednisone taper begins at the discretion of the Investigator on Day 31. The standard taper regimen is to decrease the oral prednisone dose by 5 mg weekly until a dose of 2.5 mg once daily after which it is discontinued. Prednisone taper may be accelerated or extended at the investigator’s discretion depending on the participant’s clinical response. Increased doses of steroids (e.g., pulse steroid dosing) may be considered for signs of autoimmune organ injury or potentially AAV related transaminase elevations If prednisone is not available or not tolerated, an equivalent potency glucocorticosteroid (e.g., dexamethasone) may be substituted.g Rituximab 1500 mg / m2 IV, divided in multiple doses The dosing regimen is at the discretion of the investigator. Standard regimen is to divide into 4 doses, as a dose of 375 mg / m2 on Day -14, -13, -7 and -6 prior to infusion of AFF-01Table 14Procedure Screening3PreBaseline, AFF-01 Administrationbaseline1’ and Immediate Follow UpStudy Visit Week 1 W2 W3 W4 W6 W8 W12 W26 W36 W52 WeekStudy D1 D2 D3 D4 D5 D6 D7 D10 D14 D21 D28 D42 2IVI 3M 6M 9M* 12M Day / MonthVisit Window (± 2 2 5 5 7 7 14 30 30 30 days)•Standard pretreatment for each rituximab dose include: Acetaminophen 15 mg / kg (maximum 1,000 mg), Diphenhydramine 125 mg to 50 mg PO, 30 min prior to infusion, and Methylprednisolone 10 mg / kg ivh Sirolimus 2 mg orally once daily starting Day -7 prior to infusion of AFF-01. The dose of sirolimus to be adjusted targeting a trough level of 4-8 ng / mL. In settings of hepatic or renal impairment, dose of sirolimus may be reduced to maintain trough targets. After initiation (and after any changes), trough levels of sirolimus are assessed approximately weekly. Once on a stable regimen of sirolimus, trough levels may be checked less frequently at the discretion of the investigator. Sirolimus to be discontinued on Day 90. If there is evidence of active host immune response to AFF-01 , the sirolimus regimen may be continued for up to another 30 days.i Viral vector shedding is tested until 2 consecutive results are below lower limit of detection or when the vector levels have plateaued at low or negligible level.j Skeletal muscle biopsy may be performed -30 days from baseline visit to accommodate scheduling Baseline biopsy is performed prior to initiation of immunosuppression regimen on -D14. 2 and 3 month biopsies are performed ± 14 days. 12-month biopsy is performed ± 30 daysk Endomyocardial biopsy is performed -30 days from baseline visit to accommodate scheduling. Baseline biopsy is performed prior to initiation of immunosuppression regimen on -D14. 3 month biopsy should be performed + 14 days. 12-month biopsy can be performed ± 30 daysI ELISPOT is performed prior to initiation of immunosuppression (ideally D-15) for D1 visitAbbreviations:AE=adverse event; CPK=creatine phosphokinase; ECG=electrocardiogram; ELISpot=enzyme-linked immunospot; F / U=follow-up; HepB=hepatitis B; HepC=hepatitis C; HIV=human immunodeficiency virus; LFTs=liver function tests; MRI=magnetic resonance imaging; Nabs=neutralizing antibodies; Pl=principal investigatorTable 15Scree 6-month PreBaseline & AFF-01Procedure n-ingaobservation baselin Administrational run in ebStudy Visit Week 1 W2 W3 W4 W6 W8 W1 W2 W36 W5 Week 2 6 2 Study -6M -1 M D D D D D D D D1 D1 D2 D2 D4 2M 3IVI 6M 9M* 12 Day / Month 3M 1 2 3 4 5 6 7 0 4 1 8 2 M ±14 ±14 ±7 days ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window days day day day day day day day day day days day s s s s s s s s s s Informed XConsentReview XInclusion andExclusionCriteriaBAG3 XDiagnosisGenotypeMedical X X X X X X HistoryConcomitant X X X X X X X X X X X X X X X X X X X X X Medications / ProceduresAE X X X X X X X X X X X X X X X X X X X X XAssessmentHeight X X X X Weight X X X X X X X X X X X X X X X Complete X X X X X X Physical ExamAbbreviated PE X X X X X X X X X X X X X XVital Signs0X X X X X X X X X X X X X X X X X X X X6MWT XTable 15Scree 6-month PreBaseline & AFF-01Procedure n-ingaobservation baselin Administrational run in ebStudy Visit Week 1 W2 W3 W4 W6 W8 W1 W2 W36 W5 Week 2 6 2 Study -6M -1 M D D D D D D D D1 D1 D2 D2 D4 2M 3IVI 6M 9M* 12 Day / Month 3M 1 2 3 4 5 6 7 0 4 1 8 2 M ±14 ±14 ±7 days ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window days day day day day day day day day day days day s s s s s s s s s s AFF-01 XAdministration(IV)Hospital X XAdministration& Discharge*Per Pi’sdiscretionImmunomodulationdMethylprednisol X X X Xone IVeOral Prednisone X X X X X X X X X X XfRituximabgXSirolimushX X X X X X X X X X X X X X XLaboratory TestsPregnancy XTestHepB / HepC / HI XV SerologySerum AntiXVariant 3 NAbHematology X X X X X X X X X X X X X XTable 15Scree 6-month PreBaseline & AFF-01Procedure n-ingaobservation baselin Administrational run in ebStudy Visit Week 1 W2 W3 W4 W6 W8 W1 W2 W36 W5 Week 2 6 2 Study -6M -1 M D D D D D D D D1 D1 D2 D2 D4 2M 3IVI 6M 9M* 12 Day / Month 3M 1 2 3 4 5 6 7 0 4 1 8 2 M ±14 ±14 ±7 days ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window days day day day day day day day day day days day s s s s s s s s s s Serum X X X X X X X X X X X X X X ChemistryLFT X X X X X X X X X X X X X X CPK and high X X X X X X X X X X X X X sensitivitytroponin ILipid Panel X X X X X X X X X Coagulation : X X X X X X X X X X X X X PT / PTT / D- dimer,FibrinogenComplement X X X X X X X X X X X X XLabs: C3, C4,SC5b-9CRP, TNFa, IL- X X X X X X X X X X X X X6ELISPOT X1X X X X X X X Urinalysis X X X X X X X X X X X X XVector DNA X X X X X X X X X X Shedding:serum and urineTable 15Scree 6-month PreBaseline & AFF-01Procedure n-ingaobservation baselin Administrational run in ebStudy Visit Week 1 W2 W3 W4 W6 W8 W1 W2 W36 W5 Week 2 6 2 Study -6M -1 M D D D D D D D D1 D1 D2 D2 D4 2M 3IVI 6M 9M* 12 Day / Month 3M 1 2 3 4 5 6 7 0 4 1 8 2 M ±14 ±14 ±7 days ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window days day day day day day day day day day days day s s s s s s s s s s Serum Anti-Variant 3 capsid antibodiesSerum AntiX X X X X X Variant 3 capsidantibodiesSerum X X X X X X transgeneantibodiesSkeletal Muscle X X X X X BiopsyjCardiac AssessmentsEndomyocardial X X X biopsykCardiac X X X X X X X X X X biomarkers(NT-proBNP)Echocardiogra X X X X X X X X mCardiac MRI X X X CPET (pVO2) X X X X NYHA Class X X X X X X X X X KCCQ-23 X X X X X X X X X 12-lead ECG X X X X X X X X X X XTable 15Scree 6-month PreBaseline & AFF-01Procedure n-ingaobservation baselin Administrational run in ebStudy Visit Week 1 W2 W3 W4 W6 W8 W1 W2 W36 W5 Week 2 6 2 Study -6IVI -1M D D D D D D D D1 D1 D2 D2 D4 2M 3M 6M 9M* 12 Day / Month 3M 1 2 3 4 5 6 7 0 4 1 8 2 M ±14 ±14 ±7 days ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window days day day day day day day day day day days day s s s s s s s s s s D=day; W=week; M=months; X: Denotes an on-site visit.Patients complete daily outpatient visits after D1 (D2-D7)‘virtual visita The screening period lasts up to 8 weeks. Procedures may occur over the course of several days during the screening period. The decision as to the duration of each visit is at the discretion of the PI and is based on availability of the subject, required site staff, and / or overall burden on the subject b Pre-baseline visit is completed once eligibility of the participant has been confirmed and an enrollment number issued. The pre-baseline visit is completed before the immunomodulation is initiated (ie, before visit Day -14).c virtual / telephone visitd Vital signs are monitored frequently, including assessments every 15 minutes (± 5 minutes) for 1 hour, every 30 minutes for 2 hours, every 1 hour for 2 hours, and then every 2-4 hours for the remainder of the first 24 hours following the infusion and are extended at the discretion of the investigator.d Immunomodulation is started after baseline procedures are complete and prior to AFF-01 administration.e Methylprednisolone IV is used for the Pretreatment of Rituximab. It is administered as 10 mg / kg IV on Day 1 (pre-dose), Day 2 and Day 3f Oral prednisone (1 mg / kg / day with maximum dose of 100 mg / day) beginning on Day 4 and continuing until Day 30. Prednisone taper begins at the discretion of the Investigator on Day 31. The standard taper regimen is to decrease the oral prednisone dose by 5 mg weekly until a dose of 2.5 mg once daily after which it is discontinued Prednisone taper may be accelerated or extended at the investigator’s discretion depending on the participant’s clinical response. Increased doses of steroids (e.g., pulse steroid dosing) are considered for signs of autoimmune organ injury or potentially AAV related transaminase elevations If prednisone is not available or not tolerated, an equivalent potency glucocorticosteroid (e.g., dexamethasone) is substituted, g Rituximab 1500 mg / m2IV, divided in multiple doses. The dosing regimen is at the discretion of the investigator. Standard regimen is to divide into 4 doses, as a dose of 375 mg / m2on Day -14, -13, -7 and -6 prior to infusion of AFF-01Standard pretreatment for each rituximab dose include: Acetaminophen 15 mg / kg (maximum 1,000 mg), Diphenhydramine 12.5 mg to 50 mg PO, 30 min prior to infusion, and Methylprednisolone 10 mg / kg ivh Sirolimus 2 mg orally once daily starting Day -7 prior to infusion of AFF-01. The dose of sirolimus is adjusted targeting a trough level of 4-8 ng / mL. In settings of hepatic or renal impairment, dose of sirolimus may be reduced to maintain trough targets. After initiation (and after any changes), trough levelsof sirolimus are assessed approximately weekly. Once on a stable regimen of sirolimus, trough levels may be checked less frequently at the discretion ofTable 15Scree 6-month PreBaseline & AFF-01Procedure n-ingaobservation baselin Administrational run in ebStudy Visit Week 1 W2 W3 W4 W6 W8 W1 W2 W36 W5 Week 2 6 2 Study -6M -1 M D D D D D D D D1 D1 D2 D2 D4 2M 3IVI 6M 9M* 12 Day / Month 3M 1 2 3 4 5 6 7 0 4 1 8 2 M ±14 ±14 ±7 days ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window days day day day day day day day day day days day s s s s s s s s s s the investigator. Sirolimus is discontinued on Day 90. If there is evidence of active host immune response to AFF-01 , the sirolimus regimen may be continued for up to another 30 days.i Viral vector shedding is tested until 2 consecutive results are below lower limit of detection or when the vector levels have plateaued at low or negligible level.j Skeletal muscle biopsy is performed ± 30 days from baseline visit to accommodate scheduling. Baseline biopsy is performed prior to initiation of immunosuppression regimen on -D14. 2- and 3-month biopsies are performed ± 14 days. 12-month biopsy is performed ± 30 daysk Endomyocardial biopsy is performed ± 30 days from baseline visit to accommodate scheduling. Baseline biopsy is performed prior to initiation of immunosuppression regimen on -D14. 3-month biopsy is performed ± 14 days. 12-month biopsy is performed + / - 30 daysI ELISPOT is performed on D-15 for D1 visitAbbreviations:AE, adverse event; CPK, creatine phosphokinase; ECG, electrocardiogram;; ELISpot, enzyme-linked immunospot; F / U, follow-up; HepB, hepatitis B; HepC, hepatitis C; HIV, human immunodeficiency virus; LFTs, liver function tests; MRI, magnetic resonance imaging; Nabs, neutralizing antibodies; PI,principal investigator8.14.2. List of Abbreviations

[0196] The following abbreviations are used in this Example 13 and Example 14 that follows6MWT 6-Minute Walk TestAAV Adeno-Associated VirusAEs Adverse EventsAESIs Adverse Events of Special InterestaHUS atypical Hemolytic Uremic SyndromeALP Alkaline PhosphataseALT Alanine AminotransferaseaPTT Activated Partial Thromboplastin TimeARNI Angiotensin Receptor-Neprilysin InhibitorAST Aspartate AminotransferaseBAG3 Bcl2-Associated Athanogene 3BMI Body Mass IndexBUN Blood Urea NitrogenBW Body WeightCBC Complete Blood CountcDNA complementary Deoxyribonucleic AcidCIOMS Council For International Organizations of Medical SciencescKO Conditional KnockoutCLIA Clinical Laboratory Improvement AmendmentscMRI Cardiac Magnetic Resonance ImagingCPET Cardiopulmonary Exercise TestingCKD-EPI Chronic Kidney Disease and Epidemiology equationCPK Creatine PhosphokinaseCRO Contract Research OrganizationCRP C-Reactive ProteinCTCAE Common Terminology Criteria for Adverse EventsCV Coefficient VariationDCM Dilated CardiomyopathyDLT Dose-Limiting ToxicityDSMB Data And Safety Monitoring BoardE / e’ Ratio of early mitral inflow velocity and mitral annular early diastolic velocity ECG ElectrocardiogrameCrCI Estimated Creatinine ClearanceeCRF Electronic Case Report FormECG ElectrocardiogramEDC Electronic Data CaptureEF Ejection FractioneGFP Enhanced Green Fluorescent ProteineGFR Estimated Glomerular Filtration RateELISpot Enzyme-Linked Immunosorbent SpotFIH First-In-HumanGCP Good Clinical PracticeGDPR General Data Protection RegulationGLP Good Laboratory PracticeHA HemagglutininHBc Hepatitis B core antibodyHBs Hepatitis B surface antibodyHBsAg Hepatitis B surface antigenHBV Hepatitis B virusHCV Hepatitis C virusHF Heart FailureHFrEF Heart Failure with Reduced Ejection FractionHIPAA Health Insurance Portability and Accountability ActHIV Human Immunodeficiency Virushs-CRP High Sensitivity C-Reactive ProteinHSP Heat Shock ProteinIB Investigators BrochureICD International Classification of DiseasesIGF Informed Consent FormInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for ICH Human UseIEC Independent Ethics CommitteesIgG Immunoglobulin G antibodiesIflM Immunoglobulin M antibodiesIL-6 lnterleukin-6IMP Investigational Medicinal ProductINR International Normalized RatioiPSC Induced Pluripotent Stem CellIRBs Institutional Review BoardsIV IntravenousIVd In vitro DiagnosticKCCQ Kansas City Cardiomyopathy QuestionnaireLAR Legally Authorized RepresentativeLAVI Left Atrial Volume IndexLDH Lactate DehydrogenaseLFTs Liver Function TestsLPLV Last Patient, Last VisitLTFU Long-Term Follow-UpLV Left VentricleLVAD Left Ventricular Assist DeviceMDRD Modification Of Diet in Renal DiseaseMED Minimal Effective DoseMMRM Mixed Effects Models for Repeated MeasuresMOIs Multiplicities Of InfectionMRI Magnetic Resonance ImagingmTORC Mammalian Target of Rapamycin ComplexNAbs Neutralizing AntibodiesNHP Nonhuman PrimatesNIMP Non-lnvestigational Medicinal ProductsNS Normal SalineNTproBNP N-terminal pro-Beta Natriuretic PeptideNYHA New York Heart AssociationPAG Patient Advisory CouncilPCBP Persons Of Childbearing PotentialPD PharmacodynamicPE Physical ExaminationPI Principal InvestigatorPNH Paroxysmal Nocturnal HemoglobinuriaPO Per Os (oral)PRO Patient Reported OutcomePT Prothrombin TimePTT Partial Thromboplastin TimepVO2 Peak Oxygen ConsumptionQoL Quality of LifeQTc Corrected QT intervalQTcF QT Interval Corrected Using Fridericia's FormulaRBC Red Blood CellsREMS Risk Evaluation and Mitigation StrategiesROA Route Of AdministrationSAEs Serious Adverse EventsSAP Statistical Analysis PlanSC5b-9 Soluble Complement 5b-9 complexSD Standard DeviationSGLT2 Sodium-Glucose Co-Transporter 2SGOT Serum Glutamic-Oxaloacetic transaminase (AST)SGPT Serum Glutamic-pyruvic T ransaminase (ALT)SoA Schedule Of ActivitiesSRT Safety Review TriggersSUSARs Suspected Unexpected Serious Adverse ReactionsTEAEs T reatment-Emergent Adverse EventsTMA Thrombotic MicroangiopathyTNF Tumor Necrosis FactorULN Upper Limit of NormalVG Vector GenomesWBC White Blood Cells8.14.3. Objectives and Endpoints

[0197] The objectives and endpoints for the clinical study of this Example are provided in Table 16.Table 16Objectives EndpointsPrimaryTable 16Objectives EndpointsTo characterize thesafety and tolerability • Incidence and prevalence of T reatment-Emergent Adverse Events associated with a single (TEAEs) and Serious Adverse Events (SAEs)intravenous infusion of • Incidence and prevalence of TEAE and SAEs considered by the AFF-01Investigator to be at least possibly related to AFF-01• Change from baseline in vital signs and physical examinations• Change from baseline in laboratory assessments:o Chemistryo Hematologyo Coagulation studies (PT, aPTT, Fibrinogen, D-dimer)o Liver function tests (AST, ALT, T.bili, Aik Phos)o Inflammatory biomarkers (hsCRP, TNFa, IL-6)o Muscle injury biomarkers (CPK and hs-troponin)o Urinalysis• Change from baseline in laboratory markers for complement activation (C3, C4, sC5b-9)• Change from baseline in electrocardiogram• Change from baseline in laboratory markers for immunogenicity of the capsid and transgene producto Anti-Drug Antibody to AFF-01o Anti-Drug Antibody to BAG3o ELISPOTAssess thePharmacodynamic (PD)effects of single • Change from baseline in expression levels of vector genomes, transgene intravenous dose ofAFF-01 in cardiac mRNA, and transgene protein in endomyocardial biopsy at 12 months muscleSecondaryAssess the • Change from baseline in expression levels of vector genomes, transgene Pharmacodynamic (PD) mRNA, and transgene protein in skeletal muscle biopsy at 12 months effects of singleintravenous dose ofAFF-01 in skeletalmuscle• Change from baseline in NTproBNP levelsAssess the preliminary • Change from baseline in echocardiography measurement of cardiac efficacy of single function and structure (eg, LV ejection fraction, LV end-diastolic intravenous dose of diameter, LV posterior wall thickness, left atrial volume index [LAVI], AFF-01 E / e’)Table 16Objectives Endpoints• Change from baseline in cardiac MRI (T1 mapping) measurement of cardiac function and structure (eg, LV ejection fraction, LV end-diastolic diameter, LV posterior wall thickness, LAVI, E / e’, late gadolinium enhancement [LGE])• Change from baseline in peak oxygen consumption (pVO2) by Cardiopulmonary Exercise Testing (CPET)• Percentage of participants who had a change in NYHA from baseline • Change from baseline in QoL, eg, Kansas City Cardiomyopathy Questionnaire (KCCQ-23)• Proportion of participants who experience a cardiac event defined as hospitalization for heart failure, receive a cardiac transplantation, left ventricular assist device, sustained ventricular arrhythmias, or cardiac death• Overall survival in participants receiving AFF-018.14.4. Study Design8.14.4.1 Overall Design

[0198] This is a multi-center, non-randomized, open-label, Phase 1b / Phase 2 study in participants with DOM due to mutations in BAG3. This study has two parts: Part A: dose escalation and Part B: dose expansion. The dose escalation part (Part A) is uncontrolled, while the dose expansion part (Part B) include at least a 6-month observational run-in to be used as its own natural history comparator. In the dose escalation phase (Part A), 6-10 participants across two dose cohorts (3-5 participants in each cohort) receive a single intravenous infusion of AFF-01 and are followed for 5 years total. The primary and secondary end points are assessed at 12 months, and the remaining 4 years will constitute the longterm follow-up. In the dose expansion phase (Part B), 6-12 participants are monitored for at least 6 months to establish their natural history after which they receive a single intravenous infusion of AFF-01 and are followed for 5 years with the primary and secondary end points assessed at 12 months and the long-term follow up consisting of 4 years. The 5-year follow up post treatment with an AAV based gene therapy is consistent with the draft “FDA Guidance for Industry: Long Term Follow-Up after Administration of Human Gene Therapy Products” (January 2020).8.14.5. Scientific Rationale for Study Design8.14.5.1 Rationale for Open Label Design

[0199] This FIH Phase 1b / Phase 2 study is an open-label study BAG3 DCM is a rare disease with an estimated US prevalence of 31,385 patients (based on BAG3 prevalence rate of 2.3% amongst patients with DCM in US). As such, it is not practically feasible to conduct an appropriately powered randomized controlled trial in this population. Given the rarity of the disease, the sample size of cohorts 1 and 2 are limited to 3-5 participants. With this low sample size, significant inter-individual variability that will be challenging to control by comparing to another group of smaller number of participants is anticipated. Rather, each subject’s baseline is being employed as their own control to minimize the variability. In addition, as there are no disease modifying treatments currently available, it would not be ethically appropriate to withhold a potentially curative treatment to patients who are otherwise progressing toundesirable cardiovascular outcomes such as LVAD implantation, heart transplant or even death. This open label study design has been successfully utilized in other gene therapy studies of rare inherited cardiomyopathies.8.14.5.2 Rationale for Primary and Secondary End Points

[0200] The primary objective of this FIH clinical trial is to demonstrate the safety and tolerability of intravenously administered AFF-01 As this is a FIH trial, there is no clinical experience with AFF-01 yet While preclinical data support the safety and anticipated efficacy of AFF-01, including the potential to be a one-time curative treatment for DCM due to mutations in BAG, clinical data will demonstrate its potential in humans. To continue to collect clinical experience, this study aims to demonstrate the safety and tolerability of AFF-01.

[0201] An additional primary end point of this study is the pharmacodynamic effects of AFF-01 , including transgene expression in endomyocardial biopsy samples. The degree of transgene expression in the relevant tissue, the heart, will be instrumental in dose selection decisions and demonstration of transgene expression will provide an early confirmation of the successful delivery of the therapeutic and support the potential for long term clinical efficacy

[0202] Key secondary end points of this study include assessments for preliminary efficacy include cardiac imaging by echocardiogram and cardiac MRI, circulating cardiac biomarkers, exercise capacity, and quality of life measures. These secondary end points will provide further evidence to support the clinical benefit of AFF-01 and provide guidance to the design of future studies.8.14.6. Justification for Dose

[0203] The dose of AFF-01 in cohort 1 is 1e13 vg / kg. The dose was selected based on the Minimal Effective Dose (MED) established in the cKO mouse model translated to the weight-based dose needed to obtain similar vector transduction in NHP cardiomyocytes, as well as the NHP toxicity study. The MED was identified as the lowest dose that led to improvements in EF on echocardiography in cKO mouse with demonstrated PD effects (e.g., vector transduction and BAG3 mRNA and protein expression). This was translated to a dose in NHPs that was associated with similar PD effects (similar degree of vector transduction and BAG3 expression in NHPs as observed in cKO mouse model) while being safe and well tolerated. The dose of 1e13 vg / kg with the Variant 3 capsid have previously been demonstrated to be safe and well tolerated in NHPs. The immunogenic nature of AAV is believed to generally only allow for a single dose of treatment with an AAV based gene therapy in an individual over their lifetime. If a patient does not benefit from the initial dose of systemic AAV based gene therapy, the possibility of obtaining a second systemic dose is very low due to development of neutralizing antibodies. As such, the initial dose in Cohort 1 was selected to have a reasonable likelihood of providing benefit. The dose for cohort 2 is 4e13 vg / kg. In previous AAV gene therapy studies, doses in the range of 6e13 were found to be generally safe and well tolerated. The dose for cohort 3 is decided based on data observed in cohorts 1 and 2

[0204] The intravenous route of administration (ROA) is being used as this ROA was demonstrated in mice and adult NHPs to enable widespread transduction of AFF-01 throughout the heart.8.14.7. End-of-Study Definition

[0205] The end of this study is defined as the date when the last patient, last visit (LPLV), occurs or the date at which the last data point required for statistical analysis or safety follow-up is received from the last participant, whichever occurs later8.14.8. Study Population8.14.8.1 Inclusion Criteria

[0206] Participants are eligible to be included in the study only if all the following criteria in Sections 8.14.8.1.1 to 8.14.8.1.4 apply.8.14.8.1.1 Age

[0207] Participants are 18 to 50 years of age inclusive, at the time of signing the informed consent.8.14.8.1.2 Type of Participant and Disease Characteristics• Participants with truncating mutations in BAG3• Participants with Dilated Cardiomyopathy with MRI or echocardiography demonstrating LVEF <45%• Participants New York Heart Association (NYHA) Class I, II or III• NT-proBNP>300 pg / mL for those in sinus or paced rhythm and >600 pg / mL for those in atrial fibrillation• BM I <35 kg / m2(inclusive)8.14.8.1.3 Sex and Contraceptive / Barrier Requirements

[0208] Persons of childbearing potential (PCBP) or male participants with a PCBP partner must use highly effective contraceptive during the course of the study until viral shedding has been documented to be undetectable on two consecutive tests If the use of highly effective contraception is contraindicated, then two forms of effective contraception are utilized. Female participants must abstain from egg donation and cryopreservation of germ cells during the course of the study until viral shedding has been documented to be undetectable on two consecutive tests.8.14.8.1.4 Other Inclusion Criteria• ALT or AST 21.3x ULN• eGFR > 45 mL / min / 1.73m2based on Modification of Diet in Renal Disease (MDRD) equation (Stevens 2006)• Hemoglobin > 10 g / dL (Grade <1 anemia per NCI CTCAE version 5)Platelet count > 75,000 / mm3 (Grade < 1 thrombocytopenia per NCI CTCAE version 5) 8.14.8.2 Exclusion Criteria

[0209] Participants are excluded from the study if any of the following criteria apply:Medical Conditions:• History of any prior gene therapy with AAV• Prior myocardial infarction• Prior heart transplant• Presence or requirement of a left ventricular assist device (LVAD)• Active cancer or cancer diagnosis within prior 5 yearsPrior / Concomitant Therapy:• IV therapy with positive inotropes, vasodilators, or diuretics within 30 days prior to enrollment (ie, participants must be stable on oral medical therapy)• Prior / Concurrent Clinical Study Experience• Enrollment in any other clinical trial with an investigational product within 4 weeks prior to screening or within 5 half-lives of the investigational product used in that clinical trial, whichever is longerDiagnostic Assessments:• Positive for anti-Variant 3 capsid polypeptide neutralizing antibodiesOther Exclusion Criteria:• Unable to walk > 100 meter unassisted on baseline 6MWT• Active pregnancy• Active viral infection (including human immunodeficiency virus (HIV) or positive serology for hepatitis B or C)• Any acute illness requiring hospitalization within 30 days prior to enrollment• Known hypersensitivity or contraindication to methylprednisolone, prednisone or other glucocorticosteroids or their excipients• Any current or previous condition or physical exam or laboratory test finding that, in the opinion of the Investigator, would put the subject at undue risk or would interfere with evaluation and interpretation of the investigational product safety or efficacy results

[0210] Participants with implantable cardioverter-defibrillators (ICDs) are allowed but ICDs are not required. Forthose with ICDs, MRI-compatible ICDs are preferred.8.14.9. Study Intervention(s) and Concomitant Therapy

[0211] The investigational medicinal product (IMP) in this study is AFF-01. Pre-medications for immunomodulation are considered non-IMPs.

[0212] Concomitant therapy consists of any medication (e.g., prescription drugs, over-the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a participant in addition to protocol-mandated treatment from 14 days prior to initiation of study treatment through the end of the study (60 months). All such medications are reported to the investigator and recorded on the appropriate eCRF.8.14.10. Study Intervention(s) Administered

[0213] The study interventions are provided in Table 17.Table 17Intervention MethylprednisoLabel AFF-01 lone Prednisone Rituximab Sirolimus InterventionName AFF-01 Solu-Medrol Prednisone Rituxan Rapamune Intervention One time IV Oral, tablet, Oral, tablet, Description infusion IV infusion once daily IV infusion once daily AAV based geneType therapy drug drug biologic drug Dose Solution for IV Single doseFormulation infusion Single dose vial Tablet vial Tablet 40 mg 2.5 mgUnit Dose 0.5 mg 1e 125 mg 5 mg 100 mg / 10 mL Strength(s) 14 vg / mL 500 mg 10 mg 500 mg / 50 mL 1 mg ig 20 mg 2 mg One time IV Start at 2 infusion on Day 1 mg / kg mg once 1: (maximum of dailyIV infusion 10 1500 mg / m2Cohort 1: 1e13 100 mg) frommg / kg total dose Titrate vg / kg Day 3 until Day given in divided dose to Cohort 2: 4e13 30 doses as trough 4 - vg / kg (cohort 2 Pre-medication follows: 8 ng / mL dose may for rituximab: 10 Start Discontinu potential mg / kg IVDosage ly be prednisone 375 mg / m2on e at Day 90 Level(s) higher or lower taper on Day Day -14 If evidence dependent on Immunomodulati 31safety, 375 mg / m2on of immune on: Tapering dose Day -13 reaction is tolerability, PD by 5 mg / week evident, and effi 10 mg / kg IV on 375 mg / m2oncacy) Day 1 (preuntil a dose of Sirolimus Cohort 3: TBD 2.5 mg Day -7 once may be dose), Day 2, 375 mg / m2on pending safety, daily is reached resumed Day 3 Day -6 tolerability, PD and then for up to and efficacy of discontinue another 30 earlier doses days.Table 17Intervention AFF-01 MethylprednisoLabel lone Prednisone Rituximab Sirolimus Route ofAdministrati IV infusion IV infusion Oral IV infusion Oral onImmunomodulatiUse Experimental on and Immunomodulat Immunomodula Immunomo Prophylaxis for ion tion d-ulation RituximabIMP andNIMP / AxMP IMP NIMP NIMP NIMP NIMP0214] AFF-01 is infused as a single dose to the participant. The dosing solution comprises AFF-01 diluted in 0.9% normal saline solution at a minimum of 3x and a maximum of 8x dilution. The low dose cohort is diluted 8x and the high dose cohort is diluted 3x to ensure dosing volume is within the volume range of 50 to 200 ml.

[0215] The participant receives AFF-01 in a clinical setting in a facility experienced with investigational therapeutics. Suitable settings include an in-patient hospital ward, an infusion-center, or an out-patient center. At the discretion of the investigator, participants may be hospitalized for upto 7 days prior to and subsequent to the infusion of AFF-01 for safety monitoring8.14.10.1 AFF-01 Formulation

[0216] AFF-01 drug product is formulated as a solution for IV delivery in 2.7mM KCI, 1.5mM KH2PO4, 172mM NaCI, 8.1mM Na2HPO4, 250mM L-Arginine, 0.005% Pluronic F68, pH 7.08.14.10.2 Examples of Dosing Calculations

[0217] In Cohort 1, AFF-01 is dosed at 1e13 vg / kg. An 80 kg participant receives a total of 8e14 vg. The unit dose of AFF-01 is 1e14 vg / mL. Therefore, an 80 kg patient receives 8 mL of AFF-01 diluted in 0.9% Normal Saline (NS) at 8x total volume (8 mL AFF-01 + 56 mL 0.9% NS).

[0218] In Cohort 2, AFF-01 is dosed at 4e13 vg / kg. An 80 kg participant receives a total of 3.2e15 vg. The unit dose of AFF-01 is 1e14 vg / mL. Therefore, an 80 kg patient receives 32 mL of AFF-01 diluted in 0.9% NS at 3x total volume (32 mL AFF-01 + 64 mL 0.9% NS)

[0219] Examples of dosing calculations are shown in Table 18.Table 18AFF-01 Total Dilution Volume ofBW AFF-01 Dosevg / kg Dose Based Needed AFF-01 (1e14 Volume of Total on BW with Saline vg / mL) 0.9% Saline Volume 80 kg 1e13 vg / kg 8e14 total vg 8x 8 mL 56 mL 64 mL80 kg 4e13 vg / kg 32e15 total vg 3x 32 mL 64 mL 96 mL 8.14.10.3 Pre-Treatment and Immune Modulation

[0220] Pre-treatment prophylaxis regimen comprising steroids, rituximab and sirolimus are administered to minimize the risk of immune reactions to AFF-01. Preclinical studies have not revealed any immunereactions, including complement mediated immune reactions, in response to AFF-01. Nonetheless, recent clinical data with other AAV based gene therapies have demonstrated the potential of triple immune modulation to minimize the risk of immune reactions including the formation of IgM and IgG antibodies and biochemical signs of complement activations. Initiation of rituximab prior to administration of AAV gene therapies may induce B-cell depletion via CD20 receptors on EB-cell surfaces and inhibit development of humoral immune response and decrease antibody-directed complement response Sirolimus may further induce B-cell depletion but may also lead to T-cell-mediated immunosuppression via mTORC pathways. Steroids, rituximab and sirolimus have been used clinically in heart transplantation.

[0221] The immune modulation for AFF-01 is as follows:1) Steroids:• Methylprednisolone 10 mg / kg IV on Day 1 (pre-dose), Day 2 and Day 3• Oral prednisone (1 mg / kg / day with maximum dose of 100 mg / day) beginning on Day 4 and continuing until Day 30.• Prednisone taper begins at the discretion of the Investigator on Day 31. The standard taper regimen is to decrease the oral prednisone dose by 5 mg weekly until a dose of 25 mg once daily after which it is discontinued. Prednisone taper may be accelerated or extended at the investigator’s discretion depending on the participant’s clinical response.• Increased doses of steroids (e.g., pulse steroid dosing) may be considered for signs of autoimmune organ injury or potentially AAV related transaminase elevations.• If prednisone is not available or not tolerated, an equivalent potency glucocorticosteroid (e g., dexamethasone) is substituted.2) Rituximab 1500 mg / m2 IV, divided into multiple doses• The dosing regimen is at the discretion of the investigator. The standard regimen is to divide into 4 doses, as a dose of 375 mg / m2on Day -14, -13, -7 and -6 prior to infusion of AFF-01• Pretreatment for each rituximab dose includes:o Acetaminophen 15 mg / kg (maximum 1,500 mg)o Diphenhydramine 125 mg to 50 mg PO, 30 min prior to infusion, ando Methylprednisolone 10 mg / kg iv3) Sirolimus 2 mg orally once daily starting Day -7 prior to infusion of AFF-01.• The dose of sirolimus is adjusted targeting a trough level of 4-8 ng / mL.In settings of hepatic or renal impairment, dose of sirolimus may be reduced to maintain trough targets.• After initiation (and after any changes), trough levels of sirolimus are assessed approximately weekly. Once on a stable regimen of sirolimus, trough levels may be checked less frequently at the discretion of the investigator.• Sirolimus is discontinued on Day 90.• If there is evidence of active host immune response to AFF-01 , the sirolimus regimen may be continued for up to another 30 days.

[0222] Eculizumab (Soliris) is a complement inhibitor indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). It is available as a 300 mg single use vial and is dosed 600 mg via 35 min intravenous infusion every 7 days for the first 4 weeks. For those with clear signs of complement activation and incipient Thrombotic Microangiopathy (TMA) or high likelihood of TMA, eculizumab is initiated to inhibit the complement cascade.8.14.10.4 Dose Modification and Retreatment Criteria

[0223] No dose modifications are permitted in this study. In this study, a single intravenous (IV) dose of the investigational product is administered on Day 1 (D1) No additional doses are planned as part of the study protocol Retreatment with the investigational product is not permitted under this protocol.8.14.10.5 Prior and Concomitant Therapy

[0224] Paracetamol / Acetaminophen, at doses of < 1.5 grams / day and Diphenhydramine at doses of <50 mg / day are permitted for use during the study, including for use as pre-treatment regimen for Rituximab.

[0225] Medications to prevent complications from corticosteroid use may be co-administered in accordance with institutional guidelines and may include prophylaxis for Pneumocystis jirovecii pneumonia as appropriate.

[0226] Participants should have received meningococcal vaccination appropriate for age and health condition as recommended by the Centers for Disease Control. The meningococcal vaccination may be given at least 8 weeks prior to administration of IP.

[0227] During the period of immunomodulation, participants are discouraged from receiving any live or live-attenuated vaccines.8.14.10.6 Rescue Medicine

[0228] Participants in this study have NYHA Class I, II, or III HF on stable medical therapy. Participants with any recent use of IV therapy with positive inotropes, vasodilators, or diuretics suggesting unstable disease are excluded. Nonetheless, decompensation into symptomatic acute HF requiring urgent therapy may occur over the course of 5 years follow up given the natural history of the disease. Decompensation events requiring hospitalization or IV therapy are documented as an HF event.

[0229] Participants with stable but worsening HF may have their guideline directed medical therapy adjusted as appropriate (including changes in diuretic regimen).8.14.11. Results

[0230] AFF-01 administered as a single intravenous infusion is safe, well tolerated, and efficacious.8.15. Example 14: Phase 1 / 2 Multicenter, Open-Label, Dose-Escalation and Dose- Expansion Trial to Assess the Safety, Tolerability, Pharmacodynamics, and Preliminary Efficacy of AFF-01 Administered to Adult Participants with BCL2- Associated Athanogene 3 (BAG3) Mutation-Associated Dilated Cardiomyopathy 8.15.1. Overview

[0231] This study has a number of changes as compared to the study of Example 13, including, among others, a reduced AFF-01 dose in Cohort 1 (6e12 vg / kg in this Example vs. 1e13 vg / kg in Example 13), a reduced AFF-001 dose in Cohort 2 (1e13 vg / kg in this Example vs. 4e13 vg / kg in Example 13), and a different immune modulation regimen.

[0232] A schedule of assessments for the first two cohorts is shown in Table 19. A schedule of assessments for the third cohort is shown in Table 20.Table 19PreUnBaseline, AFF-01 AdministrationProcedure Screening3baseline Follow Up schedule b and Immediate Follow Updi Study Visit Week W2 W3 W4 W6 W8 W12 W26 W36 W52 Study Day / Month D1 D2 D3 D4 D5 D6 D7 D9 D11 D14 D21 D28 D42 2M 3M 6M 9M* 12M±2 ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Windowdays days days days days days days days days days days Informed Consent XReview Inclusion andXExclusion CriteriaCardiomyopathyXgenetic testing panelMedical History X X X X X X ConcomitantMedications / X X X X X X X X X X X X X X X X X X X X X ProceduresAE Assessment X X X X X X X X X X X X X X X X X X X X X Height X X X Weight X X X X X X X X X X X X X X Complete PhysicalX X X X X XExamAbbreviated PE X X X X X X X X X X X X X X Vital Signs0X X X X X X X X X X X X X X X X X X X X Telemetry X6MWT XTable 19PreUnBaseline, AFF-01 AdministrationProcedure Screening6baseline Follow Up schedule b and Immediate Follow Updi Study Visit Week W2 W3 W4 W6 W8 W12 W26 W36 W52 Study Day / Month D1 D2 D3 D4 D5 D6 D7 D9 D11 D14 D21 D28 D42 2M 3M 6M 9M* 12M±2 ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Windowdays days days days days days days days days days days AFF-01 AdministrationX(IV)Hospital Admission &Discharge* Per Pl’s X XdiscretionImmunosuppressionMethylprednisolone IVdX X XOral Corticosteroids6X X X X X X X X X X X XLaboratory TestsPregnancy Test X X HepB / HepC / HIVX XSerologySerum Anti-Variant 3X X capsid NAbHematology X X X X X X X X X X X X X X X X X X X X Chemistry X X X X X X X X X X X X X X X X X X X X LFT X X X X X X X X X X X X X X X X X X X X CPK and hsTroponin I X X X X X X X X X X X X X X X X X X LDH X X X X X X X X X X X X X X X X X XTable 19PreUnBaseline, AFF-01 AdministrationProcedure Screening3baseline Follow Up schedule b and Immediate Follow Updi Study Visit Week W2 W3 W4 W6 W8 W12 W26 W36 W52 Study Day / Month D1 D2 D3 D4 D5 D6 D7 D9 D11 D14 D21 D28 D42 2M 3M 6M 9M* 12M±2 ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Windowdays days days days days days days days days days daysLipid Panel (Total Choi,LDL, HDL and X X X X X X X Triglycerides)Coagulation:PT / aPTT / DX X X X X X X X X X X X X X X X X X-dimer, FibrinogenComplement Labs: C3,X X X X X X X X X X X X X X X X X XC4, SC5b-9CRP, TNFa, IL-6, IgG,X X X X X X X X X X X X X X X X X X igMELISPOT X X X X X X X X X XUrinalysisfX X X X X X X X X X X X X X X X X X Urine Collection 9 X X X X X X X X X X X Vector DNA Shedding:whole blood, urine, X X X X X X X X X X X saliva and feceshSerum AntibodiesSerum Anti-Variant 3X X X X X X XCapsid TAbSerum BAG3X X X X X X XTransgene AbCardiac AssessmentsEndomyocardial biopsy' X X XTable 19PreUnBaseline, AFF-01 AdministrationProcedure Screening3baseline Follow Up schedule b and Immediate Follow Updi Study Visit Week W2 W3 W4 W6 W8 W12 W26 W36 W52 Study Day / Month D1 D2 D3 D4 D5 D6 D7 D9 D11 D14 D21 D28 D42 2M 3M 6M 9M* 12M±2 ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Windowdays days days days days days days days days days days Cardiac biomarkersX X X X X X X X X(NT-proBNP)Echocardiogram X X X X X X X Cardiac MRI X X X CPET (pVO2) X X X XNYHA Class X X X X X X XKCCQ-23 X X X X X X12-lead ECG X X X X X X X X X X X XTable 19PreUnBaseline, AFF-01 AdministrationProcedure Screening3baseline Follow Up schedule b and Immediate Follow Updi Study Visit Week W2 W3 W4 W6 W8 W12 W26 W36 W52 Study Day / Month D1 D2 D3 D4 D5 D6 D7 D9 D11 D14 D21 D28 D42 2M 3M 6M 9M* 12M±2 ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Windowdays days days days days days days days days days days D=day; W=week; M=months; X: Denotes an on-site visit.Patients complete daily outpatient visits after D1 (D2-D7).‘virtual visitaThe screening period lasts up to 12 weeks. Procedures may occur over the course of several days during the screening period. The decision as to the duration of each visit is at the discretion of the PI and is based on availability of the subject, required site staff, and / or overall burden on the subject. Subjects are not hospitalized overnight during the screening unless deemed necessary.bPre-baseline visit is completed once eligibility of the participant has been confirmed and an enrollment number issued. The pre-baseline visit is completed before the dosing day (ie, before visit Day 1)cVital signs are monitored frequently, including assessments every 15 minutes (± 5 minutes) for 1 hour, every 30 minutes for 2 hours, every 1 hour for 2 hours, and then every 2-4 hours for the remainder of the first 12 hours following the AFF-01 infusion and can be extended at the discretion of the investigator.dMethylprednisolone is administered at 2 mg / kg IV on Day 1 (pre-dose), Day 2 and Day 3eOral prednisone (1 mg / kg / day with maximum dose of 60 mg / day) is administered beginning on Day 4 and continuing until Day 30. Prednisone taper begins at the discretion of the Investigator on Day 31. The standard taper regimen is to decrease the oral prednisone dose by 5 mg weekly until a dose of 5 mg once daily for one week followed by 2.5 mg once daily for one week after which it is discontinued. Prednisone taper may be accelerated or extended at the investigator’s discretion depending on the participant’s clinical response. Increased doses of steroids (eg, pulse steroid dosing) may be considered for signs of autoimmune organ injury or potentially AAV related transaminase elevations. If prednisone is not available or not tolerated, an equivalent potency glucocorticosteroid (eg, dexamethasone) may be substituted.fSpot urinalysis to be performed. Urine collection is done at random; does not need to be fasting.a Urine collection is for a minimum of 6 continuous hours and up to 24 hours. Assessments for urine volume and urine protein are conducted.hViral vector shedding is tested until 2 consecutive results are below lower limit of detection or when the vector levels have plateaued at low or negligible level.1Endomyocardial biopsy is performed after the echocardiogram, cardiac MRI and CPET. Baseline endomyocardial biopsy is performed up to -30 days from baseline visit to accommodate scheduling. 3 month biopsy is performed ± 14 days. 12-month biopsy is performed ± 30 daysJAssessments including laboratory tests for the unscheduled visit are only conducted as appropriate. Not all indicated tests are necessarily conducted at this visitAbbreviations:AE=adverse event; CPK=creatine phosphokinase; ECG=electrocardiogram; ELISpot=enzyme-linked immunospot; F / U=fol low-up; HepB=hepatitis B; HepC=hepatitis C; HIV=humanimmunodeficiency virus; LFTs=liver function tests; MRI=magnetic resonance imaging; Nabs=neutralizing antibodies; Pl=principal investigatorTable 206-month PreBaseline &AFF-01Procedure Screening’ observational baseline13Administrationrun inStudy Visit Week Week 1 UnW2 W3 W4 W6 W8 W12 W26 W36 W52 scheduled j Study Day / Month -6M -3M -1M D1 D2 D3 D4 D5 D6 D7 D9 D11 D14 D21 D28 D42 2M 3M 6M 9M* 12M±14 ±14 ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window ±7 daysdays days days days days days days days days days days days Informed Consent XReview Inclusion andXExclusion CriteriaCardiomyopathy geneticXtesting panelMedical History X X X X X X X ConcomitantX X X X X X X X X X X X X X X X X X X X X X XMedications / ProceduresAE Assessment X X X X X X X X X X X X X X X X X X X X X X X Height X X X X Weight X X X X X X X X X X X X X X X X Complete Physical Exam X X X X X X Abbreviated PE X X X X X X X X X X X X X X X X Vital Signs0X X X X X X X X X X X X X X X X X X X X X X Telemetry XTable 206-month PreBaseline & AFF-01Procedure Screening3observational baseline6Administrationrun inStudy Visit Week Week l UnW2 W3 W4 W6 W8 W12 W26 W36 W52 scheduled i Study Day / Month -6M -3M -1M D1 D2 D3 D4 D5 D6 D7 D9 D11 D14 D21 D28 D42 2M 3M 6M 9M* 12M±14 ±14 ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window ±7 daysdays days days days days days days days days days days days 6MWT XAFF-01 AdministrationX(IV)Hospital Admission &Discharge* X XPer Pl’s discretionImmunosuppressionMethylprednisolone IVdX X XOral CorticosteroidseX X X X X X X X X X X XLaboratory TestsPregnancy Test X X HepB / HepC / HIVX XSerologySerum Anti-ATC-VariantX X3 capsid NAbHematology X X X X X X X X X X X X X X X X X X X X Serum Chemistry X X X X X X X X X X X X X X X X X X X X LFT X X X X X X X X X X X X X X X X X X X XTable 206-month PreBaseline &AFF-01Procedure Screening3observational baseline6Administrationrun inStudy Visit Week Week l UnW2 W3 W4 W6 W8 W12 W26 W36 W52 scheduled i Study Day / Month -6M -3M -1M D1 D2 D3 D4 D5 D6 D7 D9 D11 D14 D21 D28 D42 2M 3M 6M 9M* 12M±14 ±14 ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window ±7 daysdays days days days days days days days days days days days CPK and high sensitivityX X X X X X X X X X X X X X X X X X X troponin 1LDH X X X X X X X X X X X X X X X X X XLipid Panel (Total Choi,LDL. HDL and X X X X X X X Triglycerides)Coagulation: PT / aPTT / D- X X X X X X X X X X X X X X X X X X dimer, FibrinogenComplement Labs: C3,X X X X X X X X X X X X X X X X X XC4, SC5b-9CRP, TNFa, IL-6, IgG,X X X X X X X X X X X X X X X X X X igMELISPOT X X X X X X X X X XUrinalysisfX X X X X X X X X X X X X X X X X X Urine Collection 9 X X X X X X X X X X X Vector DNA Shedding:whole blood, urine, saliva X X X X X X X X X X X and feceshSerum AntibodiesTable 206-month PreBaseline &AFF-01Procedure Screening3observational baseline6Administrationrun inStudy Visit Week Week l UnW2 W3 W4 W6 W8 W12 W26 W36 W52 scheduled i Study Day / Month -6M -3M -1M D1 D2 D3 D4 D5 D6 D7 D9 D11 D14 D21 D28 D42 2M 3M 6M 9M* 12M±14 ±14 ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window ±7 daysdays days days days days days days days days days days days Serum Anti-Variant 3X X X X X X XCapsid TAbSerum BAG3 TransgeneX X X X X X XAbCardiac AssessmentsEndomyocardial biopsy ' X X X Cardiac biomarkersX X X X X X X X X X X(NT-proBNP)Echocardiogram X X X X X X X X X Cardiac MRI X X X CPET (pVO2) X X X XNYHA Class X X X X X X X X X KCCQ-23 X X X X X X X X X12-lead ECG X X X X X X X X X X X X X XTable 206-month PreBaseline & AFF-01Procedure Screening3observational baseline6Administrationrun inStudy Visit Week Week l UnW2 W3 W4 W6 W8 W12 W26 W36 W52 scheduled j Study Day / Month -6M -3M -1M D1 D2 D3 D4 D5 D6 D7 D9 D11 D14 D21 D28 D42 2M 3M 6M 9M* 12M±14 ±14 ±2 ±2 ±5 ±5 ±7 ±7 ±14 ±30 ±30 ±30 Visit Window ±7 daysdays days days days days days days days days days days days D=day; W=week; M^months; X: Denotes an on-site visit, jPatients complete daily outpatient visits after D1 (D2-D7).‘virtual visit3The screening period lasts up to 8 weeks. Procedures may occur over the course of several days during the screening period. The decision as to the duration of each visit is at the discretion of the PI and is based on availability of the subject, required site staff, and / or overall burden on the subject. Subjects are not hospitalized overnight during the screening unless deemed necessary.bPre-baseline visit is completed once eligibility of the participant has been confirmed and an enrollment number issued. The pre-baseline visit is completed before the dosing day (ie, before visit Day 1)cVital signs are monitored frequently, including assessments every 15 minutes (± 5 minutes) for 1 hour, every 30 minutes for 2 hours, every 1 hour for 2 hours, and then every 2-4 hours for the remainder of the first 12 hours following the AFF-01 infusion and are extended at the discretion of the investigator.dMethylprednisolone is administered at 2 mg / kg IV on Day 1 (pre-dose), Day 2 and Day 3eOral prednisone (1 mg / kg / day with maximum dose of 60 mg / day) is administered beginning on Day 4 and continuing until Day 30. Prednisone taper begins at the discretion of the Investigator on Day 31 The standard taper regimen is to decrease the oral prednisone dose by 5 mg weekly until a dose of 5 mg once daily for one week followed by 25 mg once daily for one week after which it is discontinued. Prednisone taper may be accelerated or extended at the investigator’s discretion depending on the participants clinical response. Increased doses of steroids (eg, pulse steroid dosing) may be considered for signs of autoimmune organ injury or potentially AAV related transaminase elevations. If prednisone is not available or not tolerated, an equivalent potency glucocorticoid (eg, dexamethasone) may be substituted.fSpot urinalysis is performed. Urine collection is done at random; does not need to be fasting.s Urine collection is for a minimum of 6 continuous hours and up to 24 hours. Assessments for urine volume and urine protein are conducted.hViral vector shedding is tested until 2 consecutive results are below lower limit of detection or when the vector levels have plateaued at low or negligible level.' Endomyocardial biopsy is performed after the echocardiogram, cardiac MRI and CPET. Baseline endomyocardial biopsy is performed up to -30 days from baseline visit to accommodate scheduling. 3-month biopsy is performed ± 14 days. 12-month biopsy is performed ± 30 daysJAssessments including laboratory tests for the unscheduled visit are only conducted as appropriate. Not all indicated tests are necessarily conducted at this visit.Abbreviations:AE=adverse event; CPK=creatine phosphokinase; ECG=electrocardiogram; ELISpot=enzyme-linked immunospot; F / U=follow-up; HepB=hepatitis B; HepC=hepatitis C;HIV=human immunodeficiency virus; LFTs=liver function tests; MRI=magnetic resonance imaging; Nabs=neutralizing antibodies; Pl=principal investigator8.15.2. Objectives and Endpoints

[0233] The objectives and endpoints for the clinical study of this Example are provided in Table 21.Table 21Objectives EndpointsPrimaryTo characterize the • Incidence and prevalence of T reatment-Emergent Adverse Events safety and tolerabilityassociated with a single (TEAEs) and Serious Adverse Events (SAEs)intravenous infusion of • Incidence and prevalence of TEAE and SAEs considered by the AFF-01 over 12 monthsInvestigator to be at least possibly related to AFF-01• Change from baseline in vital signs and physical examinations• Change from baseline in laboratory assessments:o Chemistryo Hematologyo Coagulation studies (PT, aPTT, Fibrinogen, D-dimer)o Liver function tests (AST, ALT, T.bili, Aik Phos)o Inflammatory biomarkers (hsCRP, TNFa, IL-6)o Muscle injury biomarkers (CPK, hs-troponin I)o Tissue injury biomarker (LDH)o Urinalysis• Change from baseline in laboratory markers for complement activation (C3, C4, sC5b-9)SecondaryAssess the • Change from baseline in endomyocardial biopsy levels of vector genome Pharmacodynamic (PD) at 3 and 12 monthseffects of single • Change from baseline in endomyocardial biopsy expression levels of intravenous dose of transgene mRNA at 3 and 12 monthsAFF-01 in cardiacmuscle • Change from baseline in endomyocardial biopsy expression levels of transgene protein at 3 and 12 months• Change from baseline in NT-proBNP levelsAssess the preliminary • Change from baseline in echocardiography measurement of cardiac efficacy of single function and structure (e.g., LV ejection fraction, LV end-diastolic intravenous dose of diameter, LV posterior wall thickness, left atrial volume index [LAVI], AFF-01 over 12 months E / e’)• Change from baseline in cardiac MRI (T1 mapping) measurement of cardiac function and structure (e.g., LV ejection fraction, LV end-diastolic diameter, LV posterior wall thickness, LAVI, E / e’, late gadolinium enhancement [LGE])• Change from baseline in peak oxygen consumption (pVO2) by Cardiopulmonary Exercise Testing (CPET)• Percentage of participants who had a change in NYHA from baselineTable 21Objectives Endpoints• Change from baseline in QoL, eg, Kansas City Cardiomyopathy Questionnaire (KCCQ-23)• Proportion of participants who experience a cardiac event defined as hospitalization for heart failure, receive treatment with intravenous diuretics for worsening heart failure, receive a cardiac transplantation, left ventricular assist device, sustained ventricular arrhythmias, or cardiac death• Overall survival in participants receiving AFF-01Assess the preliminary • Change from baseline in NT-proBNP levelsefficacy of a singleintravenous dose of • Change from baseline in echocardiography measurement of cardiac AFF-01 over 60 months function and structure (e.g., LV ejection fraction, LV end-diastolic diameter, LV posterior wall thickness, left atrial volume index [LAVI], E / e’)• Percentage of participants who had a change in NYHA Class from baseline• Change from baseline in QoL, e.g., Kansas City Cardiomyopathy Questionnaire (KCCQ-23)• Proportion of participants who experience a cardiac event defined as hospitalization for heart failure, receive treatment with intravenous diuretics for worsening heart failure, receive a cardiac transplantation, left ventricular assist device, sustained ventricular arrhythmias, or cardiac death• Overall survival in participants receiving AFF-01To characterize the • Incidence and prevalence of T reatment-Emergent Adverse Events long-term safety of a (TEAEs) and Serious Adverse Events (SAEs) over 60 months single intravenous doseof AFF-01 over 60 • Incidence and prevalence of TEAE and SAEs considered by the months Investigator to be at least possibly related to AFF-01 over 60 months • Change from baseline in vital signs and physical examinations over 60 months• Change from baseline in laboratory assessments (serum chemistry, hematology, liver function tests (AST, ALT, T.bili, Aik Phos), and urinalysis) over 60 months• Change from baseline in electrocardiogram (ECG) over 60 months Assess the • Change from baseline in levels of Anti-Drug Antibody (T otal Antibody) to immunogenicity of AFF- AFF-01 capsid01 over 12 months • Change from baseline in levels of Anti-Drug Antibody to BAG3• Change from baseline in ELISPOT• Change from baseline in levels of Anti-Drug Antibody (T otal Antibody) to Assess the AFF-01 capsidimmunogenicity of AFF- 01 over 60 months • Change from baseline in levels of Anti-Drug Antibody to BAG38.15.3. Justification for Dose

[0234] AFF-01 has completed GLP Toxicology studies of 3 months duration in NHP at doses of 1e13 vg / kg, 2e13 vg / kg and 4e13 vg / kg. The NOAEL in the 3-month GLP toxicology study was determined tobe 1e13 vg / kg. Therefore, the proposed clinical doses in this study are selected to not exceed 1e13 vg / kg. The dose of 1e13 vg / kg represents approximately a 10-fold lower dose than those currently being used by conventional AAV9 or AAV.rh74 capsids in other cardiovascular disease gene therapy trials which further supports the safety of the proposed dose range.

[0235] BAG3 DCM is a haplo-insufficient disease that is cell autonomous by nature as BAG3 is a nonsecreted intracellular protein. Therefore, the therapeutic goal is to achieve BAG3 gene transfer broadly across cardiomyocytes. In the BAG3 cKO+Amouse model, animals treated with AFF-01 at a dose of 9e11 vg / kg demonstrated restoration of cardiac function and improvement in cardiac structure. This was attained with a successful gene transfer in the heart quantified as 0.06 vg / DG by droplet digital PGR (ddPCR). A 28-day NHP study conducted with a vector consisting of the same capsid and the same BAG3 transgene with the addition of the HA tag to facilitate IHC assessments demonstrated a dose of 4.1e12 vg / kg achieved a similar degree of successful gene transfer with 0.07 vg / DG; suggesting a dose above 4.1e12 vg / kg in NHP may represent the approximate beginning of the therapeutic range. To account for heterogeneity in underlying disease biology and individual variability in response to treatment, a dose slightly above 4.1e12 vg / kg is selected. Of note, in the 3-month GLP toxicology study, the NOAEL of 1e13 vg / kg demonstrated successful gene transfer with 0.2 vg / DG by ddPCR.

[0236] The assumed translation from weight-based dose in NHP to human is 1:1 given the high degree of homology between the NHP and human integrin receptor (99% homology forav and 98% homology for p6 integrin subunits from cynomolgus macaque to man), the mechanism utilized by the capsid to bind and enter cardiomyocytes. The dose of AFF-01 in cohort 1 is therefore chosen to be 6e12 vg / kg, a dose slightly above 4.1e12 vg / kg to account for disease heterogeneity and individual variability in response to treatment, and the dose of AFF-01 in cohort 2 is chosen to be 1e13 vg / kg, the NOAEL in the 3 month GLP toxicology study, pending clinical safety and tolerability as well as the available pharmacodynamic and efficacy assessments in cohort 1 The dose for cohort 3 will be selected based on the safety, efficacy, and pharmacodynamic data observed in cohorts 1 and 2.

[0237] The intravenous route of administration (ROA) is used as this ROA was demonstrated in mice and adult NHPs to enable widespread transduction of AFF-01 throughout the heart.8.15.4. Study Population8.15.4.1 Inclusion Criteria

[0238] Participants are eligible to be included in the study only if all the following criteria in Sections 8.15.4.1.1 to 8.15.4.1.4 apply.8.15.4.1.1 Age

[0239] Participants are 18 to 55 years of age inclusive, at the time of signing the informed consent.8.15.4.1.2 Type of Participant and Disease Characteristics Participants with truncating mutations in BAG3• Participants with Dilated Cardiomyopathy with MRI or echocardiography demonstrating LVEF <45%• Participants New York Heart Association (NYHA) Class I, II or IIIo Participants with NYHA Class I are eligible to participate in Cohort 3 only• NT-proBNPS300 pg / mL forthose in sinus or paced rhythm and ^600 pg / mL for those in atrial fibrillation• Body weight < 100 kg8.15.4.1.3 Sex and Contraceptive / Barrier Requirements

[0240] Persons of childbearing potential (PCBP) or male participants with a PCBP partner must use highly effective contraceptive during the course of the study until viral shedding has been documented to be undetectable on two consecutive tests or when the vector levels have plateaued at low or negligible levels. If the use of highly effective contraception is contraindicated, then two forms of effective contraception are utilized. Female participants abstain from egg donation and cryopreservation of germ cells during the course of the study until viral shedding has been documented to be undetectable on two consecutive tests or when the vector levels have plateaued at low or negligible levels.8.15.4.1.4 Other Inclusion Criteria• ALT or AST <1.3x ULN• eGFR s 45 mL / min / 1.73m2based on Chronic Kidney Disease and Epidemiology equation (CKD- EPI) equation• Hemoglobin > 10 g / dL (Grade <1 anemia per NCI CTCAE version 5)• Platelet count s 75,000 / mm3 (Grade 2 1 thrombocytopenia per NCI CTCAE version 5)8.15.4.2 Exclusion Criteria

[0241] Participants are excluded from the study if any of the following criteria apply:Medical Conditions:• History of any prior gene therapy with AAV• Prior myocardial infarction• Prior heart transplant• Presence or requirement of a left ventricular assist device (LVAD)• Active cancer or cancer diagnosis with the exception of non-melanoma skin cancer or other carcinoma in situ. Patients who have completed definitive treatment for malignancy are eligible if there has been no evidence of active malignancy during the prior five years Prior / Concomitant Therapy:IV therapy with positive inotropes, vasodilators, or diuretics for heart failure within 30 days prior to enrollment (ie, participants must be stable on oral medical therapy)• Prior / Concurrent Clinical Study Experience• Enrollment in any other clinical trial with an investigational product within 4 weeks prior to screening or within 5 half-lives of the investigational product used in that clinical trial, whichever is longerDiagnostic Assessments:• Positive for anti-Variant 3 capsid polypeptide neutralizing antibodiesOther Exclusion Criteria:• Unable to walk > 100 meter unassisted on baseline 6MWT• Active pregnancy• Active viral infection (including human immunodeficiency virus (HIV) or positive serology for hepatitis B or C)• Any acute illness requiring hospitalization within 30 days prior to enrollment• Known hypersensitivity or contraindication to glucocorticosteroids or their excipients• Any current or previous condition or physical exam or laboratory test finding that, in the opinion of the Investigator, would put the subject at undue risk or would interfere with evaluation and interpretation of the investigational product safety or efficacy results

[0242] Participants with implantable cardioverter-defibrillators (ICDs) are allowed but ICDs are not required. Forthose with ICDs, MRI-compatible ICDs are preferred.8.15.5. Study Intervention(s) and Concomitant Therapy

[0243] The investigational medicinal product (IMP) in this study is AFF-01. Pre-medications for immunomodulation are considered non-IMPs.

[0244] Concomitant therapy consists of any medication (e.g., prescription drugs, over-the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a participant in addition to protocol-mandated treatment from 14 days prior to initiation of study treatment through the end of the study (60 months). All such medications are reported to the investigator and recorded on the appropriate eCRF.8.15.6. Study Intervention(s) Administered

[0245] The study interventions are provided in Table 22.Table 22Intervention Label AFF-01 Methylprednisolone Prednisone Intervention Name AFF-01 Solu-Medrol Prednisone Intervention Description One time IV infusion IV infusion Oral, tablet, once daily Type AAV based gene therapy Drug DrugDose Formulation Solution for IV infusion Single dose vials Tablet40 mg 2.5 mg125 mg 5 mgUnit Dose Strength(s) Target: 2.5e13 vg / mL500 mg 10 mg20 mg1g1 mg / kg (maximum of 60 mg) from Day 4 until Day30Onetime IV infusion onDay 1:Cohort 1: 6e12 vg / kg IV infusion of 2 mg / kg on Start prednisone taper on Dosage Level(s) Day 31Cohort 2: 1e13 vg / kg Day 1 (pre-dose), Day 2 .Standard tapering of dose Cohort3: TBD pending and Day 3by 5 mg / week until a dose safety, tolerability, PD andof 5 mg once daily for one efficacy of earlier dosesweek followed by 2.5 mg once daily for one week and then discontinue Route of Administration IV infusion IV infusion OralUse Experimental Immunosuppression Immunosuppression

[0246] AFF-01 is infused as a single dose to the participant. The dosing solution comprises AFF-01 diluted in 0.9% normal saline solution at a minimum of 3x and a maximum of 12x dilution. Different dilution regimens are utilized to generate a fixed volume of 150 ml.

[0247] AFF-01 is infused into the participant via a peripheral intravenous line over two hours at 75 ml / hr.

[0248] The participant receives AFF-01 in a clinical setting in a facility experienced with investigational therapeutics. Suitable settings include an in-patient hospital ward, an infusion-center, or an out-patient center. At the discretion of the investigator, participants may be hospitalized for upto 7 days prior to and subsequent to the infusion of AFF-01 for safety monitoring8.15.6.1 AFF-01 Formulation

[0249] AFF-01 drug product is formulated as a solution for IV delivery in 27mM KCI, 1 5mM KH2PO4, 172mM NaCI, 8.1mM Na2HPO4, 250mM L-Arginine, 0.005% Pluronic F68, pH 7.08.15.6.2 Pre-Treatment and Immune Suppression

[0250] A pre-treatment prophylaxis regimen of glucocorticoids is administered to minimize the risk of immune reactions to AFF-01. Liver injury and adverse events related to complement activation have emerged as potentially concerning immune reactions to high dose systemic AAV gene therapy. As a consequence, other systemic gene therapies targeting cardiovascular diseases have focused onaggressive immunosuppression strategies to minimize these adverse events which may inadvertently result in adverse events related to the aggressive immunosuppression itself. However, the therapeutic dose range of AFF-01 is approximately 10-fold lower than other systemic AAV gene therapies using conventional AAV capsids. As such, it is believed that AFF-01 administration may not necessitate aggressive immunosuppression and avoid its potential side effects. Preclinical studies including the 3-month GLP toxicology study has supported this strategy, showing no evidence of liver injury (liver enzymes within the upper limit of normal range) or complement activation (no thrombocytopenia, anemia, kidney dysfunction or increases in d-dimer) in NHPs at the relevant doses without any immunosuppression.

[0251] The standard immunosuppression regimen for AFF-01 used in this study is as follows:o Glucocorticoids:• Methylprednisolone 2 mg / kg IV on Day 1 (pre-dose), Day 2 and Day 3• Oral prednisone (1 mg / kg / day with maximum dose of 60 mg / day) beginning on Day 4 and continuing until Day 30• Prednisone taper to begin at the discretion of the Investigator on Day 31. The standard taper regimen is to decrease the oral prednisone dose by 5 mg weekly until a dose of 5 mg once daily for one week, followed by 2.5 mg once daily for one week, after which it is discontinued Prednisone taper may be accelerated or extended at the investigator’s discretion depending on the participant’s clinical response.• Increased doses of steroids (eg, pulse steroid dosing) may be considered for signs of autoimmune organ injury or potentially AAV related transaminase elevations.• If prednisone is not available or not tolerated, an equivalent potency glucocorticoid (eg, dexamethasone) may be substituted.

[0252] The participants are monitored closely for clinical signs and symptoms of active infection during immunosuppression with glucocorticoids.

[0253] Participants are monitored for any clinical evidence of immune activation during the course of the study. Specifically, participants have close monitoring of their liver function tests, complete blood count with peripheral blood smear, kidney function, complement activation and other immunologic markers including hsCRP, TNFa, IL-6 IgG and IgM If participants demonstrate any sign of immune activation, appropriate treatments are instituted promptly and may include adjustments to the pre-treatment prophylaxis regimen for subsequent participants.o Liver injury:• Liver injury due to systemic AAV gene therapy typically responds favorably to steroids. As such participants who have liver injury may have their glucocorticoids restarted (if they have been discontinued already) or their dose and regimen increased (if they are already on glucocorticoids).o Complement activation:• Eculizumab (Soliris) is a complement inhibitor indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). It is available as a 300 mg single use vial and is dosed at 600 mg via 35 min intravenous infusion every 7 days for the first 4 weeks. For those with clear signs of complement activation and incipient Thrombotic Microangiopathy (TMA) or high likelihood of TMA, eculizumab is initiated to inhibit the complement cascade.• At the discretion of the investigator, other approved anti-complement inhibitors may be used instead of eculizumab (e.g., ravulizumab (Ultomiris®), an anti-C5 inhibitor approved for the treatment of TMA or aHUS). The alternate anti-complement inhibitor is used according to the USPI or as per clinically standard practiceo Additional prophylaxis may be considered for subsequent participants.• If there are signs and symptoms of immune activation due to AFF-01 on the glucocorticoid only regimen, additional immune suppression may be considered to minimize risk to subsequent participants. Such a prophylaxis regimen can include:■ Rituximab 1 ,500 mg / m2IV, divided into multiple doses or an alternate anti-CD20 monoclonal antibody may be used (e.g., Obinutuzumab (Gazyva®)).■ Sirolimus 2 mg orally once daily starting prior to infusion of AFF-01.8.15.6.3 Dose Modification and Retreatment Criteria

[0254] No dose modifications are permitted in this study. In this study, a single intravenous (IV) dose of the investigational product is administered on Day 1 (D1). No additional doses are planned as part of the study protocol Retreatment with the investigational product is not permitted under this protocol.8.15.6.4 Prior and Concomitant Therapy

[0255] Paracetamol / Acetaminophen, at doses of 1.5 grams / day and Diphenhydramine at doses of ^50 mg / day are permitted for use during the study

[0256] Medications to prevent complications from corticosteroid use may be co-administered in accordance with institutional guidelines and may include prophylaxis for Pneumocystis jirovecii pneumonia as appropriate.

[0257] Participants have received meningococcal vaccination appropriate for age and health condition as recommended by the Centers for Disease Control. The meningococcal vaccination may be given at least 8 weeks prior to administration of IP

[0258] During the period of immunomodulation, participants are discouraged from receiving any live or live-attenuated vaccines.8.15.6.5 Rescue Medicine

[0259] Participants in this study have NYHA Class I, II, or III HF on stable medical therapy. Participants with any recent use of IV therapy with positive inotropes, vasodilators, or diuretics for heart failure suggesting unstable disease are excluded. Nonetheless, decompensation into symptomatic acute HF requiring urgent therapy may occur over the course of 5 years follow up given the natural history of the disease Decompensation events requiring hospitalization or IV therapy are documented as an HF event.

[0260] Participants with stable but worsening HF may have their guideline directed medical therapy adjusted as appropriate (including changes in diuretic regimen).8.15.7. Results

[0261] AFF-01 administered as a single intravenous infusion is safe, well tolerated, and efficacious.8.16. Example 15: Evaluation of Efficacy and Pharmacology of AFF-01 in BAG3 cKO+ / - Mouse Following Single IV Administration8.16.1. Overview

[0262] The first objective of this example was to evaluate cardiac function in BAG3 cKO+ / - mice after one-time intravenous (IV) treatment of AFF-01 at a single dose level, compared to BAG3 cKO+ / - and WT mice receiving formulation buffer (FB). Two other variant rAAV were included in the study. Details of rAAV genomes used in this assessment are set forth in Table 23 below.Table 23rAAV Promoter / Transgene / Regulatory elementAFF-01 ITR-CK8e-hBAG3-OPRE-BGH pA-ITRAFF-02 ITR-CK8e-hBAG3-3xHA-OPRE-BGH pA-ITRAFF-03 ITR-CK8e-hBAG3-BGH pA-ITR

[0263] All rAAV had Variant 3 capsid polypeptides (VP1 of SEQ ID NO:10 and VP2 and VP3 portions thereof)

[0264] Transthoracic echocardiogram was utilized to visualize and quantify changes in cardiac contractility and dilation Specific echocardiogram measurements were utilized to assess changes in a) cardiac contractility i e., left ventricular ejection fraction (EF%) and fractional shortening (FS%); and b) cardiac dilation i e., left ventricular internal diameter (LVID). The primary endpoint determining therapeutic efficacy was defined as statistically significant improvement in the echocardiogram measurement of cardiac output (EF% in BAG3 cKO+ / - mice) with additional measurements e.g., FS% treated as supportive endpoints. All BAG3 cKO+ / - mice utilized in the study were confirmed to have cardiac functional deficit at 10 weeks of age prior to being utilized for study.

[0265] The second objective of this study was to compare two different frequencies of cardiac ultrasound (bi-monthly (every two weeks), and monthly (every four weeks)) to evaluate improvement of cardiac function To accomplish this, study animals receiving different treatments of test or control articles were also prospectively assigned to one of the two ultrasound regimens as shown in the study design in Table 24.Table 24Group T reatment Mouse Dose (vg / kg) N value and Ultrasound genotype sex timepoints (weeks) 1 FB WT N / A 6F, 6M Baseline (BL),2, 4, 6, 8 2 FB WT N / A 6F, 6M BL, 4, 8 3 FB BAG3 cKO+ / - N / A 5F, 5M BL, 2, 4, 6, 8 4 FB BAG3 cKO+Z- N / A 5F, 5M BL, 4, 8 5 AFF-02 BAG3 cKO+ / - 9.6e11 5F, 5M BL, 2, 4, 6, 8 6 AFF-03 BAG3 cKO+ / - 3.2e12 6F, 5M BL, 2, 4, 6, 8 7 AFF-01 BAG3 cKO+ / - 95e11 5F, 5M BL, 2, 4, 6, 8 8 AFF-01 BAG3 cKO+Z- 9.5e11 5F, 5M BL, 4, 89 AFF-03 BAG3 cKO+Z- 1.1e12 3F, 3M BL, 4, 88.16.2. Results8.16.2.1 Confirmation of Cardiac Functional Deficit and Dilation Phenotype BAG3 cKO+ / - Mice Prior to Dosing

[0266] Nine-week-old WT and BAG3 cKO+ / - mice utilized in this study were evaluated using transthoracic cardiac ultrasound at the beginning of the study. Multiple measurements assessing cardiac contractility and dilation phenotype were recorded On a functional level, BAG3 cKO+ / - mice demonstrated significantly lower cardiac ejection fraction % (EF%) and fractional shortening (FS%), when compared with age-matched WT mice in study (FIGS. 20A and 20B). In comparison to WT mice, the BAG3 cKO+ / - mouse hearts also showed significantly higher left ventricular internal diameter at endsystole (LVIDs), left ventricular internal diameter at end-diastole (LVIDd) and thinner left ventricular posterior wall thickness at systole (LVPWs) (FIGS. 20C-20E). Overall, based on ultrasound measurements conducted prior to treatments in study, BAG3 cKO+ / - mice presented features indicative of DOM; for instance, significantly dilated left ventricles and functional deficiency for cardiac-contractility. These observations made at 9-weeks of age provided phenotypic confirmation of disease onset in BAG3 cKO+ / - mice, in comparison to WT littermates utilized in study prior to dosing at 10 weeks of age.8.16.2.2 AFF-01 Improves Cardiac Function and Reduces Cardiac Dilation in BAG3 cKO+ / - Mice

[0267] Upon confirmation of cardiac functional deficit indicating onset of DCM phenotype, BAG3 cKO+ / -mice at 10-weeks of age, along with age-matched WT mice, were treated as assigned in Table 24. BAG3 cKO+ / - mice receiving AFF-01 treatment showed significantly higher ejection fraction and fractional shortening measurements as compared to FB treatment (FIGS. 21 A and 21 B). Similarly, BAG3 cKO+ / -mice receiving AFF-01 also demonstrated significantly lower LVIDs and increased LVPW, along with a trend of reduced LVIDd, compared with FB treatment (FIGS. 21 C-21 E).

[0268] Additional measurements are shown in Table 25. Overall, at 8-weeks post dosing AFF-01 significantly corrected key features of DCM including measurements of cardiac contractility and amelioration of cardiac dilation phenotype in BAG3 cKO+ / - mice. Additionally, cardiac function and left ventricular diameter in BAG3 cKO+Z- mice treated with AFF-01 were comparable to WT mice treated with FB indicating rescue of disease phenotype.Table 25Measurement WT BAG3 cKO+Z- BAG3 cKO+Z- (FB) (FB) (AFF-01)HR (bpm) 415+9.16 406+11.80 468±13.86LVIDs (mm) 2.980±0.05 3.432±0.06 3.151±0.08LVIDd (mm) 4.107±0.04 4.338±0.06 4.214±0.07LVPWs (mm) 0.950±0.03 0.818±0.03 0.904±0.03EF (%) 53.535±1.33 42.833±1.23 50.236±1.42FS (%) 27.460±0.93 20.975±0.68 25.403±0.86

[0269] Representative M-mode echocardiogram images captured in WT and BAG3 cKO+ / - mice further illustrated improvements in LV function following treatment with AFF-01 (FIG. 22; BAG3 CKO+ / - / AFF-01, right), compared to BAG3 cKO+Z- mice treated with FB (FIG. 22; BAG3 cKO+Z-ZFB, center). Notably, images of BAG3 cKO+ / - mice treated with AFF-01 are similar to those of WT mice receiving FB treatment, indicating effective therapeutic intervention.8.16.2.3 Comparison of Ultrasound Frequency on Cardiac Function in WT and BAG3 cKO+ / - Mice

[0270] Mouse echocardiography is generally conducted under anesthesia in cardiovascular research. Several studies have demonstrated a relationship between sedation and changes in cardiac function. To evaluate that exposing BAG3 cKO+ / - mice to multiple rounds of anesthesia could impact cardiac function and possibly interfere with interpretation of therapeutic efficacy, cardiac ultrasound measurements were collected for study animals at either bi-monthly or monthly frequency post treatment per study design (Table 24). The effect of AFF-01 on improvement in cardiac function in BAG3 cKO+ / - mice was compared between bi-monthly and monthly ultrasound regimens. Cardiac ultrasound testing performed on a bi-monthly (FIG. 23A), or monthly (FIG. 23B) frequency showed significant improvement in cardiac ejection fraction by 8-weeks post injection of AFF-01. AFF-01-treated animals in the bi-monthly ultrasounds showed limited and variable improvement in ejection fraction, whereas AFF-01 -treated animals receiving monthly ultrasound testing exhibited more pronounced and less variable improvement in ejection fraction (FIGS. 23A and 23B). The increased variability observed in the bi-monthly ultrasound group was also seen in control groups. In summary, in comparison to mice that underwent more frequent, bi-monthly ultrasound regimen, the animals which underwent ultrasound testing at less frequent, monthlyinterval showed lower variability in cardiac activity as measured by %EF.8.16.2.4 Pharmacodynamics of AFF-01 in BAG3 cKO+ / - Mice

[0271] Pharmacodynamic endpoints of the study included vector genome (VG) biodistribution measured by ddPCR, vector-derived RNA expression measured by RT-ddPCR and BAG3 protein expression measured by quantitative western blot (ProteinSimple Jess™) across various treatments.

[0272] First, quantification of vector genomes per diploid genome (vg / dg) was performed in genomic DNA samples extracted from cardiac tissue of study animals using ddPCR. Specifically, 9-weeks after rAAV administration, BAG3 cKO+ / - mice receiving AFF-01 showed significantly higher vector biodistribution in cardiac tissue compared to FB treatments (FIG. 24A). Next, RNA extracted from cardiac tissue of study animals was used to evaluate expression of vector-derived mRNA as percentage of RPP30 housekeeping gene (%RPP30) using RT-ddPCR. Similarly, BAG3 cKO+ / - mice receiving AFF-01 treatment also demonstrated significantly higher vector RNA expression compared to FB group (FIG. 24B). Corresponding samples from WT mice receiving FB treatments (WT / FB) were not processed for DNA and RNA analyses as the measurement is irrelevant.

[0273] Pharmacodynamic measurements of AFF-01 were focused on cardiac tissue Biodistribution and expression levels were measured in two additional tissues: quadriceps skeletal muscle and liver. For quantification of BAG3 protein in cardiac tissue of mice in this study, total protein was extracted from frozen mouse heart tissue lysates. ProteinSimple Jess™ automated western blot assay was used to evaluate total human BAG3 protein expressed in cardiac tissue. BAG3 protein in AFF-01 treated BAG3 cKO+ / - mice was compared with FB treated wildtype or BAG3 cKO+ / - mice (FIG. 24C). FB-treated BAG3 cKO+ / - mice expressed approximately 0.43 fold BAG3 protein, compared to FB-treated WT mice, confirming BAG3 haplo-insufficiency in the BAG3 cKO+ / - mice. AFF-01 treated BAG3 cKO+ / - mouse heart tissue had higher BAG3 protein compared to FB treated BAG3 cKO+ / - and WT mice, which wasapproximately 8-fold over endogenous WT levels (FIG. 24C) AFF-01-treated mice showed higher BAG3 mRNA expression in quadriceps, and liver as compared to FB treatments (data not shown).8.16.2.5 Immunohistochemical Evaluation of BAG3 cKO+ / - Mouse Heart Sections with hBAG3 Antibody

[0274] Distribution of vector-derived hBAG3 protein expression was visualized and measured semi-quantitatively using hBAG3 immunohistochemistry (IHC). Analysis of mouse heart IHC sections showed successful hBAG3 expression in cardiomyocytes of BAG3 cKO+ / - mouse hearts. Consistent with the molecular analyses of DNA, mRNA and BAG3 protein expression, specific expression of BAG3 in AFF-01 -treated animals throughout the mouse myocardium was observed, compared to FB group.Quantification of representative images showed an average of 66% of cardiomyocytes were positive for hBAG3 protein expression at the AFF-01 dose level of 95e11 vg / kg (FIGS. 25A and 25B). Results from quantification of cardiomyocyte distribution of hBAG3 expression from other treatment groups showed similar BAG3 protein expression levels (results not shown). Similar to other pharmacodynamic measurements of DNA, RNA and BAG3 protein, the cardiomyocyte coverage of AFF-01 (66%) was comparable to the dose-matched construct containing the HA tag, AFF-02

[0275] Finally, microscopic evaluation of H&E-stained heart sections revealed that BAG3 cKO+ / - mice treated with 95e11 vg / kg of AFF-01 (T able 24, Group 7) show minimal cardiomyocyte degeneration in 3 / 10 animals. There were no early deaths nor AFF-01-related macroscopic findings. Similar cardiac findings were also observed in study groups AFF-02 and AFF-03. Importantly, the histopathological changes observed in the study were minimal both in magnitude and frequency. This is supported by the observation that the histopathological changes were seen in 20-30% of the animals and in -0.1% of cardiomyocytes per heart section in the aforementioned treatment groups. Liver and quadriceps muscle were also evaluated, and no histologic changes were seen in these tissues for any group in this study. No test article-related changes in body weights were observed and all mice survived until the scheduled necropsy date.8.17. Example 16: Dose Ranging Study of AFF-01 in Adult BAG3 cKO+Z- Mice 8.17.1. Overview

[0276] In this Example, the therapeutic efficacy of AFF-01 was studied in the BAG3 cKO+ / - mouse model across three dose-levels. The study parameters, including dose levels, were informed by the results from the study of Example 15 described in Section 8.16. Therapeutic efficacy was measured as improvement in cardiac function based on transthoracic cardiac ultrasound performed across study animals at multiple timepoints post injection The associated pharmacodynamics of AFF-01 was assessed in the terminal necropsy timepoint at 9 weeks post injection. Study parameters including dose levels and timing of ultrasound measurements were informed by the conclusions of Example 15 described in Section 8 16 Study design is shown in Table 26 Genotype-verified BAG3 cKO+ / - and WT mice were assigned to different treatment groups after phenotypic confirmation of cardiac functional deficit.Table 26Group Mouse T reatment Dose N value Ultrasound Analysis genotype (vg / kg) and sex timepoints(weeks)1 WT FB N / A 4M, 4F N / A RT ddPCR, 2 WT AFF-01 3e11 4M, 4F N / A ddPCR, 3 WT AFF-01 6e11 4M, 4F N / A Jess™, 4 WT AFF-01 9e11 4M, 4F N / A H&E 5 WT FB N / A 9M, 6F BL, 4, 8 Ultrasound, 6 BAG3 FB N / A 9M, 6F BL, 4, 8 RT ddPCR, cKO+ / - ddPCR, 7 BAG3 AFF-01 3e11 9M, 6F BL, 4, 8 Jess™, cKO+ / - H&E 8 BAG3 AFF-01 6e11 9M, 6F BL, 4, 8cKO+ / - 9 BAG3 AFF-01 9e11 9M, 6F BL, 4, 8cKO+ / -

[0277] To assess therapeutic efficacy in the BAG3 cKO+ / - mouse model with AFF-01 at three different dose-levels in order to identify the minimum effective dose, cardiac function was measured after different treatments. Specifically, transthoracic ultrasound measurements were utilized to evaluate cardiac function and dilation across study animals at predetermined timepoints: at baseline (BL, prior to dosing), at 4 weeks post dosing, and at 8 weeks post dosing. Therapeutic efficacy was compared at the final ultrasound timepoint (8 weeks post dosing). All mice were sacrificed, and tissues harvested for pharmacodynamic evaluations using biochemical and histological analyses at 9 weeks post injection 8.17.2. Results8.17.2.1 Confirmation of Cardiac Functional Deficit and Dilation Phenotype in BAG3 cKO+ / - Mice Utilized in the Study Prior to Dosing

[0278] Nine week old WT and BAG3 cKO+ / - mice were evaluated using transthoracic cardiac ultrasound prior to dosing study animals. Multiple measurements assessing cardiac contractility and dilation phenotype were recorded On a functional level, BAG3 cKO+ / - mice demonstrated significantly lower cardiac ejection fraction (EF%) and fractional shortening (FS%), when compared with age-matched WT mice in study (FIGS. 26A and 26B). In comparison to WT mice, the BAG3 cKO+ / - mouse hearts also showed significantly higher left ventricular internal diameter at end-systole (LVIDs) and reduced left ventricular posterior wall thickness at systole (LVPWs (FIGS. 26C and 26E). While a similar trend of higher left ventricular internal diameter at end-diastole (LVIDd) was also observed in BAG3 cKO+ / -mouse hearts when compared to WT littermates, this change was not statistically significant (FIG. 26D). Overall, based on ultrasound measurements conducted prior to treatments in study, BAG3 cKO+ / - mice presented features indicative of DCM, such as significantly dilated left ventricles and cardiac contractility impairment. These observations made at 9 weeks of age provided phenotypic confirmation of disease onset in BAG3 cKO+ / - mice, in comparison to WT littermates utilized in this study prior to dosing at 10 weeks of age.8.17.2.2 AFF-01 Improves Cardiac Function and Reduces Cardiac Dilation in BAG3 cKO+ / - Mice

[0279] Multiple measurements assessing cardiac contractility and dilation phenotype were recorded at 8 weeks post treatment. First, echocardiography measurements were compared between BAG3 cKO+ / -and WT mice receiving FB treatments. Comparing cardiac functional measurements, BAG3 cKO+ / - mice treated with FB demonstrated significantly lower cardiac EF% and FS%, when compared with FB treated WT mice (FIGS. 27A-27B). Comparing cardiac structural measurements, BAG3 cKO+ / - mice treated with FB also showed significantly higher LVIDs when compared to FB treated WT mice. While a similar trend of higher LVIDd, and lower LVPWs were also observed in BAG3 cKO+ / - mouse hearts when compared to WT littermates, these changes were not statistically significant (FIGS. 27C-27E). Overall, at 8 weeks post dosing, BAG3 cKO+ / - mice continued to present functional and structural cardiac features consistent with DCM phenotype.

[0280] Next, echocardiography measurements were compared between BAG3 cKO+ / - mice receiving AFF-01 and FB treatments. Comparing cardiac functional measurements, BAG3 cKO+ / - mice receiving AFF-01 at high dose (HD, 9e11 vg / kg) showed significantly higher EF% and FS%, as compared to FB treatments (FIGS. 27A and 27B). Comparing cardiac structural measurements, BAG3 cKO+ / - mice receiving AFF-01 at high dose (HD, 9e11 vg / kg) demonstrated significantly lower LVIDs, along with a trend toward reduced LVIDd, and higher LVPWs compared to FB treatment (FIGS. 27C-27E). Although BAG3 cKO+ / - mice receiving AFF-01 at mid dose (MD, 6e11 vg / kg), and low dose (LD, 3e11 vg / kg) showed a trend of improvement in the functional and structural cardiac features of DCM as measured by echocardiography, these changes were not statistically significant as compared to FB treatments (FIGS.27A-27E and Table 27). Overall, BAG3 cKO+ / - mice receiving AFF-01 treatments at high dose (HD, 9e11 vg / kg) showed significant improvement in functional and structural cardiac features of DCM compared to FB treatments. Importantly, echocardiography measurements were comparable between BAG3 cKO+ / -mice receiving AFF-01 treatments at high dose (HD, 9e11 vg / kg), and WT mice treated receiving FB treatments, further supporting phenotypic correctionTable 27Measurement WT BAG3 cKO+ / - BAG3 cKO+ / - BAG3 cKO+ / - BAG3 cKO+ / - (FB) (FB) (AFF-01 LD) (AFF-01 MD) (AFF-01 HD) EF (%) 50.898±1.49 44.307±1.65 47.140±2.08 46.696±1.70 50.529±1.72 FS (%) 25754+092 21 850+094 23596+1 24 23264+1 02 25583+1 04 LVIDs (mm) 3.100+0.07 3.380±0.07 3.290+0.08 3.272+0.09 3.271±0.07 LVIDd (mm) 4.173±0.07 4.321±0.04 4.299±0.05 4.258±0.08 4.236±0.05 LVPWs (mm) 0.895±0.03 0.817±0.04 0.845±0.04 0.875±0.03 0.932±0.04HR (bpm) 413+9.25 427+13.57 440+13.41 427±10.50 439±11.42

[0281] Representative M-mode echocardiogram images captured in WT and BAG3 cKO+ / - study animals further illustrated improvements in LV function following treatment with AFF-01 compared to BAG3 cKO+ / - mice treated with FB Notably, images of BAG3 cKO+ / - mice treated with AFF-01 at HD were similar to those of WT mice receiving FB treatment, suggesting effective therapeutic intervention (FIGS. 28A-28E).8.17.2.3 Pharmacodynamics of AFF-01 in BAG3 cKO+ / - Mice

[0282] Pharmacodynamic endpoints in this study included vector genome (VG) biodistribution measured by ddPCR, vector-derived RNA expression measured by RT-ddPCR, BAG3 protein expression measuredby quantitative western blot (Jess™), and immunohistochemistry to detect distribution of AFF-01 derived BAG3 protein expression.

[0283] First, vector genomes per diploid genome (vg / dg) were quantified in genomic DNA samples extracted from cardiac tissue of study animals using ddPOR. Nine weeks after receiving AFF-01, BAG3 cKO+ / - mice showed higher vg / dg levels in cardiac tissue compared to FB treatments in BAG3 cKO+ / -mice or WT mice. Dose dependent increase was not observed for vg / dg levels in the cardiac tissue of BAG3 cKO+ / - mice treated with AFF-01 (FIG. 29A). Background vg / dg levels observed in FB treated BAG3 cKO+ / - mice were higher than WT mice receiving FB treatment (FIG. 29A).

[0284] Next, RNA extracted from cardiac tissue of study animals was used to evaluate expression of vector-derived mRNA as percentage of RPP30 housekeeping gene (%RPP30) using RT-ddPCR. BAG3 cKO+ / - mice receiving AFF-01 demonstrated significantly higher vector RNA expression compared to FB treatments across all three dose levels (FIG. 29B) Dose-dependent increase was observed for RNA expression in the cardiac tissue of BAG3 cKO+ / - mice treated with AFF-01 (FIG. 29B) Background RNA expression levels observed in FB treated BAG3 cKO+ / - and WT mice were comparable (FIG. 29B).

[0285] Quantification of BAG3 protein was conducted for heart tissue. Total protein was extracted from frozen mouse heart tissue lysates. ProteinSimple Jess™ automated western blot assay was used to evaluate total BAG3 protein expressed in cardiac tissue. BAG3 cKO+ / - mice expressed approximately 0.39-fold BAG3 protein, compared to WT mice (FIG. 29C). These results provided biochemical confirmation of BAG3 haplo-insufficiency in BAG3 cKO+ / - mice utilized in the study. Compared with FB, AFF-01 treated BAG3 cKO+ / - mouse heart tissue resulted in higher and dose-dependent increase in BAG3 protein expression. An approximately 7-fold higher BAG3 protein expression was observed in the HD (9e11 vg / kg) treatment group compared to WT mouse heart (FIG 29C)

[0286] Analysis of mouse heart IHC sections showed successful BAG3 expression in cardiomyocytes of BAG3 cKO+ / - mouse hearts. Consistent with molecular analyses of DNA, RNA and BAG3 protein levels, specific overexpression of BAG3 in AFF-01-treated mice throughout the mouse myocardium was observed, compared to FB groups (FIGS. 30A-30E). Treatments in WT mice also resulted in higher and dose-dependent increase in % cardiomyocyte transduction in heart tissue, compared to no specific staining in the FB treatment groups. Specifically, hBAG3 immunohistochemistry was used to detect percent positive cells in the left ventricle of the heart Immunostaining was observed primarily in cardiomyocytes. There was a dose-dependent increase of 8.4%, 22.1% and 41.9% positive cardiomyocytes in the 3e11 vg / kg, 6e11 vg / kg and 9e11 vg / kg WT groups respectively (groups 2-4 in Table 26). There was a dose dependent increase of 5.4%, 40.2% and 55.7% positive cardiomyocytes in the 3e11 vg / kg, 6e11 vg / kg, and 9e11 vg / kg BAG3 cKO+ / - groups respectively (groups 7-9 in T able 26). In addition to IHC, an exploratory in situ hybridization readout utilizing probes against the AFF-01 transcript was also performed. OPRE ISH showed a dose dependent increase in both WT and BAG3 cKO+ / - 6e11 vg / kg and 9e11 vg / kg animals.

[0287] Microscopic evaluation of H&E-stained heart sections was performed to evaluate histopathologic changes. There were no AFF-01 -related microscopic findings in WT mice (groups 1-5 in Table 26). Therewere AFF-01 -related microscopic findings present in the heart of BAG3 cKO+ / - mice at 9e11 vg / kg (group 9 in Table 26). In 3 out of 15 BAG3 cKO+ / - animals at 9e11 vg / kg (group 9 in table 26) there was minimal degeneration in cardiomyocytes. Histopathological changes observed in the study were minimal both in magnitude and frequency, which is supported by the observation that the histopathological changes were seen in 20-30% of the mice and in -0.1 % of cardiomyocytes per heart section. Liver and quadriceps muscle were also evaluated, and no histologic changes were seen in these tissues for any group in this study. No test article-related changes in body weights were observed. AFF-01 was well tolerated in both WT and BAG3 cKO+ / - animals, there were no early deaths nor AFF-01 -related macroscopic findings in any group.

[0288] In summary, AFF-01 treatment in the BAG3 cKO+Z- mouse model at a dose of 9e11 vg / kg resulted in improvement of functional and structural cardiac features of DCM.8.18. Example 17: Evaluation of the Kinetics of AFF-01 Biodistribution and Expression in BAG3 Haplo-insufficient Conditional Knockout Mouse Model of BAG3 Dilated Cardiomyopathy8.18.1. Overview

[0289] The study of this Example had two objectives: the primary objective was to evaluate kinetics of AFF-01 biodistribution in the BAG3 cKO+ / - disease mouse model of BAG3-DCM and the secondary objective was to evaluate expression levels of therapeutic cargo expressing BAG3 as a result of AFF-01 treatment at various timepoints after treatment. To achieve these objectives, genotype-verified BAG3 cKO+ / - mice were treated at 10 weeks of age, after onset of cardiac function deficit, with either AFF-01 or formulation buffer (FB) treatments. Animals from various treatment groups were sacrificed and tissues harvested at each timepoint as shown in Table 28 Tissue samples were first processed for DNA extraction and quantification of AFF-01 vector genome biodistribution using qualified digital droplet polymerase chain reaction (ddPCR) assay. Upon ddPCR analysis, any tissue type deemed positive for vector genome biodistribution was also processed for RNA extraction and RNA expression analysis using qualified reverse transcriptase-ddPCR (RT-ddPCR) assay. In addition to DNA and RNA measurements across multiple tissues, two tissues (cardiac (heart) and a representative skeletal muscle (quadriceps)) were processed for an exploratory BAG3 protein expression measurement using qualified ProteinSimple Jess™ quantitative western blot assay. Similar to DNA and RNA measurements, the exploratory BAG3 protein measurement was also designed to evaluate kinetics and durability of BAG3 protein overexpression after treatment of AFF-01 in BAG3 cKO+ / - disease mouse model of BAG3-DCM Table 28Group Mouse Treatment Dose N value Euthanasia Tissues collected genotype (IV (vg / kg) and sex timepointdelivery) (days)1 BAG3 cKO+ / - FB N / A 2F, 2M 14 Injection site, 2 BAG3 cKO+ / - AFF-01 9.50E+11 3F, 2M 14 gonad, adrenal 3 BAG3 cKO+ / - FB N / A 2F, 2M 28 gland, brain, spinal 4 BAG3 cKO+ / - AFF-01 9.50E+11 3F, 2M 28 cord (cervical, 5 BAG3 cKO+ / - FB N / A 2F, 2M 42 thoracic, and 6 BAG3 cKO+ / - AFF-01 9.50E+11 3F, 2M 42 lumbar), liver, 7 BAG3 cKO+ / - FB N / A 2F, 2M 90 kidney, lung, heart, spleen, blood,8 BAG3 cKO+ / - AFF-01 9.50E+11 3F, 2M 909 BAG3 cKO+ / - FB N / A 2F, 2M 140 bicep, quad, and10 BAG3 cKO+ / - AFF-01 950E+11 3F, 2M 140 pancreas 8.18.2. Results8.18.2.1 Kinetics of AFF-01 Vector Genome Distribution

[0290] In total, 15 tissue samples and one blood sample were collected from each AFF-01 or FB control treated mice at five timepoints after treatment. Genomic DNA was extracted from all samples for ddPCR. Data from each study animal were represented as normalized vector genome per diploid genome (vg / dg) levels for each treatment group across sample types and timepoints.

[0291] AFF-01 vg biodistribution was consistently detected in heart tissue where peak vg / dg measurement was observed at 42-days post treatment (average 0.14 vg / dg). At timepoints beyond 42-days, minimal reduction in biodistribution was observed in the heart (average 0.05 vg / dg) at 140-days post treatment (FIG. 31A). In BAG3 cKO+ / - mice receiving FB treatment, vg biodistribution in the heart tissue was below limit of quantification (BLOQ) at all timepoints except for a minimal detected signal at 42-days (average 0.01 vg / dg) and 90-days (average 003 vg / dg) respectively (Tables 29A and 29B).

[0292] Highest levels of vg biodistribution were observed in the liver tissue derived from study animals treated with AFF-01 across various timepoints (FIG. 31A). Similar to heart, peak vg / dg measurement was observed in the liver at 42-days post treatment (average 0.44 vg / dg) and remained stable through 140-days post treatment (average 0.54 vg / dg) In general, lower vg biodistribution levels were observed in skeletal muscles and peripheral tissues Consistently vg biodistribution higher than background was observed in adrenal glands across all time points with an average 0.04 vg / dg detected at 140 days post treatment. While elevated vg biodistribution level was observed in the injection-site (tail) tissue at the earliest timepoint (average 0.92 vg / dg at 14-days post treatment), this value significantly declined to average 0.02 vg / dg by 140-days post treatment. Similarly, lowvg biodistribution levels were observed in the spleen tissue at earlier timepoints (average 0.05 at 28 days post treatment) whereas the vg / dg levels reduced to BLOQ at 140-days post treatment. BLOQ to very low levels of vg biodistribution were observed in several other tissues including the quadriceps, biceps, pancreas, kidney, lung, gonad, and brain (FIG. 31A and Tables 29A and 29B). Similar to multiple tissue samples in the study, blood also showed peak vg biodistribution (average 83.6 copies per 10ng DNA) at 42 days post treatment, which declined to near background levels by 140-days post treatment (FIG. 31 B).Table 29AGroup DNA distribution (vq / dq)Heart Quadriceps Biceps Liver Spleen Adrenal SCO SOT Gland1 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 0.02 + 0.01 3 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 5 0.01 ± BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 0.007 0.03 ± BLOQ BLOQ BLOQ BLOQ BLOQ 005 ± BLOQ 0.01 0029 BLOQ BLOQ BLOQ BLOQ BLOQ 002 + BLOQ BLOQ0.01Table 29AGroup DNA distribution (vg / dg)Heart Quadriceps Biceps Liver Spleen Adrenal SCO SOT Gland2 0.08 ± BLOQ BLOQ 0.16 ± 0.03 ± 0.06 ± 022 ± 0.02 ±0.02 0.06 0.01 0.02 0 18 0.01 4 0.10 ± BLOQ BLOQ 0.39 ± 0.07 ± 0.08 ± BLOQ 0.13 ±0.01 0.12 0.02 0.01 0.11 6 0.14 ± 0.04 ± 0.02 0.05 ± 0.44 ± 0.04 ± 0.04 ± BLOQ BLOQ 0.04 0.04 0.18 0.02 0.018 0.07 ± 0.04 ± 0.01 BLOQ 0.43 ± BLOQ 0.04 ± BLOQ BLOQ 0.02 0.18 0.0210 0.05 ± BLOQ 0.03 ± 0.54 ± BLOQ 0.03 ± BLOQ BLOQ0.01 0.01 0.11 0.01Table 29BGroup DNA distribution (vg / dg) Blood SLC Brain Tail Pancreas Kidney Lung Gonad (Cp / 10ng DNA) 1 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 3 001 ± BLOQ BLOQ 003 + 001 + 003 + BLOQ BLOQ 0.00 0.01 0.00 0.025 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 7 BLOQ 0.02 ± BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 0.019 0.04 ± BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 0.012 BLOQ BLOQ 0.92 ± BLOQ BLOQ BLOQ BLOQ 11.69 ±0.27 2.80 4 BLOQ BLOQ 0.27 ± 0.05 ± 0.01 ± 0.01 ± BLOQ 22.51 ±0.13 0.03 0.00 0.00 6.42 6 BLOQ BLOQ 0 12 + BLOQ BLOQ BLOQ BLOQ 8362 +0.07 65.88 8 BLOQ BLOQ 0.50 ± BLOQ BLOQ BLOQ BLOQ 33.39 ±0.18 21.47 10 BLOQ BLOQ 002 + BLOQ BLOQ BLOQ BLOQ 677 +0.00 4.928.18.2.2 Kinetics of AFF-01 Vector-Derived RNA Expression

[0293] Tissue samples positive for vg biodistribution were processed for RNA expression analysis across various timepoints. In total, seven tissue samples were processed for RNA expression. Total RNA was extracted from all samples for RT-ddPCR based measurement of RNA expression. RNA measurements were represented as vector-derived mRNA expressed as a percentage of RPP30 housekeeping gene (%RPP30) in each tested tissue sample

[0294] Results of this assessment is summarized in Tables 30A and 30B, and FIG. 32. Briefly, in BAG3 cKO+ / - mice receiving FB treatment RNA expression was BLOQ at all timepoints except for a minimal detected signal at 14-days in cervical spinal cord (average 0.68% RPP30) and 28-days in kidney (average 5.28% RPP30) AFF-01-derived RNA expression was consistently detected in the heart tissue with peak RNA level observed at 42-days post treatment (average 270.49% RPP30). At timepoints beyond 42-days, minimal reduction in RNA expression was observed in the heart (average 175.14% RPP30) at 140-days post treatment. Highest levels of RNA expression were observed in the liver tissue samples from AFF-01- treated mice across various timepoints. Peak RNA expression in liver wasobserved at 90-days post treatment (average 603.63% RPP30) and remained stable through 140-days post treatment (average 528.88% RPP30). High RNA expression was also observed in the injection site (tail) tissue at 2 tested timepoints, average 923.04% RPP30 and 1101.61% RPP30 at 14 days and 90-days post treatment, respectively. Although, significant variability and fluctuation in measurements was observed in the tail tissue along with significant reduction in RNA expression to average 34.54% RPP30 by 140-days post treatment. Moderate RNA expression was observed in the adrenal gland tissue (average 75.42% RPP30) up to 42-days post treatment which declined significantly (average 7.76%RPP30) by 140-days post treatment. RNA expression in other tested tissue samples i.e., quadriceps, biceps and spleen were BLOQ or minimal (average <10% RPP30). Overall, there was durable and high RNA expression after AFF-01 administration in heart and liver tissues, with low levels of RNA expression in adrenal gland, quadriceps, biceps, and spleen tissues, which matched vg biodistribution of AFF-01.Table 30AGroup RNA Expression % of RPP30 reference)Heart Quadriceps Biceps Liver Spleen Adrenal see SOT Gland1 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ 0.62 ± 0.13 BLOQ 3 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ N.D. BLOQ 5 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ N.D. N.D. 7 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ N.D. N.D. 9 BLOQ BLOQ BLOQ BLOQ N.D. BLOQ N.D. N.D. 2 49.16 BLOQ BLOQ 217.90 6.16 ± 87.30 + BLOQ BLOQ + + 2.76 37.4511 98 115.804 129.74 BLOQ BLOQ 432.96 0.93 ± 66.72 ± N.D. BLOQ + + 0.47 14.5916 18 150.126 270.49 4.03 ± 0.36 BLOQ 525.59 BLOQ 75.42 ± N.D. N.D.+ + 17.396692 267.828 152.48 BLOQ BLOQ 603.63 BLOQ 15.10 N.D. N.D.+ + ±4.064364 279.6810 175.14 2.49 ± 1.14 BLOQ 528.88 N.D. 7.70 N.D. N.D.± + ±3.493422 183.72N.D. = Not determinedTable 30BGroup RNA Expression (% of RPP30 reference) Blood SLC Brain Tail Pancreas Kidney Lung Gonad (Cp / 10ng RNA) 1 N D. N.D. BLOQ N.D. N D N.D. N.D. N.D. 3 N.D. BLOQ N.D. 7.16 ± BLOQ N.D. N.D.4.095 N D N D BLOQ N D N D N.D. N D N D 7 N D. N.D. BLOQ N.D. N D N.D. N.D. N.D. 9 N.D. N.D. BLOQ N.D. N.D. N.D. N.D. N.D. 2 N D. N.D. 923.04 N D. N.D N.D. N.D. N D.+471.774 BLOQ N.D. 119.26 N.D. BLOQ BLOQ N.D. N.D.± 7070Table 30B Group RNA Expression (% of RPP30 reference) Blood SLC Brain Tail Pancreas Kidney Lung Gonad (Cp / 10ng RNA) 6 N D. N.D. 20.42 ± N D. N.D N.D. N.D. N D.14 188 N D. N.D. 1102.6 N.D. N.D N.D. N.D. N.D.+958.1410 N D. N.D. 36.09 + N.D. N.D N.D. N.D. N.D.27.328.18.2.3 Kinetics of BAG3 Protein Expression Due to AFF-01T reatment

[0295] Two tissues (cardiac muscle (heart) and a representative skeletal muscle (quadriceps)) were selected for BAG3 protein expression measurements. For quantification of BAG3 protein, quantitative western blot was performed on total protein extracted from frozen heart and quadriceps tissue lysates across various timepoints. BAG3 protein levels in AFF-01 -treated BAG3 cKO+ / - mice were represented as fold-change over FB treatments.

[0296] Results of this assessment are shown in FIG. 33 and Table 31. Briefly, AFF-01-derived BAG3 protein expression was consistently detected in heart tissue with peak protein levels observed at 42-days post treatment (average BAG3 protein level of 26.14-fold over FB treated BAG3 cKO+ / - mice). At timepoints beyond 42-days, there was minimal change in BAG3 protein expression in the heart (average BAG3 protein level of 2051-fold over FB treated BAG3 cKO+ / - mice) at 140-days post treatment.Minimal BAG3 protein expression was also observed in quadriceps muscle. Specifically, an average of 1.13-fold and 1.32-fold over FB treated BAG3 cKO+ / - mice was observed in the quadriceps tissue at 42-, and 140-days post treatment, respectively. Overall, in comparison to FB treatments, durable and high BAG3 protein expression was observed in the AFF-01-treated group in heart tissue up to 140-days post treatment.Table 31Group AUC BAG3 Protein fold change overFB-treated BAG3 cKO+ / - mouse tissuesHeart Quadriceps Heart Quadriceps1 56625±30474 57619±25853 1.00±0.54 1.00±0.453 42675±15075 49017±20593 1.00±0.35 1.00±0.425 68325±11852 59520± 18826 1.00±0.17 1.00±0.317 52525±13503 67667±33121 1.00±0.25 1.00±0.499 75650±22116 59148±4775 1.00±0.29 1.00±0.082 325000±188288 54134±21880 5.74±3.32 0.94±0.384 625200± 142294 68539±24100 14.65±3.33 1.40+0.496 1785800±1176753 67046±24343 26.14±17.22 1.13±0.418 704400±609839 75695±33860 13.41±11.62 1.12±0.5010 1553000+1852540 77939+45315 20.51+24.49 1.32+0.768.19. Example 18: Efficacy of AFF-01 in BAG3 cKO+ / - Mice Compared to Rh74 Vector 8.19.1. Overview

[0297] Rh74 tropism is similar to AAV9 in mouse heart. The objective of this Example was to assess efficacy and pharmacodynamics of AFF-01 (with HA tag) in BAG3 cKO + / - mice compared with rAAV having Rh74 capsid and the same AAV genome as AFF (with HA tag) when dosed at 10 weeks of age (WOA).8.19.2. Materials and Methods8.19.2.1 Study Design

[0298] Animals were randomized into five groups and provided treatments as shown in Table 32.Table 32Group Mouse Dose Weeks atstrain Vector (vg / kg) N dosing Tissues Analysis 1 WT FB NA 15 10 US -BS, 8, 2 cKO FB NA 15 10 11 WPI Nx- 3 cKO AFF-01 +HA 9e11 15 10 12 WPI RT ddPCR, 4 cKO Rh74-Ck8e BAG3- 15 10 Heart. Liver,3HA-OPRE 9e11 quadriceps ddPCR, cKO Rh74-Ck8e BAG3- 15 10 JESS™ 5 3HA-OPRE 9e13 (Protein),IHC, H&E

[0299] Ejection fraction was measured at baseline and 11 weeks post injection (WPI). Fractional shortening, and left ventricular internal diameter at end-systole thickness were measured at 11 WPI. Four samples from the right quad of each heart were collected for biochemical and histological assays at 12 WPI (necropsy). Heart samples 1, 2, and 3 were used for RT-ddPCR, ddPCR, and BAG3 JESS™ analyses, and sample 4 was collected as a backup tissue. Left quad of the heart was used for IHC 8.19.3. Results

[0300] Ejection fraction percentage comparison between cKO and WT groups showed significant differences to WT group 1 at the baseline level (FIG 34A). AFF-01 showed therapeutic efficacy in cKO mice, with the level of AFF-01 efficacy not observed with either of the Rh74 treatment groups. Ejection fraction results are shown in FIG. 34B. Fractional shortening results are presented in FIG. 34C. Left ventricular internal diameter at end-systole (LVIDs) thickness results are shown in FIG. 34D.

[0301] Pharmacological assessments showed that at 9e11 vg / kg dose (groups 3 and 4), AFF-01 showed greater vector genomes per diploid genome and greater BAG3 expression than rAAV with Rh74 capsid. At the 9e13 vg / kg dose, the rAAV with Rh74 capsid showed higher vector genomes per diploid genome values and higher BAG3 protein expression. Differences in vector genomes per diploid genome are shown in FIG. 34E Differences in BAG3 expression by immunohistochemistry (IHC) staining are shown in FIG. 34F. Differences in BAG3 protein expression by Jess™ are shown in FIG 34G (fold change compared to WT) and FIG. 34H (area under the curve (AUG)). IHC staining is shown in FIG. 35. Percentage values indicate percent human BAG3 positive cardiomyocytes.8.20. Example 19: A 3-Month Interim Phase and 6-Month Main Phase Biodistribution and Toxicology Study Via Intravenous Infusion Administration in Non-Human Primates 8.20.1. Overview

[0302] The objective of this Example was to assess the potential toxicity and biodistribution AFF-01 , when given once via intravenous (IV) infusion to non-human primates (cynomolgus macaques).8.20.2. Materials and Methods8.20.2.1 Experimental Design

[0303] Animals were randomized into six groups and provided treatments as shown in Table 33Table 33Number of Animals / sex (excluding unscheduled Test Dose ImmunoInfusion DoseGroup level rate volume euthanasia)Article suppressants (mL / hr) (mL) Necropsy Necropsy (vg / kg)Day 91 Day 181 1 Control 0 No 20 10 1M, 1F 1M,1F 2 Control 0 Yes 20 10 1F 1M 3 AFF-01 1e13 No 20 10 2M, 1F 2M, 1F 4 AFF-01 2e13 No 20 10 2M, 1F 2M, 1F 5 AFF-01 4e13 No 20 10 2M, 1F 2M, 1F 6 AFF-01 4e13 Yes 20 10 2M, 1F 1M, 1F8.20.2.2 Preparation of Formulations

[0304] AFF-01 was stored frozen in glass vials Formulation buffer was stored frozen in 15 mL conical tubes Formulation buffer was moved to refrigerated (2°C to 8°C) storage the day prior to dosing. Test article remained frozen until dosing day On the day of dosing an appropriate number of test article vials were thawed at room temperature for at least 1 hour in order to dose all groups. Thawed test material was pooled and inverted prior to dilution. An RNase and DNase free 50 mL conical tube, labeled with the Study No., Animal Identification (ID) No , and Group No. was prepared for every animal. For Groups 1 and 2, 4.2 mL buffer control and 8.4 mL saline was added for a total working volume of 126 mL. For Groups 3, 4, 5, and 6, the initial dilution to obtain the appropriate vgs (vector genomes) were diluted in buffer control to achieve a volume of 4.2 mL total. The volume of buffer was added to the 50 mL conical tube first and then the calculated volume of AFF-01 was added. After this dilution was performed, an additional 8.4 mL of 0.9% Sodium Chloride for Inj., USP was added to the 50 mL dosing solution tube, resulting in a total working volume of 12.6 mL. The final working volume was inverted (no vortexing) 10 times to ensure contents were thoroughly mixed. Each prepared “Dosing Volume” was transferred to an appropriately sized dosing syringe labeled with matching study and animal ID information. The prepared dosing syringe was used within 4 hours of preparation Any remaining pooled test material was saved and stored frozen at -60°C to -90°C, protected from light8.20.2.3 Administration Of Immunosuppressants

[0305] To mitigate a potential immunogenicity response, an immunosuppression regimen was administered to Groups 2 and 6. The immunosuppressants were administered the same time each day (± 2 hour) based on the first animal dosed each day (Table 34).Table 34Immunosuppressant Route of Treatment Additional Details Administration FrequencyMethylprednisolone IV Days-14 (PreFor administration,Rituximab), -7 (PreMethylprednisolone was Rituximab), 1 (at administered via saphenous or least 1-3 hours prior other suitable vein via slow bolus to Test Article over at least 1 minute. Individual administration), 2 doses were based on the most and 3 recent body weights Prednisone Oral Gavage Daily starting on For administration, Prednisone was Day 4 and through withdrawn from stirred formulations Day 77 and dosed. Individual doses were based on the most recent body weights. After each dose, and prior to removal of the gavage tube, the tube was flushed with 10 mL of tap water.Rituximab IV Days -14 and -7 For administration, Rituximab was administered via saphenous or other suitable vein via slow bolus over at least 1 minute. Individual doses were based on the most recent body weightsSirolimus Oral Gavage Daily, from Day -7 to For administration, Sirolimus was Day 47 (at least 1-3 withdrawn from stirred formulations hours prior to Test and dosed Individual doses were Article based on the most recent body administration on weights. After each dose, and prior Day 1). to removal of the gavage tube, the tube was flushed with 10 mL of tap water.Diphenhydramine IM Day -14 and -7 (at Doses were administered via bolus least 30 minutes intramuscular injection into the prior to Rituximab quadriceps muscle on the hind infusion) leg(s). The location of each injection (e.g., left or right quadriceps) was recorded. The needle was insertedperpendicular to the skin surface 8.20.2.4 Administration Of Test Materials

[0306] Test materials were administered once via IV restrained peripheral infusion (intermittent), via a medical grade peripheral dosing catheter. The first day of dosing was designated as Day 1 for each individual animal. The test article and vehicle were administered over 30 minutes as an intravenous infusion via the right saphenous (or another suitable) vein via a percutaneously placed catheter. A new sterile indwelling catheter was placed prior to dose. Doses were administered using an infusion pump and sterile disposable reservoir / syringe8.20.3. Results

[0307] AFF-01 was administered once via intravenous infusion to male and female cynomolgus macaques at 1 e13, 2e13, or 4e13 vg / kg with or without immunosuppressants and was tolerated at alldoses evaluated. On Day 91, AFF-01-related microscopic findings at2e13 vg / kg included minimal degeneration / necrosis in the heart and minimal degeneration / regeneration in the skeletal muscle of the biceps brachii, quadriceps, and esophagus and mononuclear cell infiltration in the esophagus. At 4e13 vg / kg, AFF-01-related microscopic findings included minimal to mild degeneration / necrosis, hemorrhage, hemosiderin pigment, and fibrosis in the heart and degeneration / regeneration and / or mononuclear cell infiltration in the biceps brachii, diaphragm, and quadriceps muscles as well as the skeletal muscle of the esophagus. At 4e13 vg / kg, degeneration / regeneration was also observed in the skeletal muscle of the tongue, larynx, and anal sphincter. AFF-01-related microscopic findings did not appear to be influenced by the inclusion or exclusion of the immunosuppressive regimen. Degeneration / necrosis in the heart and minimal degeneration / regeneration in the esophagus were considered adverse at S2e13 vg / kg. Based on these findings, the no-observed-adverse-effect-level (NOAEL) for 3 months was considered to be 1e13 vg / kg in males and females. On Day 181, AFF-01 related microscopic findings at 1e13 vg / kg included minimal degeneration / necrosis in the heart and minimal degeneration / regeneration in the diaphragm. At 2e13 vg / kg, AFF-01-related microscopic findings included minimal degeneration / necrosis and minimal fibrosis in the heart and minimal degeneration / regeneration in the skeletal muscle of the tongue and intravenous infusion site. At 4e13 vg / kg, AFF-01-related microscopic findings included mild to moderate degeneration / necrosis, minimal fibrosis, minimal hemosiderin pigment, and mild mononuclear cell infiltration above control threshold in the heart, minimal degeneration / regeneration in the quadriceps muscle and skeletal muscle of the esophagus and anal sphincter, and minimal mononuclear cell infiltration of the esophagus. AFF-01 -related microscopic findings did not appear to be influenced by the inclusion or exclusion of the immunosuppressive regimen. Minimal to moderate degeneration / necrosis in the heart at >1e13 vg / kg and minimal degeneration / regeneration in the esophagus at 4e13 vg / kg were considered adverse. Based on these findings, the NOAEL for 6 months was not determined.8.21. Example 20: A 3-Month Non-GLP Biodistribution Study Via Intravenous Infusion Administration in Non-Human Primates8.21.1. Overview

[0308] The objective of the study of this Example was to evaluate safety and pharmacodynamics of AFF-01 after a one-time intravenous treatment in male and female cynomolgus macaques at the dose levels of 3e12 vg / kg and 6e12 vg / kg. Safety of AFF-01 was evaluated in study animals through in-life observations such as cage-side observations, body weight, clinical pathology, and through histopathology at the 3-month scheduled necropsy timepoint Pharmacodynamics of AFF-01 were evaluated within tissues derived from NHPs at the 3-month scheduled necropsy timepoint. Successful pharmacodynamics was defined by measurement of AFF-01 derived vector genome (vg) biodistribution, and RNA expression in tissues In addition, BAG3 protein expression was evaluated in comparison to formulation buffer treated NHPs using Jess™ quantitative western blot assay. In addition to pharmacodynamics, safety of various treatments was evaluated in study animals through in-life observations such as cage-side observations, body weight, clinical pathology, and histopathology.8.21.2. Materials and Methods8.21.2.1 Experimental Design

[0309] Animals were randomized into three groups and provided treatments as shown in Table 35.Table 35Group Test Dose level Route of Dose volume Number of Necropsy Article (vg / kg) Administration (ml_) Animals / sex Day 1 FB 0 IV infusion o 10 2M, OF 91 2 AFF-01 3e12 ver30 min 10 2M, 1F 913 AFF-01 6e12 10 2M, 1F 918.21.2.1 Dose Selection

[0310] Safety and pharmacodynamics of AFF-01 were evaluated in cynomolgus macaques at doselevels > 1e13 vg / kg in Example 18 described in Section 8.19. In the current Example, safety and pharmacodynamics of AFF-01 were evaluated in cynomolgus macaques at a low dose-level of 3e12 vg / kg (3-fold dose reduction from 1e13 vg / kg), and an intermediate dose-level of 6e12 vg / kg 8.21.2.2 Administration of Test Materials

[0311] Infusions were administered at a rate of 20 mL / hr over 30 minutes using an infusion pump.8.21.2.3 Pharmacodynamic Evaluations

[0312] Pharmacodynamic evaluations in this study included vector genome (vg) biodistribution measured by ddPCR, vector derived RNA expression measured by RT-ddPCR, and BAG3 protein expression measured by quantitative Western blot (Jess™)8.21.3. Results8.21.3.1.1 Vector Genome Biodistribution

[0313] Seven tissue samples derived upon necropsy conducted 3-months post treatment were processed for vg biodistribution analysis by ddPCR. Specifically, five regions of NHP heart (left ventricle, right ventricle, interventricular septum, left atrium, and right atrium), and two additional tissues (quadriceps and liver) were processed for AFF-01 vg analysis. ddPCR analysis utilizing primers specific to RPP30 control gene was also conducted in the same reaction as AFF-01 vg measurement, in order to normalize vg levels per NHP diploid genome. RPP30 levels also confirmed presence of NHP DNA in all samples tested across all 3 treatment groups. Results of RPP30 ddPCR analysis ranged from 1719 to 23680 copies RPP30 per 20 ng DNA.

[0314] Mean RPP30 copies / pL showed similar magnitude across groups and tissue types (FIG. 36 and T able 43). Vg biodistribution measurements were represented as vector genomes per diploid genomes using the formula (OPRE / RPP30)X2. Tabulated summary of AFF-01 derived vg measurements in each tissue sample from AFF-01 and FB control treatment groups are shown in FIG. 36 and Table 36.Table 36GroupTtt reamen1 FB N D ( / k)osevggA BLOQ BLOQ 0.01 0.04 BLOQ BLOQ BLOQ ±0.01 ±0.012 AFF-01 3e12 0.01 0.01 0.01 0.03 0.01 0.01 7.83 ±3 A Lf Viltteenrce0.01 ±000 ±000 ±001 ±000 ±000 ±309 FF-01 6e12 0.16 0.16 0.08 0.10 0.06 0.10 30.07±0.08 ±0.07 ±0.03 ±0.04 ±0.01 ±0.05 ±11.83Rih Vilttgenrce

[0315] BLOQ results for AFF-01 vg measurements were observed in most tissue samples derived from NHPs receiving FB treatments (Group 1 ), except for IVS sample from one animal, and left atrium sample from another animal, which showed minimal value in th Itiltnervenrcuare detection range of the assay. The vg / dg values observed in tissues derived from FB treated NHPs were a Stepumttributed to sporadic cross-contamination in a few instances at the time of tissue collection or sample processing. Observations of OPRE detection above assay LOQ in samples from FB treated NHPs were minima Lf Aitteral in frequency, close to lower limit of quantification (LLOQ) threshold for the assay, and do not affect the interpretation of the results.Consistent measurement of AFF-01 vg biodistribution was made in all tissue samples analyzed from Rih AtitgraAFF-01 treatment groups (Group 2 and 3), with the exception of one animal in Group 2, which showed BLOQ vg measurement in every tissue except liver, and one animal in Group 3 where BLOQ vg measurement was seen in left atrium. Comparing Groups 2 and 3, AFF-01 dose-depen Qdiuarcepsdent increase in vg / dg measurements was observed across all tested tissue types (FIG. 36 and Table 36).

[0316] At the 6e12 vg / kg dose level of AFF-01 , comparing across tissue types analyzed for AFF Li-ver01 vg measurements, highest vg / dg measurement were detected in the liver tissue, (average 3007 vg / dg detected). This was followed by left and right ventricles (average 0.16 vg / dg), followed by the IVS (average 0.15 vg / dg). Lastly, comparable and lower AFF-01 vg biodistribution was observed in the atria and quadriceps tissues (averages ranging from 0.06 to 0.10 vg / dg)

[0317] In summary, Day 91 ddPCR analysis showed AFF-01 vg biodistribution measurements in nearly all tested samples at 6e12 vg / kg dose level (Group 3). Samples derived from NHPs receiving 3e12 vg / kg dose level of AFF-01 (Group 2) showed lower vg biodistribution in comparison to the 6e12 vg / kg Group in all tissues, with some nearing the lower limit of quantification or BLOQ.8.21.3.1.2 AFF-01 RNA Expression by RT-ddPCR

[0318] Seven tissue samples derived upon necropsy conducted 3-months post treatment were processed for OPRE RNA expression analysis by RT-ddPCR. Specifically, five regions of NHP heart (left ventricle, right ventricle, interventricular septum, left atrium and right atrium), and two additional tissues (quadriceps and liver) were processed by RT-ddPCR analysis for AFF-01 RNA measurements. RT-ddPCR analysis using primers specific to RPP30 control gene was conducted in the same reaction asAFF-01 RNA measurement in order to normalize RNA levels per NHP RPP30 control gene. RPP30 Grouplevels also confirmed presence of NHP RNA in all samples tested across all 3 treatment groups. Results of RPP30 RT-ddPCR analysis ranged from 4591 to 59408 copies RPP30 per 20 ng RNA. The mean RPP30 copie Ttt reamens / pL showed similar magnitude across groups and tissue types. To normalize vector OPRE RNA expression results to endogenous RNA expression of RPP30 control gene, a calculation of relative expression was performed using the mean AFF-01 OPRE RNA and RPP30 results for each sample. Relative expression wa D ( / k)osevggs reported as a percentage value, (QPRE / RPP30)X100. Tabulated summary of AFF-01 derived RNA measurements in each tissue sample across AFF-01 and FB control treatment groups are shown in FIG. 37 and Table 37.Lft Vilteenrce

[0319] BLOQ results for AFF-01 RNA expression measurements were observed in all tissue samples derived from NHPs receiving FB treatments (Group 1), except for left ventricle samples from two animals,Rih Vilttgenrcewhich showed minimal value in the detection range of the assay. The sporadic RNA expression values observed in tissues derived from FB control treated NHPs were attributed to cross-contamination at the time of tissue collection or sample processing Such ob Iilttnervenrcuarservations were minimal in frequency and close to lower limit of quantification (LLOQ) threshold for the assa Styepum and do not affect the interpretation of the results. Consistent measurement of AFF-01 RNA expression was made in all tissue samples analyzed from AFF-01 treatment groups (Group 2 and 3) with the exception Lft Aitera of one animal in Group 2, which showed BLOQ RNA measurement in every tissue except left ventricle and liver. Comparing Groups 2 and 3, AFF-01 dose-dependent increase in RNA expression measurements was seen in all 7 tested tissues (FIG. 37 and Table 37). At the 6e12 vg / kg dose level of AFF-01, com Rih Aittgraparing across tissue types analyzed for RNA expression measurements, highest AFF-01 RNA expression measurement was detected in the quadriceps tissue, (average 501 13% RPP30). This was followed by ex Qdiuarcepspression in left and right ventricles (average 21.22% RPP30), and IVS (average 21.40% RPP30). This was followed by lower RNA expression levels observed in the liver (average 8.05% RPP30) and atria (average 0.53% RPP30). Liver

[0320] In summary, Day 91 RT-ddPCR analysis showed AFF-01 derived RNA expression measured in nearly all tested samples at the 6e12 vg / kg dose level (Group 3). Samples derived from NHPs receiving 3e12 vg / kg dose level of AFF-01 (Group 2) showed lower RNA expression in comparison to the 6e12 vg / kg Group in all tissues, with some nearing the lower limit of quantification or BLOQ.Table 371 FB NA 0.54 BLOQ BLOQ BLOQ BLOQ BLOQ BLOQ ±0.132 AFF-01 3e12 3.15 3.43 2.29 0.53 0.83 0.72 4.61 ±1.46 ±1.52 ±1.57 ±0.41 ±0.65 ±0.38 ±0.85 3 AFF-01 6e12 21 22 11 34 21 40 1 43 422 501 13 805±9.50 ±3.86 ±1.30 ±0.64 ±1.52 ±256.96 ±1.178.21.3.1.3 BAG3 Protein Expression by ProteinSimple Jess™ Quantitative Western Blot

[0321] For quantification of BAG3 protein expression, total protein was extracted from frozen NHP heart tissue lysates. Briefly, ProteinSimple Jess™ quantitative western blot assay was used to evaluate total BAG3 protein. Correcte Groupd area under the curve (AUC) was generated by normalizing BAG3 AUC detected to total protein in each sample. BAG3 concentration in pg / ul was interpolated using an 8-point standard curve prepared with recombinant human BAG3 BAG3 protein expression in cardiac tissue samples derived from AFF-01 treated NHP Lft Vilteenrces was represented as fold-change of corrected AUC over corresponding samples from formulation buffer control treated NHPs in the study.

[0322] BAG3 protein expression in AFF-01 Rih Vilttgenrce treatment groups was represented in individual heart region (FIG. 38A) or averaged across all heart regions sampled for analysis (FIG. 38B). Overall, BAG3 protein expression was detected in heart samples from NHPs administered AFF-01 at both dose levels (3e12Iilttnervenrcuarvg / kg and 6e12 vg / kg). Specifically, at the dose of 3e12 v Stgepum / kg, up to 1.24-fold BAG3 protein expression was detected in comparison to formulation buffer control treated animals. A dose-dependent increase in BAG3 protein expression between 3e12 vg / kg and 6e12 vg / kg do Atisraing groups was not observed in all heart regions In addition to the graphical representation of BAG3 protein expression shown in FIGS 38A and 38B, tabulated summary of the BAG3 protein expression data from each treatment group is shown in Table 38. Overall, across four tested cardiac regions (left ventricle, right ven H (lltteararicle, interventricular septum,i) regonsand atria), the two tested dose levels of AFF-01 resulted in minimal and comparable BAG3 protein overexpression of upto 1.24X (Table 38). Comparing cardiac regions, at the 3e12 vg / kg dose level, minimally higher BAG3 protein expression was observed in the left and right ventricles, and the atria, as compared to interventricular septum. These minimal regional differences were not observed in the 6e12 vg / kg dose level, where comparable BAG3 protein expression levels were measured in all four cardiac regions analyzed.Table 381 1.00 + 1.00 + 1.00 + 1.00 + 1.00 +0.43 0.04 0.10 0.33 0.212 1.24 ± 1.17 ± 1.00 ± 1.19 ± 1.15 ±0.08 0.08 0.27 0.43 0.243 1.00 + 1.02 + 1.08 + 0.93 + 1.01 +0.22 0.17 0.13 0.25 0.188.21.3.1.4 Interpretation of Pharmacodynamics

[0323] Biodistribution (vg) and RNA expression were detected in different anatomical locations of the heart, quadriceps, and liver tissues in NHPs administered AFF-01, at 3 months post treatment. The pharmacodynamic measurements showed an AFF-01 dose-dependent increase, with tissues derived from NHPs receiving the higher 6e12 vg / kg dose (Group 3) showing higher vg and RNA levels, compared to corresponding tissues from NHPs receiving the lower 3e12 vg / kg dose (Group 2).

[0324] While the primary purpose of this Example was to evaluate AFF-01 pharmacodynamics in the heart tissue, vg biodistribution and RNA expression were also measured in the quadriceps and liver tissues. Although the highest measured AFF-01 vg biodistribution was observed in the liver tissue, AFF-01 RNA expression in liver was comparable or lower than heart and quadriceps tissues. This observation is consistent with the muscle-specificity of the CK8e promoter utilized in the AFF-01 vector.

[0325] Without being bound by theory, it is believed that successful transduction of the heart tissue is central to the efficacy of AFF-01 gene therapy in BAG3 DCM. AFF-01 vg and RNA measurements were consistently detected at 6e12 vg / kg dose-level in several NHP tissues including multiple heart regions. NHPs receiving 3e12 vg / kg dose level of AFF-01 showed lower vg and RNA measurements in comparison to the 6e12 vg / kg Group in all tissues, with some nearing the lower limit of quantification or BLOQ. It is noted that one animal showed multiple BLOQ measurements for AFF-01 vg and RNA. This animal at Day -7 (prior to AFF-01 treatment) seroconverted with a NAb titer of 1 : 10, indicating the level of NAbs which may affect gene transfer. Overall, results of vg and RNA measurements in this Example indicated that AFF-01 exposure levels achieved in the NHP heart resulted in meaningful pharmacodynamics consistent with the therapeutic strategy for AFF-01

[0326] BAG3 protein expression was detected in the cardiac tissue of NHPs administered with AFF-01 and FB. The magnitude of increase in BAG3 expression was not AFF-01 dose-dependent, and it was variable across anatomical location of the cardiac tissue sample.

[0327] On average, across all heart regions processed for analysis, the two tested dose levels of AFF-01 resulted in a slight increase in total BAG3 expression Specifically, average -1.15-fold and -1.01 -fold BAG3 protein expression over the FB treated group was measured in 3e12 vg / kg and 6e12 vg / kg AFF-01 treatment groups, respectively. BAG3 protein measured in this study utilized a quantitative Western blot method which does not differentiate between endogenous (NHP-derived) and human (vector-derived) BAG3.

[0328] Human and NHP BAG3 proteins share high sequence homology (967% sequence identity at the amino acid level). Due to this, commercially available detection antibodies do not differentiate between the two proteins. As a result of this limitation, it is important to note that a dose-response relationship was not observed, nor expected in this study for total BAG3 protein expression in NHP cardiac tissue. BAG3 expression in cardiomyocytes is associated with a diverse set of functions e.g., protein turnover and maintenance of sarcomeric integrity. Possibly due to its role in cellular homeostasis, total BAG3 levels are known to be tightly regulated at steady state. It is conceivable that the absence of a clear AFF-01 dose-dependent increase in total BAG3 protein observed in normal NHPs utilized in this study could be explained by endogenous mechanisms of autoregulation.8.21.3.2 Summary of the Results

[0329] AFF-01 dose-dependent increase in vg and RNA levels were observed in NHP heart, skeletal muscle, and liver. The AFF-01 6e12 vg / kg group showed consistent detection of vg and RNA levels, whereas matching vg and RNA levels for the AFF-01 3e12 vg / kg group were lower, in some cases nearing the lower detection limit of test methods. A slight increase in total BAG3 protein expression (1.15X) was observed in the heart of NHPs dosed at 3e12 vg / kg of AFF-01, compared to the FB treatment group. Heart tissue obtained from animals dosed with 6e12 vg / kg of AFF-01 showed similar BAG3 protein expression (1.01X) when compared with formulation buffer treatments. A dose-response relationship was not observed for total BAG3 protein expression in NHP cardiac tissue at the AFF-01 dose-levels tested in this study The absence of a clear AFF-01 dose dependent increase in total BAG3 protein observed in healthy NHPs utilized could be explained by endogenous mechanisms of autoregulation or variability in sampling at these lower doses.

[0330] The results in Examples 15-20 provide further justification for the doses selected in Example 14. In the BAG3 cKO+ / - mouse model, the minimum effective dose was determined to be 9e11 vg / kg; a dose at which AFF-01 normalized the EF and improved the structural features of the heart including the left ventricular dilatation and posterior wall thinning. Doses below 9e11 vg / kg showed numerical improvements that were not statistically significant. At 9e11 vg / kg, AFF-01 demonstrated successful gene transfer with 0.06 vg / dg by ddPCR, increased mRNAto 215% of housekeeping gene RPP30, and transduced 55% of cardiomyocytes by immunohistochemistry with overall increase in human BAG3 protein levels by 7-fold compared to formulation buffer treatment In NHP, AFF-01 showed similar pharmacological activity at a dose of 6e12 vg / kg with successful gene transfer demonstrated by 0.16 vg / dg by ddPCR and increased mRNA of 21% of RPP30. While mRNA values achieved in NHPs at 6e12 vg / kg were lower than what was seen in the BAG3 cKO+ / - mouse model treated with 9e11 vg / kg, mouse models have historically demonstrated greater mRNA expression in response to AAV gene therapy compared to NHP across capsids and transgenes Nonetheless, the DNA values were similar between these doses in BAG3 cKO+ / - mouse model and NHP suggesting similar degree of successful gene transfer using AFF-01. Therefore, 6e12 vg / kg in NHP is considered to be a pharmacologically active dose. In addition, NHPs treated with 6e12 vg / kg of AFF-01 tolerated the dose well and were without any histopathological findings in the heart at 3 months. In the 6-month GLP toxicology study, 4e13 vg / kg, the highest dose tested, was declared the maximum tolerated dose (MTD). Dose-dependent cardiomyocyte degeneration / necrosis was observed on histopathology which were not associated with any clinical correlate or changes in high sensitivity troponin I at 6 months; suggesting the observations are likely not clinically relevant. Therefore, the dose of 6e12 vg / kg has been demonstrated to be a safe dose in NHP with a 67x margin to the declared MTD The maximum dose for the study of Example 14 is 1e13 vg / kg 1e13 vg / kg is a dose that showed infrequent and minimal severity grade histologic findings in the heart in NHPs in the 6-month GLP toxicology study and was without any clinical sequelae including elevations in Troponin I. The dose also has a 4x margin to the declared MTD of 4e13 vg / kg.9. CITATION OF REFERENCES

[0331] All publications, patents, patent applications and other documents cited in this application are hereby incorporated by reference in their entireties for all purposes to the same extent as if each individual publication, patent, patent application or other document were individually indicated to be incorporated by reference for all purposes. In the event that there is an inconsistency between the teachings of one or more of the references incorporated herein and the present disclosure, the teachings of the present specification are intended.10. SEQUENCES

[0332] Certain sequences of the present disclosure are provided in Table S below.Table SDescription Sequence SEQ ID NOTargeting SAQRGDRGQI 1 Peptide 1 (VRHI)Targeting ASSRGDFNNL 2 Peptide 2 (VRVIII)Targeting ENKRGDYTSM 3 Peptide 3 (VRVIII)Targeting ENRRGDFNNL 4 Peptide 4 (VRVIII)Peptide NSTSGASTNDNA 5 Segment 1 (VRI)Peptide SGTTGGSSNDNT 6 Segment 2 (VRI)Peptide NSTSGGSSNDNA 7 Segment 3 (VRI) (WT)Variant 1 MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVL 8 amino acid PGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNH sequence (full) ADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKR PVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPA APSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRV ITTSTRTWALPTYNNHLYKQISNSTSGASTNDNAYFGYSTPWGYFDFNR FHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANN LTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGS QAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDR LMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPS YRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEG EDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQV ATNHQSAQRGDRGQIAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWA KIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSF ITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEG VYSEPRPIGTRYLTRNLVariant 2 MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVL 9amino acid PGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNHTable SDescription Sequence SEQ ID NOsequence (full) ADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKR PVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPA APSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRV ITTSTRTWALPTYNNHLYKQISSGTTGGSSNDNTYFGYSTPWGYFDFNR FHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANN LTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGS QAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDR LMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPS YRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEG EDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQV ATNHQASSRGDFNNLAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWA KIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSF ITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEG VYSEPRPIGTRYLTRNLVariant 3 MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVL 10 amino acid PGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNH sequence (full) ADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKR PVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPA APSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRV ITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNR FHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANN LTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGS QAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDR LMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPS YRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEG EDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQV ATNHQENKRGDYTSMAQAQTGWVQNQGILPGMVWQDRDVYLQGPIW AKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNS FITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTE GVYSEPRPIGTRYLTRNLVariant 4 MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVL 11 amino acid PGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNH sequence (full) ADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKR PVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPA APSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRV ITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNR FHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANN LTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGS QAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDR LMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPS YRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEG EDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQV ATNHQENRRGDFNNLAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWA KIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSF ITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEG VYSEPRPIGTRYLTRNLVariant 3 TAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDP 20 amino acid QPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDS sequence QWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTP (VP2) WGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDN NGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYG YLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYA HSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGR NYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPA MASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVA TESYGQVATNHQENKRGDYTSMAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFTable SDescription Sequence SEQ ID NO NKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNV EFAVNTEGVYSEPRPIGTRYLTRNLVariant 3 MASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWAL 21 amino acid PTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRD sequence WQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTD (VP3) SDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYC LEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLY YLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVT QNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLI FGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQENKRG DYTSMAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFH PSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVS VEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGT RYLTRNL AAV9 MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVL 32 reference PGYKYLGPGNGLDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLKYNH sequence ADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKR PVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPA APSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRV ITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNR FHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANN LTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGS QAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDR LMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPS YRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEG EDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQV ATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDG NFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTG QVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRP IGTRYLTRNL BAG3 (protein) MSAATHSPMMQVASGNGDRDPLPPGWEIKIDPQTGWPFFVDHNSRTTT 100 (UniProt WNDPRVPSEGPKETPSSANGPSREGSRLPPAREGHPVYPQLRPGYIPIP 095817) VLHEGAENRQVHPFHVYPQPGMQRFRTEAAAAAPQRSQSPLRGMPET TQPDKQCGQVAAAAAAQPPASHGPERSQSPAASDCSSSSSSASLPSSG RSSLGSHQLPRGYISIPVIHEQNVTRPAAQPSFHQAQKTHYPAQQGEYQ THQPVYHKIQGDDWEPRPLRAASPFRSSVQGASSREGSPARSSTPLHS PSPIRVHTVVDRPQQPMTHRETAPVSQPENKPESKPGPVGPELPPGHIP IQVIRKEVDSKPVSQKPPPPSEKVEVKVPPAPVPCPPPSPGPSAVPSSPK SVATEERAAPSTAPAEATPPKPGEAEAPPKHPGVLKVEAILEKVQGLEQA VDNFEGKKTDKKYLMIEEYLTKELLALDSVDPEGRADVRQARRDGVRKV QTILEKLEQKAIDVPGQVQVYELQPSNLEADQPLQAIMEMGAVAADKGK KNAGNAEDPHTETQQPEATAAATSNPSSMTDTPGNPAAP BAG3 ATGAGCGCCGCCACCCACTCGCCCATGATGCAGGTGGCGTCCGGCA 101 (nucleotide) ACGGTGATCGCGACCCTTTGCCCCCCGGATGGGAGATCAAGATCGA CCCGCAGACCGGCTGGCCCTTCTTCGTGGACCACAACAGCCGCACC ACTACGTGGAACGACCCGCGCGTGCCCTCTGAGGGCCCCAAGGAGA CTCCATCCTCTGCCAATGGCCCTTCCCGGGAGGGCTCTAGGCTGCC GCCTGCTAGGGAAGGCCACCCTGTGTACCCCCAGCTCCGACCAGGC TACATTCCCATTCCTGTGCTCCATGAAGGCGCTGAGAACCGGCAGGT GCACCCTTTCCATGTCTATCCCCAGCCTGGGATGCAGCGATTCCGAA CTGAGGCGGCAGCAGCGGCTCCTCAGAGGTCCCAGTCACCTCTGCG GGGCATGCCAGAAACCACTCAGCCAGATAAACAGTGTGGACAGGTG GCAGCGGCGGCGGCAGCCCAGCCCCCAGCCTCCCACGGACCTGAG CGGTCCCAGTCTCCAGCTGCCTCTGACTGCTCATCCTCATCCTCCTC GGCCAGCCTGCCTTCCTCCGGCAGGAGCAGCCTGGGCAGTCACCAGCTCCCGCGGGGGTACATCTCCATTCCGGTGATACACGAGCAGAACGTTable SDescription Sequence SEQ ID NO TACCCGGCCAGCAGCCCAGCCCTCCTTCCACCAAGCCCAGAAGACG CACTACCCAGCGCAGCAGGGGGAGTACCAGACCCACCAGCCTGTGT ACCACAAGATCCAGGGGGATGACTGGGAGCCCCGGCCCCTGCGGG CGGCATCCCCGTTCAGGTCATCTGTCCAGGGTGCATCGAGCCGGGA GGGCTCACCAGCCAGGAGCAGCACGCCACTCCACTCCCCCTCGCCC ATCCGTGTGCACACCGTGGTCGATAGGCCTCAGCAGCCCATGACCC ATCGAGAAACTGCACCTGTTTCCCAGCCTGAAAACAAACCAGAAAGT AAGCCAGGCCCAGTTGGACCAGAACTCCCTCCTGGACACATCCCAAT TCAAGTGATCCGCAAAGAGGTGGATTCTAAACCTGTTTCCCAGAAGC CCCCACCTCCCTCTGAGAAGGTAGAGGTGAAAGTTCCCCCTGCTCCA GTTCCTTGTCCTCCTCCCAGCCCTGGCCCTTCTGCTGTCCCCTCTTC CCCCAAGAGTGTGGCTACAGAAGAGAGGGCAGCCCCCAGCACTGCC CCTGCAGAAGCTACACCTCCAAAACCAGGAGAAGCCGAGGCTCCCC CAAAACATCCAGGAGTGCTGAAAGTGGAAGCCATCCTGGAGAAGGTA CAGGGGCTGGAGCAGGCTGTAGACAACTTTGAAGGCAAGAAGACTG ACAAAAAGTACCTGATGATCGAAGAGTATTTGACCAAAGAGCTGCTG GCCCTGGATTCAGTGGACCCCGAGGGACGAGCCGATGTGCGTCAGG CCAGGAGAGACGGTGTCAGGAAGGTTCAGACCATCTTGGAAAAACTT GAACAGAAAGCCATTGATGTCCCAGGTCAAGTCCAGGTCTATGAACT CCAGCCCAGCAACCTTGAAGCAGATCAGCCACTGCAGGCAATCATGG AGATGGGTGCCGTGGCAGCAGACAAGGGCAAGAAAAATGCTGGAAA TGCAGAAGATCCCCACACAGAAACCCAGCAGCCAGAAGCCACAGCA GCAGCGACTTCAAACCCCAGCAGCATGACAGACACCCCTGGTAACCC AGCAGCACCG BAG3 ATGAGCGCCGCCACCCACTCGCCCATGATGCAGGTGGCGTCCGGCA 102 (nucleotide) ACGGTGACCGCGACCCTTTGCCCCCCGGATGGGAGATCAAGATCGA (alternative) CCCGCAGACCGGCTGGCCCTTCTTCGTGGACCACAACAGCCGCACC ACTACGTGGAACGACCCGCGCGTGCCCTCTGAGGGCCCCAAGGAGA CTCCATCCTCTGCCAATGGCCCTTCCCGGGAGGGCTCTAGGCTGCC GCCTGCTAGGGAAGGCCACCCTGTGTACCCCCAGCTCCGACCAGGC TACATTCCCATTCCTGTGCTCCATGAAGGCGCTGAGAACCGGCAGGT GCACCCTTTCCATGTCTATCCCCAGCCTGGGATGCAGCGATTCCGAA CTGAGGCGGCAGCAGCGGCTCCTCAGAGGTCCCAGTCACCTCTGCG GGGCATGCCAGAAACCACTCAGCCAGATAAACAGTGTGGACAGGTG GCAGCGGCGGCGGCAGCCCAGCCCCCAGCCTCCCACGGACCTGAG CGGTCCCAGTCTCCAGCTGCCTCTGACTGCTCATCCTCATCCTCCTC GGCCAGCCTGCCTTCCTCCGGCAGGAGCAGCCTGGGCAGTCACCAG CTCCCGCGGGGGTACATCTCCATTCCGGTGATACACGAGCAGAACGT TACCCGGCCAGCAGCCCAGCCCTCCTTCCACCAAGCCCAGAAGACG CACTACCCAGCGCAGCAGGGGGAGTACCAGACCCACCAGCCTGTGT ACCACAAGATCCAGGGGGATGACTGGGAGCCCCGGCCCCTGCGGG CGGCATCCCCGTTCAGGTCATCTGTCCAGGGTGCATCGAGCCGGGA GGGCTCACCAGCCAGGAGCAGCACGCCACTCCACTCCCCCTCGCCC ATCCGTGTGCACACCGTGGTCGATAGGCCTCAGCAGCCCATGACCC ATCGAGAAACTGCACCTGTTTCCCAGCCTGAAAACAAACCAGAAAGT AAGCCAGGCCCAGTTGGACCAGAACTCCCTCCTGGACACATCCCAAT TCAAGTGATCCGCAAAGAGGTGGATTCTAAACCTGTTTCCCAGAAGC CCCCACCTCCCTCTGAGAAGGTAGAGGTGAAAGTTCCCCCTGCTCCA GTTCCTTGTCCTCCTCCCAGCCCTGGCCCTTCTGCTGTCCCCTCTTC CCCCAAGAGTGTGGCTACAGAAGAGAGGGCAGCCCCCAGCACTGCC CCTGCAGAAGCTACACCTCCAAAACCAGGAGAAGCCGAGGCTCCCC CAAAACATCCAGGAGTGCTGAAAGTGGAAGCCATCCTGGAGAAGGTA CAGGGGCTGGAGCAGGCTGTAGACAACTTTGAAGGCAAGAAGACTG ACAAAAAGTACCTGATGATCGAAGAGTATTTGACCAAAGAGCTGCTG GCCCTGGATTCAGTGGACCCCGAGGGACGAGCCGATGTGCGTCAGG CCAGGAGAGACGGTGTCAGGAAGGTTCAGACCATCTTGGAAAAACTT GAACAGAAAGCCATTGATGTCCCAGGTCAAGTCCAGGTCTATGAACTCCAGCCCAGCAACCTTGAAGCAGATCAGCCACTGCAGGCAATCATGGTable SDescription Sequence SEQ ID NO AGATGGGTGCCGTGGCAGCAGACAAGGGCAAGAAAAATGCTGGAAA TGCAGAAGATCCCCACACAGAAACCCAGCAGCCAGAAGCCACAGCA GCAGCGACTTCAAACCCCAGCAGCATGACAGACACCCCTGGTAACCC AGCAGCACCG BAG3 ATGAGCGCCGCCACCCACTCGCCCATGATGCAGGTGGCGTCCGGCA 103 (nucleotide) ACGGTGATCGCGACCCTTTGCCCCCCGGATGGGAGATCAAGATCGA (alternate 2) CCCGCAGACCGGCTGGCCCTTCTTCGTGGACCACAACAGCCGCACC ACTACGTGGAACGACCCGCGCGTGCCCTCTGAGGGCCCCAAGGAGA CTCCATCCTCTGCCAATGGCCCTTCCCGGGAGGGCTCTAGGCTGCC GCCTGCTAGGGAAGGCCACCCTGTGTACCCCCAGCTCCGACCAGGC TACATTCCCATTCCTGTGCTCCATGAAGGCGCTGAGAACCGGCAGGT GCACCCTTTCCATGTCTATCCCCAGCCTGGGATGCAGCGATTCCGAA CTGAGGCGGCAGCAGCGGCTCCTCAGAGGTCCCAGTCACCTCTGCG GGGCATGCCAGAAACCACTCAGCCAGATAAACAGTGTGGACAGGTG GCAGCGGCGGCGGCAGCCCAGCCCCCAGCCTCCCACGGACCTGAG CGGTCCCAGTCTCCAGCTGCCTCTGACTGCTCATCCTCATCCTCCTC GGCCAGCCTGCCTTCCTCCGGCAGGAGCAGCCTGGGCAGTCACCAG CTCCCGCGGGGGTACATCTCCATTCCGGTGATACACGAGCAGAACGT TACCCGGCCAGCAGCCCAGCCCTCCTTCCACCAAGCCCAGAAGACG CACTACCCAGCGCAGCAGGGGGAGTACCAGACCCACCAGCCTGTGT ACCACAAGATCCAGGGGGATGACTGGGAGCCCCGGCCCCTGCGGG CGGCATCCCCGTTCAGGTCATCTGTCCAGGGTGCATCGAGCCGGGA GGGCTCACCAGCCAGGAGCAGCACGCCACTCCACTCCCCCTCGCCC ATCCGTGTGCACACCGTGGTCGATAGGCCTCAGCAGCCCATGACCC ATCGAGAAACTGCACCTGTTTCCCAGCCTGAAAACAAACCAGAAAGT AAGCCAGGCCCAGTTGGACCAGAACTCCCTCCTGGACACATCCCAAT TCAAGTGATCCGCAAAGAGGTGGATTCTAAACCTGTTTCCCAGAAGC CCCCACCTCCCTCTGAGAAGGTAGAGGTGAAAGTTCCCCCTGCTCCA GTTCCTTGTCCTCCTCCCAGCCCTGGCCCTTCTGCTGTCCCCTCTTC CCCCAAGAGTGTGGCTACAGAAGAGAGGGCAGCCCCCAGCACTGCC CCTGCAGAAGCTACACCTCCAAAACCAGGAGAAGCCGAGGCTCCCC CAAAACATCCAGGAGTGCTGAAAGTGGAAGCCATCCTGGAGAAGGTA CAGGGGCTGGAGCAGGCTGTAGACAACTTTGAAGGCAAGAAGACTG ACAAAAAGTACCTGATGATTGAAGAGTATTTGACCAAAGAGCTGCTGG CCCTGGATTCAGTGGACCCCGAGGGACGAGCCGATGTGCGTCAGGC CAGGAGAGACGGTGTCAGGAAGGTTCAGACCATCTTGGAAAAACTTG AACAGAAAGCCATTGATGTCCCAGGTCAAGTCCAGGTCTATGAACTC CAGCCCAGCAACCTTGAAGCAGATCAGCCACTGCAGGCAATCATGGA GATGGGTGCCGTGGCAGCAGACAAGGGCAAGAAAAATGCTGGAAAT GCAGAAGATCCCCACACAGAAACCCAGCAGCCAGAAGCCACAGCAG CAGCGACTTCAAACCCCAGCAGCATGACAGACACCCCTGGTAACCCA GCAGCACCG MLC2 promoter TTAGACAATGGCAGGACCCAGAGCACAGAGCATCGTTCCCAGGCCA 300 (rat) GGCCCCAGCCACTGTCTCTTTAACCTTGAAGGCATTTTTGGGTCTCAC GTGTCCACCCAGGCGGGTGTCGGACTTTGAACGGCTCTTACTTCAGA AGAACGGCATGGGGTGGGGGGGCTTAGGTGGCCTCTGCCTCACCTA CAACTGCCAAAAGTGGTCATGGGGTTATTTTTAACCCCAGGGAAGAG GTATTTATTGTTCCACAGCAGGGGCCGGCCAGCAGGCTCCTTGAATT C BAG3 promoter GCAAGCCCTCATCAGTTATTTTTCTATGATTCTGTCTCTCTGTCCCCTC 301CTTACAAGGAAAGTAATTTTGAAACAACCAATCCAGTCTTGGTTCTTT GTTTCTGCTTTCTTCAGCCCTTCTCTGTCTATAAAACCAACCTCTTCTG CTCAGCTCATGGGAGCACTTATTCTAATTTAATGGAGATGTTGCCCAA TTTCTAGAATCACAAATAAGATCTTTAACAATAAAAGTTAAAAAATGAA AATCAACAACAACAACAACAAAAAAGATCTTTAAATGTGTTGTAATTTT CTCCTTTGACAGGTTACAAGTGCAATTGAATAAACCAAACAAAAAATGTCATGGTTATTCGGTCTTTACTTCCCAAATCAGGGTCAAGATATAAGATable SDescription Sequence SEQ ID NO TAGCAAGAACCAATCTCTACCATAAAAAAGATCCAGACCCAAGAAAAT GTGATTTATCTTTAAAGCTGCAACGAAACTTTCTTTTTAGTCTAGGAGA CTAAAAGCCATCAGTTGATACAATCTCTTTTTTTCTTGAAGTTTCCAAA GGAAGGCAGGTGAGTTTGCACTGACTTCCATTTTCTCCCTGGCTTCC TTCCGGTGTCAGATGAGAGTCCCCGCGCTCCTCCCGGACAGCCCTC AGGGTCCTCGGCTATCATATATGGGGGAGGGGGTGGAGGTGGGCGA GATGGTTTTGTTTGTACAGGAAGGACGGGCGGCAGGCACGGGGAGC ACGGGCTCCGGCCCCGGGAACACTCACTCGGCGCAAAGGAGAGGG AGAGAGCGACTATGAAAGCCGAAACCCGCCCGGGGCGCACGGAGG ACGGCCCCAGTCCAGCTCGTCCGGCTTCCCACCCGCAGGCGGACCC CGAAGCCGCGCCCGCGCCCGCCCGCGGCGACTCCGGCCCGGGCAC GCGCACGAGTCGGAAGGGGGAGGGGCGGGAGGAGGTGGGGGAGG GGCGAGCGGGCCGAGGCCCCGCCCCCGCTCCTCTGCCCCGCCCGC CGCGATTATAGCCGATGACTCAGGGCGGAGCTCC CK8e promoter TGCCCATGTAAGGAGGCAAGGCCTGGGGACACCCGAGATGCCTGGT 302TATAATTAACCCAGACATGTGGCTGCCCCCCCCCCCCCAACACCTGC TGCCTCTAAAAATAACCCTGCATGCCATGTTCCCGGCGAAGGGCCAG CTGTCCCCCGCCAGCTAGACTCAGCACTTAGTTTAGGAACCAGTGAG CAAGTCAGCCCTTGGGGCAGCCCATACAAGGCCATGGGGCTGGGCA AGCTGCACGCCTGGGTCCGGGGTGGGCACGGTGCCCGGGCAACGA GCTGAAAGCTCATCTGCTCTCAGGGGCCCCTCCCTGGGGACAGCCC CTCCTGGCTAGTCACACCCTGTAGGCTCCTCTATATAACCCAGGGGC ACAGGGGCTGCCCTCATTCTACCACCACCTCCACAGCACAGACAGAC ACTCAGGAGCCAGCCAGC TNNT2-400 GTTGCCTTCTGCCCCCCAACCCTGCTCCCAGCTGGCCCTCCCAGGC 310CTGGGTTGCTGGCCTCTGCTTTATCAGGATTCTCAAGAGGGACAGCT GGTTTATGTTGCATGACTGTTCCCTGCATATCTGCTCTGGTTTTAAATA GCTTATCTGAGCAGCTGGAGGACCACATGGGCTTATATGGCGTGGG GTACATGTTCCTGTAGCCTTGTCCCTGGCACCTGCCAAAATAGCAGC CAACACCCCCCACCCCCACCGCCATCCCCCTGCCCCACCCGTCCCC TGTCGCACATTCCTCCCTCCGCAGGGCTGGCTCACCAGGCCCCAGC CCACATGCCTGCTTAAAGCCCTCTCCATCCTCTGCCTCACCCAGTCC CCGCTGAGACTGAGCAGACGCCTCCA TNNT2-600 GTCATGGAGAAGACCCACCTTGCAGATGTCCTCACTGGGGCTGGCA 311GAGCCGGCAACCTGCCTAAGGCTGCTCAGTCCATTAGGAGCCAGTA GCCTGGAAGATGTCTTTACCCCCAGCATCAGTTCAAGTGGAGCAGCA CATAACTCTTGCCCTCTGCCTTCCAAGATTCTGGTGCTGAGACTTATG GAGTGTCTTGGAGGTTGCCTTCTGCCCCCCAACCCTGCTCCCAGCTG GCCCTCCCAGGCCTGGGTTGCTGGCCTCTGCTTTATCAGGATTCTCA AGAGGGACAGCTGGTTTATGTTGCATGACTGTTCCCTGCATATCTGCT CTGGTTTTAAATAGCTTATCTGAGCAGCTGGAGGACCACATGGGCTT ATATGGCGTGGGGTACATGTTCCTGTAGCCTTGTCCCTGGCACCTGC CAAAATAGCAGCCAACACCCCCCACCCCCACCGCCATCCCCCTGCC CCACCCGTCCCCTGTCGCACATTCCTCCCTCCGCAGGGCTGGCTCA CCAGGCCCCAGCCCACATGCCTGCTTAAAGCCCTCTCCATCCTCTGC CTCACCCAGTCCCCGCTGAGACTGAGCAGACGCCTCCAaMHC AGAGCCCCTATCCATGGAATCTGGAGCCTGGGGCCAACTGGTGTAAA 312TCTCTGGGCCTGCCAGGCATTCAAAGCAGCACCTGCATCCTCTGGCA GCCTGGGGAGGCGGAAGGGAGCAACCCCCCACTTATACCCTTTCTC CCTCAGCCCCAGGATTAACACCTCTGGCCTTCCCCCTTCCCACCTCC CATCAGGAGTGGAGGGTTGCAGAGGGAGGGTAAAAACCTACATGTC CAAACATCATGGTGCACGATATATGGATCAGTATGTGTAGAGGCAAG AAAGGAAATCTG...

Claims

WHAT IS CLAIMED IS:

1. A recombinant adeno-associated virus (rAAV) comprising:(a) a capsid comprising a VP1 polypeptide having the amino acid sequence of SEQ ID NQ:10; and(b) a genome comprising:(i) a 5' inverted terminal repeat (ITR);(ii) a CK8e promoter;(iii) a coding sequence for a BAG3 polypeptide;(iv) a posttranscriptional regulatory element;(v) a bovine growth hormone (BGH) polyadenylation signal; and(Vi) a 3' ITRfor use in a method of treating an adult human subject suffering from BCL2-Associated Athanogene 3 (BAG3) mutation-associated dilated cardiomyopathy, wherein the method comprises intravenously administering to the subject a rAAV dose ranging from 4e12 vg / kg to 5e13 vg / kg.

2. The rAAV for use according to claim 1, wherein the capsid further comprises a VP2 polypeptide having the amino acid sequence of SEQ ID NO:20.

3. The rAAV for use according to claim 1 or claim 2, wherein the capsid further comprises a VP3 polypeptide having the amino acid sequence of SEQ ID NO:

214. The rAAV for use according to any one of claims 1 to 3, wherein: (a) the 5' ITR comprises the nucleotide sequence of SEQ ID NQ:600, (b) the 0K8e promoter comprises the nucleotide sequence of SEQ ID NO:302, (c) the BAG3 polypeptide comprises the amino acid sequence of SEQ ID NO: 100, (d) the coding sequence for the BAG3 polypeptide comprises the nucleotide sequence of SEQ ID NO: 102, (e) the posttranscriptional regulatory element comprises the nucleotide sequence of SEQ ID NO:400, (f) the BGH polyadenylation signal comprises the nucleotide sequence of SEQ ID NO:401, (g) the 3' ITR comprises the nucleotide sequence of SEQ ID NO:608, or (h) a combination thereof.

5. The rAAV for use according to any one of claims 1 to 4, wherein the genome comprises the nucleotide sequence of SEQ ID NO:810.

6. The rAAV for use according to any one of claims 1 to 5, wherein the dose of the rAAV is 5e12 vg / kg to 5e13 vg / kg, 8e12 vg / kg to 1.25e13 vg / kg, 8e12 vg / kg to 1.25e13 vg / kg, 1e13 vg / kg to 5e13 vg / kg, 3e13 vg / kg to 5e13 vg / kg, 1e13 vg / kg, 2e13 vg / kg, 3e13 vg / kg, or 4e13 vg / kg.

7. The rAAV for use according to any one of claims 1 to 5, wherein the dose of the rAAV is 4e12 vg / kg to 2e13 vg / kg, 4e12 vg / kg to 1.25e13 vg / kg, 6e12 vg / kg to 1.25e13 vg / kg, or 6e12 vg / kg to 1e13 vg / kg, 4e12 vg / kg, 5e12 vg / kg, 6e12 vg / kg, 7e12 vg / kg, 8e12 vg / kg, 9e12 vg / kg.

8. The rAAV for use according to any one of claims 1 to 5, wherein the dose of the rAAV is 1 e13 vg / kg.

9. The rAAV for use according to any one of claims 1 to 5, wherein the dose of the rAAV is 6e12 vg / kg.

10. The rAAV for use according to any one of claims 1 to 9, wherein the rAAV is administered as a single dose.

11. The rAAV for use according to any one of claims 1 to 10, wherein the rAAV is formulated as a liquid pharmaceutical composition.

12. The rAAV for use according to claim 11 , wherein the liquid pharmaceutical composition is at a pH of 65 to 75 (e.g., 7.0) and comprises 27mM KCI, 1.5mM KH2PO4, 172mM NaCI, 8.1mM N32HPO4, 250mM L-Arginine, and 0.005% (w / v) poloxamer 188.

13. The rAAV for use according to any one of claims 1 to 12, wherein the rAAV is administered as an infusion.

14. The rAAV for use according to any one of claims 1 to 13, wherein the method further comprises administering a first steroid and optionally a second steroid to the subject15. The rAAV for use according to claim 14, wherein the first steroid is methylprednisolone (e.g., at a dose of 1 mg / kg to 10 mg / kg).

16. The rAAV for use according to claim 14 or claim 15, wherein the method comprises administering a second steroid.

17. The rAAV for use according to claim 16, wherein the second steroid is prednisone (e.g., administered orally at a maximum initial dose up to 100 mg / day).

18. The rAAV for use according to any one of claims 1 to 17, wherein the method further comprises administering an anti-CD20 antibody and / or sirolimus to the subject.

19. The rAAV for use according to any one of claims 1 to 18, wherein the subject is 18-65 years old, e.g., 18-60 or 18-55.

20. The rAAV for use according to any one of claims 1 to 19, wherein the subject has a truncating BAG3 mutation.

21. A liquid pharmaceutical composition in the form of a solution having a pH of 65 to 7.5 and comprising:(a) a recombinant adeno-associated virus (rAAV) comprising:(i) a capsid comprising a VP1 polypeptide having the amino acid sequence of SEQ ID NO:10; and(ii) a genome comprising:(1) a 5' inverted terminal repeat (ITR);(2) a CK8e promoter;(3) a coding sequence for a BAG3 polypeptide;(4) a posttranscriptional regulatory element;(5) a bovine growth hormone (BGH) polyadenylation signal sequence; and (6) a 3' ITR;(b) 2.7mM KOI;(c) 1.5mM KH2PO4;(d) 172mM NaCI;(e) 8.1mM Na2HPO4;(f) 250mM L-Arginine; and(g) 0.005% poloxamer 188.

22. The liquid pharmaceutical composition of claim 21 , wherein the capsid further comprises a VP2 polypeptide having the amino acid sequence of SEQ ID NO:2023. The liquid pharmaceutical composition of claim 21 or 22, wherein the capsid further comprises a VP3 polypeptide having the amino acid sequence of SEQ ID NO:21.

24. The liquid pharmaceutical composition of any one of claims 21 to 23, wherein: (a) the 5' ITR comprises the nucleotide sequence of SEQ ID NQ:600, (b) the CK8e promoter comprises the nucleotide sequence of SEQ ID NO:302, (c) the BAG3 polypeptide comprises the amino acid sequence of SEQ ID NO: 100, (d) the coding sequence for the BAG3 polypeptide comprises the nucleotide sequence of SEQ ID NQ:102, (e) the posttranscriptional regulatory element comprises the nucleotide sequence of SEQ ID N0:400, (f) the BGH polyadenylation signal comprises the nucleotide sequence of SEQ ID NO:401, (g) the 3' ITR comprises the nucleotide sequence of SEQ ID NQ:608, or (h) a combination thereof.

25. The liquid pharmaceutical composition of any one of claims 21 to 24, wherein the genome comprises the nucleotide sequence of SEQ ID NO:810.

26. A method of preparing a solution for infusion, comprising diluting the liquid pharmaceutical composition of any one of claims 21 to 25 with a saline solution.

27. An IV infusion bag comprising a diluted liquid pharmaceutical composition obtained or obtainable by the method of claim 26